
==== Front
Mol Cancer
Mol Cancer
Molecular Cancer
1476-4598
BioMed Central London

2101
10.1186/s12943-024-02101-z
Review
Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma
Chan Yau-Tuen 1
Zhang Cheng 1
Wu Junyu 1
Lu Pengde 1
Xu Lin 1
Yuan Hongchao 1
Feng Yibin 1
Chen Zhe-Sheng chenz@stjohns.edu

12
Wang Ning ckwang@hku.hk

1
1 https://ror.org/02zhqgq86 grid.194645.b 0000 0001 2174 2757 School of Chinese Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong
2 grid.264091.8 0000 0001 1954 7928 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, 8000 Utopia Parkway, Queens, NY 11439 USA
6 9 2024
6 9 2024
2024
23 18930 7 2024
23 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Liver cancer is a global health challenge, causing a significant social-economic burden. Hepatocellular carcinoma (HCC) is the predominant type of primary liver cancer, which is highly heterogeneous in terms of molecular and cellular signatures. Early-stage or small tumors are typically treated with surgery or ablation. Currently, chemotherapies and immunotherapies are the best treatments for unresectable tumors or advanced HCC. However, drug response and acquired resistance are not predictable with the existing systematic guidelines regarding mutation patterns and molecular biomarkers, resulting in sub-optimal treatment outcomes for many patients with atypical molecular profiles. With advanced technological platforms, valuable information such as tumor genetic alterations, epigenetic data, and tumor microenvironments can be obtained from liquid biopsy. The inter- and intra-tumoral heterogeneity of HCC are illustrated, and these collective data provide solid evidence in the decision-making process of treatment regimens. This article reviews the current understanding of HCC detection methods and aims to update the development of HCC surveillance using liquid biopsy. Recent critical findings on the molecular basis, epigenetic profiles, circulating tumor cells, circulating DNAs, and omics studies are elaborated for HCC diagnosis. Besides, biomarkers related to the choice of therapeutic options are discussed. Some notable recent clinical trials working on targeted therapies are also highlighted. Insights are provided to translate the knowledge into potential biomarkers for detection and diagnosis, prognosis, treatment response, and drug resistance indicators in clinical practice.

Keywords

Hepatocellular carcinoma
Biomarkers
Cancer diagnosis
Cancer surveillance
Cancer treatment
Therapeutic option
Tissue biopsy
Liquid biopsy
Serological biomarkers
Circulating tumor cells
Cell-free DNA
Circulating tumor DNA
Non-coding RNAs
Methylation
Tumor-derived vesicles
Metabolomics
Surgical resection
TACE
HAIC
Local ablation
Liver transplantation
Targeted therapies
Immunotherapies
Artificial intelligence
Clinical trials
http://dx.doi.org/10.13039/501100003802 University Research Committee, University of Hong Kong 109000349 Research Grant Committee of Hong Kong17119621 http://dx.doi.org/10.13039/501100005847 Health and Medical Research Fund 21222151 Innovation and Technology FundPRP/028/22FX issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Liver cancer is the second most lethal cancer worldwide, with hepatocellular carcinoma (HCC) being the most prevalent subtype, accounting for 90% of cases. Common risk factors include viral infections such as hepatitis B/C virus (HBV/HCV) infections, chronic liver diseases (CLDs) like fatty liver or cirrhosis, alcohol abuse, and metabolic diseases including diabetes. Other less common risk factors are hemochromatosis, autoimmune hepatitis, and exposure to certain environmental toxins. HCC is often challenging to diagnose due to the absence or ambiguity of symptoms. Early-stage symptoms typically encompass abdominal pain, weight loss, and fatigue, while later stages may involve jaundice, ascites, and fever. The insidious progression of chronic liver conditions further complicates the monitoring of liver diseases. Moreover, the heterogeneity of HCC at the molecular and histological levels contributes to the complexity of diagnosis and treatment. Apart from the apparent hepatitis virus, the presence of somatic alterations due to prolonged hepatic damage, aging, or inherited genetic susceptibility can result in hepatocarcinogenesis. Since patients typically do not undergo genetic testing until suspicion of liver diseases arises, these markers hold less significance in predicting HCC. Instead, they play a more substantial role in prognostic predictions and disease management. While this review does not delve into the genetic changes that lead to the development of HCC, they have been discussed extensively in other articles [1–7].

Consequently, surveillance programs and early detection tests are critical for the timely diagnosis and treatment of HCC. Screening efforts primarily target populations with multiple risk factors, such as known carriers of the hepatitis virus, individuals with cirrhosis, or those with a family history of HCC. Meta-analyses have supported the benefits of surveillance on HCC to improve patients’ survival and clinical outcomes [8, 9]. HCC can often be diagnosed using non-invasive imaging, like computer tomography (CT) / magnetic resonance imaging (MRI), due to its characteristic radiographic features, such as arterial hyperenhancement, venous washout, and capsule enhancement [10]. The Liver Imaging Reporting and Data System (LI-RADS) is an established scoring system for HCC diagnosis among HBV-infected and cirrhotic patients, with a 67% sensitivity and 93% specificity [11] for detecting tumor nodules larger than 1 cm in diameter [12]. Risk stratification is currently solely determined by LI-RADS. However, a biopsy is still necessary for patients with LR-4 or above observations without known risk factors for HCC or those with atypical imaging findings. The NCCN recommends core-needle biopsy for highly suspicious lesions for HCC that do not meet imaging criteria or specific patient categories [13]. Furthermore, the utilization of biomarkers, such as AFP, prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) (or named as des-gamma-carboxy prothrombin (DCP)), and glypican-3 (GPC3), has shown promise in improving the early detection of HCC. Only about half of the patients can be diagnosed through surveillance at a curative stage of the disease. Patients with early or intermediate-stage HCC may undergo curative therapies such as surgical resection, locoregional ablation, or liver transplantation. However, advanced-stage HCC patients are limited to chemotherapy or systemic treatments, such as chemoembolization, sorafenib, and nivolumab. Even though around half of HCC patients receive systemic therapies, the median overall survival (OS) remains limited due to the lack of effective therapeutic options.

Given the challenges in treating advanced-stage HCC, even with the advent of novel systemic therapies, it is imperative to explore improved methods for early detection, diagnosis, and prevention. To this end, significant insights into disease biology have been gleaned from genomic, transcriptomic, and epigenomic studies. These studies have led to identifying several molecular subclasses of HCC that exhibit distinct prognostic and therapeutic implications. This review aims to analyze various biomarkers that can offer valuable information on early detection, disease management, and therapeutic options. Additionally, clinical trials targeting some of these markers will be highlighted. For example, developing personalized medicine approaches, such as immunotherapy and targeted therapy, has shown potential in improving HCC treatment outcomes. Immune checkpoint inhibitors (ICIs), such as pembrolizumab and atezolizumab, have demonstrated promising results in clinical trials, while targeted therapies, such as lenvatinib and regorafenib, have exhibited significant improvements in OS. Furthermore, advancements in the understanding of the tumor microenvironment and the role of non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have opened new avenues for the development of novel diagnostic and therapeutic strategies. The application of liquid biopsies, mainly circulating tumor DNA (ctDNA) and extracellular vesicles, has also garnered interest as a non-invasive method for the early detection and monitoring of HCC.

In summary, developing numerous detection methods aims to gain insights through various biomarkers, enabling patients with HCC to benefit from early detection and diagnosis of the disease. This, in turn, can enhance their therapeutic regimens and increase survival probability. Consequently, this review will discuss current findings of biomarkers for early screening, detection, and diagnosis, as well as treatment options and response. Ongoing clinical trials targeting specific biomarkers will also be covered.

Current and promising diagnostic biomarkers for HCC

Current diagnostics using imaging and tissue biopsy

The American Association for the Study of Liver Diseases suggests that patients with a high risk of HCC perform ultrasound liver surveillance twice a year [14]. Although ultrasound is the most handy routine surveillance, its sensitivity is only 50%, while specificity is more than 90%. However, its detection is limited to early lesions and tumor nodules, which may reduce the therapeutic window [15]. CT and MRI are much more sensitive for diagnosing HCC, with over 90% sensitivity and specificity for tumors larger than 2 cm in diameter [16]. Despite its high sensitivity and accuracy, the cost of this cross-sectional imaging is high, and it is only feasible to be included in routine surveillance once evident signals appear.

Current stratification standards for HCC patients are based on tumor burden and cancer-related characteristics, including liver function and physical status [17]. Imaging techniques, including ultrasound, CT, and MRI, are commonly used to determine the size and number of tumor nodules in the liver. The modified Child-Pugh classification (CPC) proposed by Pugh et al. in 1973, which includes ascites, hepatic encephalopathy, prothrombin time, serum bilirubin, and albumin levels, has been used for many years to assess the remaining hepatic function in HCC-diagnosed patients [18, 19]. Still, its accuracy for use in HCC has been questioned in recent years [20, 21]. With the advancement of detection methods, improved anti-viral therapies to maintain liver function, and more prevalence of non-viral-associated HCC, more patients have been diagnosed with CPC A liver function recently, and it is no longer providing enough information for determining staging and prognosis in most cases [20, 22]. In addition to other technical limitations, it is suggested that the albumin-bilirubin (ALBI) grade is more potent in differentiating the HCC prognosis in most patients [21, 23–25]. The 2022 BCLC staging strategy recommended the ALBI score and AFP concentration for hepatic function assessment regardless of tumor burden [26]. The importance of portal hypertension in HCC is also underlined, and it often correlates with advanced conditions such as prior variceal bleeding, which should be considered, especially in patients with cirrhosis before surgical resection [27, 28].

A tissue biopsy is not usually performed unless the imaging can only provide marginal evidence of the diagnosis. For example, suppose the lesion is small and cannot be identified by imaging, or in the cases of non-cirrhotic liver disease, in that case, tissue biopsy can help make a precise diagnosis [29]. A biopsy can also help differentiate less common liver cancer subtypes from HCC and provide genetic mutation information directly from the tumor tissues [30]. It is essential in the design of precision medicine. However, tissue biopsy is an invasive method, which is potentially causing pain and bleeding in addition to liver damage. Also, there is a slight risk of inducing intrahepatic metastasis when tumor cells detach from the primary site and move to other sites along the wound [31].

After all, tissue biopsy remains a crucial tool for diagnosing HCC, as it can provide a definite diagnosis through histological evidence. Pathologists can more accurately perform tumor staging, which benefits the patient. Tissue biopsies can be used to monitor treatment response and provide prognostic information. Furthermore, it helps us know more about cancer biology, new biomarkers, and the creation of new treatments. The biopsy tissue is valuable for many pre-clinical studies to look for potential biomarkers or drug targets before the enrolment of actual patients in clinical studies. Nevertheless, due to the limitations of tissue biopsy, it is not feasible to utilize this method for surveillance. This is precisely the juncture where the potential of liquid biopsy comes to the fore, demonstrating its unique value and advantages. Details of ultrasound, imaging, and tissue biopsy are beyond the scope of this review, and the remaining sections will focus on the molecular biomarkers of HCC.

Current research in liquid biopsy diagnostics

Using liquid biopsy to screen for cancer and detect treatment response is critical as it can provide in-time information with minimal invasion to the patients [32, 33]. The most common fluid obtained in clinical settings is blood. Still, there are also other body fluids such as urine, ascites fluids, bile, saliva, etc. [34]. Current research directions aim to push forward the ability of liquid biopsy to obtain as much valuable information as a typical biopsy (Fig. 1). Large-scale HCC surveillance programs for high-risk individuals are limited to ultrasound with or without serum alpha-fetoprotein (AFP). AASLD is against the recommendation of using biomarkers to diagnose HCC, provided that the accuracy is insufficient until more solid validations in phase III and IV biomarker studies emerge [14, 35]. The following will discuss the current and potential biomarkers in various aspects of HCC to develop a more systematic and comprehensive panel for economical but sensitive HCC screening and diagnostic methods to improve patient outcomes.Fig. 1 Biomarkers of HCC diagnosis. The current surveillance methodology for Hepatocellular Carcinoma (HCC) primarily involves ultrasound and serum AFP measurements, sometimes supplemented with imaging techniques. In instances where diagnosis or treatment options are ambiguous, tissue biopsy is often employed to confirm the histological structure of the tumor. Liquid biopsy offers a minimally invasive alternative for gaining insights into tumor heterogeneity. Recent research has identified potential biomarkers from diverse sources, including serological components, genetic materials, cells, and vesicles. Among these candidate biomarkers, circulating tumor DNAs and omics stand out due to their ability to reflect the complexity of HCC tumors. These technologies offer great promise in understanding the intricacies of HCC and developing more effective and personalized treatment strategies

Serological diagnostic biomarkers

Unless the doctor strongly suspects that the patients are likely to develop HCC, non-invasive measures, such as imaging and liquid biopsies, are typically performed in standard clinical practice for patients with an elevated risk of HCC. The most prevalent serum protein marker is AFP, whose expression is increased during tumorigenesis. AFP is a fetal glycoprotein, the analog of albumin in the fetus, and its expression should be reduced after birth [36]. For a long time, serum AFP levels have been considered the “gold standard” for screening tests when used in conjunction with ultrasonography [37, 38]. However, the level of AFP fluctuates a lot among patients with liver diseases. The cut-off for AFP in diagnosing HCC is generally considered to be 20 ng/mL [39]. AFP alone has a sensitivity of about 60% when the cut-off value is at 20 ng/mL, but it decreases quickly to below 50% when the value is raised to 50 ng/mL [40, 41]. It decreases to around 40 to 50% in patients with cirrhosis, while specificity remains relatively the same [15, 42]. Tumors of size smaller than 3 cm in diameter also reduce the sensitivity of AFP to about 25%, compared to more than half when > 3 cm [43]. However, this value may vary depending on the findings from the corresponding ultrasound examination. Therefore, it is generally recommended to be used with imaging techniques due to its variable sensitivity and specificity [29]. Also, the sensitivity and specificity both decrease in patients with acute and chronic liver diseases, especially hepatitis patients or HBV carriers [37, 41, 44]. Notably, elevated ALT can also impair the specificity of AFP in detecting HCC [45]. The serum ALT levels were correlated with AFP levels even in patients without HCC, and it became a confounding factor for the diagnosis. On the other hand, early-stage or small tumor HCC may not elevate AFP levels [36], so the combination with ultrasound is still likely to provide a false negative result. Consequently, in 2018, the AASLD guideline for liver diseases no longer recommended ultrasound plus AFP tests every 6 months for high-risk individuals [46]. Instead, ultrasound with or without AFP tests is suggested, as they cannot determine if AFP tests in surveillance can improve survival.

AFP-L3 is a glycosylated isoform of AFP, which reacts strongly with lens culinaris agglutinin. AFP-L3 is typically used in triple tests for pregnancy, but it also has a vital role in diagnosing HCC. AFP-L3 is usually reported as the percentage of AFP-L3 in total AFP, and 10% to 15% is the recommended cut-off [39, 47]. AFP-L3% is approved by the FDA for HCC stratification but not in surveillance programs due to its low sensitivity alone. Among patients with HCV-associated HCC, the sensitivity and specificity for AFP-L3% alone is 37% and 84.9% to 92%, but when combined with AFP, the numbers increase to 69.5% to 77% and 80.2% to 86.6% [47, 48].

In addition to AFP-L3%, PIVKA-II is introduced to the liquid biopsy test for diagnosis of HCC, especially in AFP-negative patients. PIVKA-II is detected in almost 90% of patients with HCC [49], and it is recommended that the Asia-Pacific region be included in routine surveillance programs for HCC [50]. However, similar to AFP-L3%, it is only for risk stratification but has not yet been approved by the FDA for HCC surveillance. The suggested cut-off value for PIVKA-II combined with AFP in small tumor HCC is 40 mAU/mL [43, 51]. In the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial, AFP combined with PIVKA-II can have a sensitivity and specificity as high as 91% and 74%, respectively. In comparison, the numbers reduce to 73% and 71% when tested 12 months before diagnosis [43]. Additionally, AFP-L3% and DCP levels are not associated with increased total AFP, making them good candidate markers for combined use with AFP for detecting HCC [47, 52].

As a result, algorithms with multiple biomarkers, such as GALAD score and HCC early detection screening (HES), are coming on stage. GALAD is calculated using gender, age, AFP, AFP-L3%, and DCP [53]. Longitudinal GALAD, which calculated the weighted average of multiple screening tests of an individual, demonstrated an area under the receiver operating characteristic (ROC) curve (AUC) of 0.85 and 0.83, even for early-stage HCC [54]. HES is a predictive model that includes results of AFP, ALT, platelets, and the age of the AFP test [55]. In the improved HES V2.0, AFP-L3% and DCP are included in the algorithm, which outperformed the sensitivity of GALAD in a cohort study in patients with hepatic cirrhosis by about 7% [55].

Additionally, several other clinically utilized biomarkers warrant mention. GPC3, a surface proteoglycan similar to AFP, usually is not detected in healthy adult liver but only in fetal liver. However, GPC3 is overexpressed in patients with HCC and is detectable in both tumor tissue and the serum [56]. It can also differentiate HCC from AFP-negative nodules, which makes it a potential biomarker on top of AFP [57, 58]. The mRNA and protein levels of GPC3 in viral-related HCC are high [59] while absent in healthy livers. However, the expression of GPC3 in non-viral HCC still needs to be clearly illustrated. The serum level of GPC3 was measured using ELISA, but the percentage of positive patients ranged from 36 to 95% in different studies [60, 61]. However, GPC3 levels may not show significant differences in early-stage HCC [62].

Besides, osteopontin (OPN) has also been reported to be a promising serological biomarker for HCC diagnosis. OPN is important in hepatic inflammation under acute or chronic liver diseases [63]. In early studies, OPN had limited or similar diagnostic value compared with AFP, but later on, it was reported to possess superior performance over AFP, with AUC ranging from 0.7 to > 0.9 [64–66]. OPN performs much better than AFP in small tumor HCC, with AUC of 0.85, sensitivity and specificity of 79.2% and 79.6% [67]. It also has an excellent diagnostic value in AFP-negative samples. The combination of OPN with AFP outperforms AFP alone.

Heat shock protein 70 (HSP70) is an oncogene that promotes tumor cell survival and proliferation and possesses anti-apoptosis effects [68]. HSP70 is located on the membrane of primary HCC cells, but it is also released into the circulation and is significantly higher than normal controls [68, 69]. The level of HSP70 can differentiate precancerous lesions with early HCC (p < 0.001) or early HCC with progressed HCC (p < 0.001), which demonstrated that it could be a sensitive biomarker for the detection and staging of HCC [70]. A recent study in 2022 suggested that when HSP70 is combined with GPC3, they have an absolute sensitivity and specificity of 100% [71]. However, the scale of this research is not large, and using HSP70 as a surveillance protein target is still not convincing.

Golgi membrane protein 1 (GOLM1, also known as Golgi protein-73, GP73) is a transmembrane protein on the Golgi complex. The level of GP73 is found to be significantly higher in patients with HCC, and it has a sensitivity and specificity of 69% and 75% for predicting HCC, which is much better than AFP (62% vs. 25%) in the same cohort to detect early HCC [72]. Its level is independent of serum AFP level [72]. Although the level of GP73 in HBV carriers and cirrhosis patients is elevated to a small extent, its sensitivity and specificity in detecting HCC remain as high as 74.6% and 97.4% when the cut-off is at 35 ng/ml [73]. The meta-analysis also reported that GP73 has the best diagnostic value for HCC among different biomarkers [74]. GP73 is also a promising therapeutic target for HBV-associated HCC patients [75].

Circulating tumor cells to predict HCC

Circulating tumor cells (CTCs) are cells isolated from tumors that travel in the circulation. Some CTCs can survive the attack by immune cells and then reach distant metastatic sites. Well-characterized CTCs are direct proof of the presence of cancer, but the isolation of CTCs is not easy. Standard techniques to isolate CTCs in related research utilize cell size, density, and immunogenicity to carry out positive and negative enrichment [76]. Since there is no universal surface marker for CTCs due to their heterogeneity, there is not yet a “golden standard” method for isolating CTCs [77]. Some CTC purification platforms allow the capturing of CTCs and then proceeding for subsequent downstream analysis, such as NGS and in situ hybridization [78].

Efforts to isolate CTCs for cancer diagnosis have been ongoing for decades. A study conducted by [79] revealed that CTCs were only present in patients with HCC but were not found in patients with CLD, cirrhosis, or healthy individuals [79]. The sensitivity is about 52%. With the advancement in the CTC capturing technology, a group from China can capture CTCs from 90.18% of patients from a cohort of 112 HCC patients with a new RNA-in situ hybridization-based platform [80]. Among the patients with HBV, two patients were detected with CTCs, which eventually developed into HCC within half a year, demonstrating its potential for diagnosing undetected tumor nodules. A study using nine candidate genes as a multi-marker panel detecting CTCs with stem-like properties in peripheral blood [81]. CD45 cells were depleted by negative enrichment, RNAs were extracted directly from the remaining sample, and qRT-PCR was performed to measure the gene expression levels. The CTC panel has an AUC of 0.88 and a sensitivity of 72.5% for detecting HCC, while the performance is also good considering early-stage HCC or AFP-negative HCC.

The current consensus on CTC isolation focuses on EpCAM+/CK+/CD45− cells [82]. EpCAM-based detection of CTCs has been employed in HCC diagnosis. Techniques like CellSearch™, an immunoaffinity-based CTC enrichment platform, have isolated CTCs in HCC patients. EpCAM+ CTCs are detected in two-thirds of HCC patients [83]. In 2014, a platform was developed by negative enrichment of CTCs, followed by quantitative PCR. It showed a three-forth consistency with the CellSearch™ system [84].

CTC profiling is an essential aspect of liquid biopsy; nevertheless, its importance in cancer diagnosis is not as high as its role in recurrence, therapeutic response, or oncology research [85]. Very few CTCs are found in the bloodstream, and their quantity is proportional to the tumor size. This makes detecting CTCs in early-stage diseases quite challenging [86]. It is almost not practical to isolate CTCs in clinical settings for the diagnosis of cancer. Instead, specific cancer-related genes in CTCs, or CSCs, are amplified and detected by reverse transcription PCR as the easiest method. The main objective of current CTC research is to enhance the sensitivity and specificity of CTC detection to achieve accurate and comprehensive molecular characterization. CTCs are not exact copies of each other but come from different tumor parts and can change under various conditions. Tumor cells in different parts of the body can also vary. Liquid biopsy using CTCs is not just a less invasive biopsy but a new way to understand tumor cells throughout the body. Since CTCs are released from the primary or distant metastatic tumors, the genetic makeup of these cells reveals information about the heterogeneity, mutations, and potential resistance to treatments. Research has shown that primary and metastatic tumors are processing high heterogeneities [87, 88]. CTC detection and isolation can help precision medicine by finding molecular characteristics and markers for targeted therapy. Furthermore, CTCs can be isolated from patients’ peripheral blood and cultured in vitro to become organoids. The tissue culture can be applied for drug response testing, checking the cellular signaling, and stimulating therapeutic strategies. It is also beneficial for new drug development.

Using cell-free DNA / circulating tumor DNA to detect HCC

Cell-free DNAs (cfDNAs) refer to nucleic acid content in the circulation, usually released from dead cells as regular cell turnover or pathologies [89, 90]. CfDNA is present in normal humans and majorly comes from blood cells [91]. Different from CTC analysis, before cfDNA analysis, all cells are removed from the peripheral blood. In patients with cancer, tissues and organs undergo uncontrolled cell deaths, which will release large amounts of nucleic acids into the circulation, contributing to the ctDNA. Since ctDNA originated from tumor cells, analysis of ctDNA content can show a collection of heterogeneous tumor cells that carry the mutations and epigenetic patterns of the tumor. Also, macrophages engulf some CTCs, releasing the nucleic acids to be cfDNA. So, ctDNA is usually regarded as fragmented DNA from tumor tissues and as part of the cfDNA content. The proportion of ctDNA in total cfDNA can differ substantially, from less than 1% to more than 90% [92]. In general, patients with HCC have higher ctDNA levels in the circulation, which is also an indicator of tumor burden. More published research has provided molecular profiling of HCC ctDNA, and its role in the screening and early detection of HCC is an emerging trend. A systematic review analyzed 15 studies with 3,686 patients, and the pooled sensitivity and specificity of using cfDNA to predict HCC is 0.83 and 0.90, while the AUC is 0.93 [93]. The following part will discuss the applications and pros and cons of ctDNA as a detection tool.

Peripheral blood is the most frequent source for extracting cfDNA, although it can also be detected in other fluids such as saliva, ascites, and urine. There is an ongoing discussion about whether to extract cfDNA from serum or plasma, with some research indicating higher concentrations in serum due to contamination from blood cell lysis. However, plasma is generally the preferred sample in most investigations [94, 95]. Storing and extracting cfDNA necessitates specialized methods because of its short half-life, with plasma separation recommended within six hours using EDTA tubes [96]. The technology of capturing cfDNA from circulation has been improved. Theoretically, ctDNA can carry the whole genome from tumor cells, providing valuable information about the mutational profiles and heterogeneity. The FDA approved a recently marketed product that analyzes patients’ blood samples for alterations in 47 genes [97]. This product is designed to detect genetic mutations that may potentially lead to certain cancers, including HCC.

Detecting cfDNA requires highly sensitive and specific techniques, which can identify various DNA-based changes that reflect the DNA status in cancer cells. The most simple tool to check the presence of ctDNA or carried mutations is quantitative PCR (Table 1). However, this is limited to relatively higher concentrations of cfDNA, and the heterogeneity of HCC may affect the significance. Bisulfite conversion is widely adapted to convert unmethylated cytosines to uracil to detect methylation on the HCC-associated genes, resulting in a difference in the DNA sequence between methylated and unmethylated regions. While digital droplet PCR offers high precision and sensitivity, it cannot cover an extensive range of sequences, making NGS more appropriate for multiple gene profiling [98, 99]. Target sequencing, whole exome sequencing [100], or ultra-deep sequencing are usually adapted in molecular biology research to study the profiling or mutation patterns within the cfDNA. Despite this, the sensitivity and specificity of NGS may be hindered by the mistakes of DNA polymerase and amplification reactions, so molecular barcoding approaches are used to identify the correct gene alterations [101] accurately. Since the cost of utilizing NGS to screen for ctDNA is high, custom-designed sequencing panels or low-depth whole-genome sequencing approaches appear to facilitate the screening [101, 102].Table 1 Summary of selected research output on cfDNA related to diagnosis and prognosis of HCC

	Marker	Description	Ref.	
1	TERT promoter	- Modified droplet digital polymerase chain reaction

G > A TERT mutation at -124 bp was found in the blood of 69% of patients. Patients with a mutation have shorter DFS (p = 0.02). Risk of disease recurrence was about three times higher in patients with the mutation (p = 0.03).

	[98]	
2	With liver MRI	- NGS of cfDNA from plasma, combined with liver MRI

cfDNA was found in the blood of 36 patients with cirrhosis, and NGS detected 20 different genetic variants. Specific HCC-related gene mutations in cfDNA could help identify patients with LC at increased risk of developing HCC.

	[103]	
3	139 somatic mutations	- Custom-designed sequencing panel with 354 target genes

Number of mutations, variant allele frequency, and concentration of ctDNA linearly correlated with tumor size. Patients with mutations experienced shorter DFS, and increased the risk of recurrence (HR = 7.655, p < 0.0001). Status of cfDNA increases risk of recurrence (HR = 10.293, p < 0.0001).

	[101]	
4	5-HMC signature	- Genome-wide 5-HMC sequencing of cfDNA

Distribution pattern of 5-HMC regions can differentiate HCC patients, LC patients, and healthy volunteers. HCC score combined with protein biomarkers, achieves 92.75% accuracy in distinguishing HCC patients from LC patients. HCC score is effective in identifying high-risk patients for recurrence after surgery and serves as an independent indicator for RFS (p = 0.00865) and OS (p = 0.000739). HCC score values are positively correlated with tumor burden changes during follow-up.

	[104]	
5	CNVs and SNVs	- Target sequencing and low-coverage whole-genome sequencing

Plasma samples before surgery displayed genetic variations that matched the patients’ tumor tissues, and these variations changed during follow-up, correlating with tumor burden. A strategy using comprehensive ctDNA mutation profiles was developed to accurately assess tumor burden, showing high consistency with imaging results. This approach detected tumor occurrence an average of 4.6 months earlier than imaging and outperformed serum biomarkers like AFP, AFP-L3%, and Des-Gamma-Carboxy Prothrombin (DCP). It was effective in detecting minimal residual disease (MRD) and predicting patients’ outcomes for RFS (p = 0.001) and OS (P = 0.001); combining ctDNA with DCP further improved MRD detection sensitivity.

	[105]	
6	160 SNVs	- Target sequencing and whole exome sequencing

160 subclonal SNVs were identified in tumor tissues, peritumor tissues, and matched PBMCs, with 96.9% of these mutations also found in plasma samples. Two clusters of SNVs are related to cancer progression. Circulating levels of tumor stem somatic mutations could reflect tumor burden and predict prognosis earlier than traditional methods. HCK (p.V174M) mutation was identified as being associated with tumor recurrence and metastasis and was found to promote the migration and invasion of HCC cells.

	[100]	
7	TP53, CTNNB1	- Customized cfDNA next-generation sequencing panel

In 65% of patients, at least one pathogenic variant was found in two major HCC driver genes, TP53 and CTNNB1. There were 16 variants of TP53 and nine variants of CTNNB1 identified. The identified variants in TP53 and CTNNB1 genes are crucial in understanding the genetic basis of HCC and may help in developing targeted therapies.

	[106]	
8	Mutation variant frequency change (MVFC)	- Unique molecular identifier target sequencing on plasma and PBMCs

Plasma mutations with MVFC < 0.2 were found to be enriched for tumor mutations identified in tumor tissues, and their frequency changes correlated with tumor burden. The presence of MVFC-identified tumor mutations after surgery was associated with shorter RFS, indicating MRD. Combining MVFC-identified tumor mutations and AFPimproved MRD detection (P < 0.0001). The MVFC-based identification of tumor mutations was confirmed to be applicable using a different gene panel, highlighting its potential utility in monitoring and predicting HCC outcomes.

	[107]	
9	Serum DNA integrity	- Real-time quantitative polymerase chain reaction

The Triton/Heat/Phenol method was deemed effective to extract quality DNA. The integrity of serum DNA in HOC patients was significantly higher than in HBV patients or healthy individuals. The integrity of DNA was linked to factors such as tumor size, TNM stage, and the presence of lymph node and distant metastasis.

	[108]	
10	TERT promoter, TP53, CTNNB1, ARID1A, TSC2, etc.	- NGS assay with 129 validated genes

Genomic alterations were found in 92.2% of advanced HCC patients, with common mutated genes including TERT promoter, TP53, CTNNB1, ARID1A, and TSC2. Paired tumor NGS was conducted on 37 patients, showing high concordance in mutations between patient-matched plasma samples. In 27% of tumor-plasma samples, alterations were detected in cfDNA analysis but not in patient-matched tumors. Higher average variant allele fraction correlated with elevated AFP, increased tumor volume, and no previous systemic therapy, but not with OS in treatment-naive patients.

	[109]	
11	TERT promoter C228T, TP53, CTNNB1, PIK3CA, NRAS	- Droplet digital PCR

TERT mutation occurs in all patients with one or more ctDNA mutations. Maximal VAF is linearly correlated with larger tumor size and AFP level. ctDNA correlated with poor OS.

	[110]	
12	GPBAR1	- Methylation-specific polymerase chain reaction

Hypermethylation of the TGR5 promoter is significantly higher in HCC than CHB and HCs (p < 0.01). Increased sensitivity when combined with AFP

	[111]	
13	TERT promoter, TP53, CTNNB1, AXIN1, ARID1A	- Ultra-deep sequencing targeting HCC driver genes

Patients who had more than 2 ng/mu L of cfDNA at diagnosis experienced higher mortality rates (p = 0.01). These patients had a higher number of mutated genes and more mutations in cfDNA, and associated with disease recurrence (p < 0.01). Patients with more than four mutations detected in cfDNA were at a higher risk of death (p = 0.042).

	[112]	
14	UBE2Q1	- Methylation-specific polymerase chain reaction assay

Lower methylation frequencies of UBE2Q1 from the circulating cfDNA was found in HBV-related HCC patients, compared with LC, CHB and HCs (p < 0.05). Combining with AFP increases sensitivity and specificity.

	[113]	
15	cfDNA integrity	- Quantitative PCR of ALU amplicon

cfDNA integrity lower in patients with HCC or other liver cancers, but higher in benign diseases and healthy individuals

	[114]	
16	TP53, CTNNB1, TERT promoter	- Droplet digital PCR

More than half of the patients were found to have at least one of the four genetic mutations. None of the mutants were detected in adjacent liver tissues among the matched tumour tissues.

	[115]	
17	INK4A	- Pyrosequencing on the CpG sites of the INK4A promoter

Hypermethylation on INK4A in HCC than controls detected in the circulating cfDNA.

	[116]	
18	CTNNB1, TP53, NFE2L2, ARID1A	- Targeted sequencing of cancer associated genes

Mutations are detected in majority of the HCC patients, and it does not affect the cfDNA concentrations. Higher cfDNA and mutation rates associated with shorter OS (p < 0.001).

	[117]	
19	Methylation fingerprint panels	- Genome-wide DNA methylation analysis

The study identified three panels: cancer-specific biomarker panels, a pan-GI panel, and a multi-cancer prediction panel, with high AUC values ranging from 0.85 to 0.98 for detecting various gastrointestinal cancers.

	[118]	
20	RNF135, LDHB	- Methylation Sensitive High-Resolution Analysis

Combined RNF135 and LDHB analysis has a sensitivity of 57% on HCC, compared with AFP at 45%. When combined with HCC, the sensitivity is 70%.

	[119]	
21	cfDNA concentration and integrity	- Real-time quantitative PCR

HCC patients have higher level of cfDNA in serum than CLD and healthy controls. Increased DNA fragmentation and poor DNA integrity.

	[120]	
22	HRNR, TTN	- Whole-exome sequencing of cfDNA

Single nucleotide variations were present in somatic genes in cfDNA, including in ZNF814, HRNR, ZNF492, ADAMTS12, FLG, OBSCN, TP53, and TTN. Level of cfDNA is higher in patients with HCC than chronic hepatitis patients.

	[121]	
23	TERT promoter, TP53, NTRK3, JAK1	- Ultra-deep sequencing of all exons

Mutations are detected in plasma cfDNA from plasma/serum samples of HCC patients.

	[122]	
24	TERT promoter, TP53, CTNNB1, ARID2, ARID1A, NFE2L2, AXIN1, KRAS	- Targeted sequencing with ultra-high coverage and molecular barcoding

About half of the HCC patients have at least one mutations, and rate s are higher in advanced stages. TP53 has the worst survival, whereas CTNNB1 and TERT does not affect survival. Combining AFP and prothrombin improved detection rate.

	[123]	
25	GNB4, Riplet	- Methylation-specific polymerase chain reaction

Significantly higher CTCs in HCC compared with HBV patients. GNB4 and Riplet methylation were different, and is able to diagnosis HCC at 0.98 when combined with CTCs.

	[124]	
26	TERT promoter, CTNNB1, TP53	- MiSeq for targeted deep sequencing

Mutations associated with vascular invasion (p = 0.04), predict shorter RFS for HCC patients (p < 0.001).

	[125]	
27	Wnt signaling pathway	- QUADAS-2 tool

Hypermethylation of Wnt/Beta-catenin signaling pathway is correlated with tumor size, TNM stage, distant metastasis, and HBV infection (p < 0.05).

	[126]	
28	TERT promoter, TP53, CTNNB1	- Ultradeep sequencing of cfDNA

High levels of cfDNA showed worse PFS and OS. Mutations combined with AFP can stratify the prognosis of HCC patients.

	[127]	
29	TERT promoter	- QuantStudio 3D Digital PCR

Mutation is associated with tumor diameter (p = 0.015), and tumor volume after TACE (p < 0.001). Higher cfDNA levels predict better PFS with TKI initiation (p = 0.004).

	[128]	
30	TERT promoter	- qPCR and Droplet digital PCR

cfDNA increases with HCC stage, and associated with poor prognosis. Greater cfDNA is associated with better therapeutic response to treatment.

	[129]	
31	Fragment length profiles	- Next generation sequencing

The fragment length profiles can differentiate ctDNA from white blood cells, non-tumor cells, and heterogeneous mutations.

	[130]	
32	ctDNA and mutations	- Whole exome sequencing

ctDNA increase with disease progression. ctDNA positive predicts recurrence and extrahepatic metastasis (p = 0.01), and vascular invasion of portal vein.

	[131]	
33	CTNNB1	- Droplet digital PCR

Detection rate of HCC by CTNNB1 mutation is 9.5%, and 13.5% when tumor tissues are combined. Mutation is not related to OS.

	[132]	
34	Alu247	- Quantitative PCR

HCC cases have higher level of Alu247 and RNase P coding DNA than controls (HBeAg-negative CHB patients). No difference in cfDNA concentration, Alu115, integrity index, and mitochondrial DNA copies.

	[133]	
35	TP53, CTNNB1, AXIN1, TERT promoter	- HCC screen

Identify HCC from HBsAg+ patients by combining somatic mutations detected in cfDNA with serum AFP levels. Sensitivity 100%, specificity 94%, PPV 17%.

	[134]	
36	Somatic copy number aberration	- Low-depth whole-genome sequencing

Machine learning based statistical model to analyse copy number variation in ctDNA, with AUC of 0.92.

	[102]	
37	TP53 R249S	- Mass spectrometry and quantitative PCR from cfDNA

Seasonal fluctuation in R249S levels, higher concentration in HBsAg+ individuals from April to July.

	[135]	
38	Aberrant DNA methylation	- DNA methylation-based digital droplet PCR

Level of cfDNA is higher in patients with HCC than HC. Methylation ratio cut-off at 15.7% has an sensitivity of 78.57% for predicting HCC.

	[136]	
39	GSTP1	- Quantitative PCR

88.5% tumour tissues, 69% non-tumor tissues, 50% ctDNA samples, were exhibiting GSTP1 promoter CpG island hypermethylation. No PBMC samples tested positive for methylation.

	[137]	
40	Mutation and methylation panel	- Mutation Capsule Plus

90% sensitivity with 94% specificity, detected four out of five HCC cases from a cohort of 311 asymptomatic HBV carrier with normal ultrasound diagnosis and AFP level.

	[138]	
41	931 mutation sites across 21 genes	- Circulating Single-Molecule Amplification and Resequencing Technology

Sensitivities of 81.25% for all stages and 66.67% for early HCC. High accuracy in differentiating AFP-negative, AFP-L3-negative, and PIVKA-II-negative HCC.

	[139]	
42	Panel of HCC mutations	- Next generation sequencing

AUC 0.92, sensitivity 65%, specificity 100% regardless of AFP status. Rate of mutations is greater in recurrent HCC than non-recurrent (p < 0.05).

	[99]	
43	Methylation, mutations and protein-HCC	- M2P-HCC

M2P-HCC is an independent predictor of HCC risk. AUC 0.88, combining AFP and ultrasound, yield inferior performance.

	[140]	
44	TP53, CTNNB1, TERT promoter, RASSF1A	- Urine cfDNA detection by quantitative PCR

Significant quantities of ctDNA detected in urine samples. ctDNA marker detection independent of serum AFP. Combining AFP yield AUC of 0.904.

	[141]	
45	NLRP7, NLRP2, NLRP3	- Whole-genome bisulfite sequencing

Hypomethylation of programmed-cell death genes (PRGs) including NLRP7, NLRP2, and NLRP3 in HCC tissues; NLRP3 methylation levels correlated with expression level (r = 0.51). Hypomethylated PRGs can discriminate between early HCC patients and healthy controls in cfDNA analysis (AUC = 0.94), and associated with poor HCC prognosis.

	[142]	
46	Intergenic and repeat reigons of HBV integration sites	- Low-pass genome-wide bisulfite sequencing

Significant enrichment of cfDNA in intergenic and repeat regions, especially in HBV integration sites. Hypomethylation only in HCC but not in hepatitis and cirrhosis patients. AUC value > 0.85 and a prediction performance of 0.954 in the validation cohort.

	[143]	
47	GNB4, Riplet	- Whole genome bisulphite sequencing

Combining methylation of GNB4 and Riplet in plasma cfDNA, sensitivity, specificity, and AUC are 84%, 92%, and 0.92, superior to AFP.

	[144]	

In particular, the TERT promoter is the most common mutation in HCC. Many studies have reported that the TERT promoter mutation is associated with HCC occurrence, recurrence, and poorer survival [98, 109, 112, 125]. Apart from TERT promoter, other commonly reported mutations such as CTNNB1, TP53, AXIN1, KRAS, ARID2, etc., are also detected in cfDNA, and their presence and association with HCC development are almost the same as somatic cell mutations [101, 106, 109, 112, 123]. Besides single gene mutations, abnormal methylation on oncogenes or tumor suppressor genes is also related to oncogenesis. For example, a study uses a newly developed methylation-sensitive high-resolution analysis (MS-HRM) platform to detect the methylation levels of RNF135 and LDHB [119]. The sensitivity of the combined MS-HRM is 57%, which is better than 45% of AFP from the same cohort. When combined with AFP, the sensitivity is as high as 70%. The details of detectable methylations are discussed in the later section.

In addition, several research groups have reported single-nucleotide variants (SNVs) and copy number variants (CNVs) related to HCC in cfDNAs. Cai et al. utilized low-coverage whole-genome sequencing to perform a targeted sequencing that can check the genetic profiles of the cfDNAs from HCC patients [105]. They found that SNVs and CNVs information from ctDNA and corresponding serological biomarkers, including DCP at the cut of of 20 ng/mL, can predict clinical outcomes and detect HCC with satisfactory sensitivity (p < 0.0001).

Besides, DNA integrity has also been considered a biomarker for HCC in recent research. DNA with shorter lengths preferentially carrying the tumor-associated CNVs. Also, it is more likely to detect high levels of mitochondrial DNA in the cfDNA from HCC patients [145]. Huang et al. also reported similar findings, that cfDNA integrity is reduced in patients with HCC, and it is promising to be a biomarker for detecting HCC in surveillance with a sensitivity of 43.4% and AUC of 0.705 [114]. The cfDNA integrity is lower than those with benign nodules and healthy controls. Also, patients with HCC or other types of liver cancer have comparable cfDNA integrity (p = 0.7356) as those without tumors (p = 0.9138). CfDNA fragmentation is a nonrandom process where cfDNA fragments with specific genetic endings likely originate from HCC [146]. Detection of the tumor-associated endings, which are prevalent across the genome, may provide a simple but effective method for identifying the presence of tumors through serological surveillance.

Besides circulating isolated nucleic acids, genetic materials in plasma exosomes are also a new potential diagnostic target for HCC [147]. For instance, circular RNA Circ0006602 is one of the five circRNAs found to be up-regulated in the plasma exosomes of HCC patients compared with healthy individuals. As a diagnostic marker, the AUC of exosomal Circ0006602 to HCC patients was 0.907, with a p-value of < 0.001. The sensitivity is 77.70%, with a high specificity (93.3%) [148]. In another recent study, high-throughput sequencing was used to analyze the exosomal miRNA levels isolated from patients’ HCC tissues. After cross-validation with plasma exosomes, miR-483-5p was identified to have the power to differentiate individuals with or without HCC (AUC = 0.898), which is slightly better than the plasma miR-483-5p counterpart (AUC = 0.868) [149]. The sensitivity is, though, similar to AFP, at around 80–85%, with the specificity at 90.38%. Similar research also reported that other miRNA candidates (miR-122-5p, let-7d-5p, and miR-425-5p) had HCC early diagnostic power (AUC at 0.660 to 0.808) [150]. These studies suggest that serum exosome-derived small RNAs are potential biomarkers for HCC diagnosis in clinical settings.

Similar to CTCs, the utilization of ctDNA in clinical applications encounters obstacles. Identifying ctDNA among a large pool of cfDNA originating from other cell types presents technical difficulties. Furthermore, it remains uncertain if ctDNA can precisely reflect the genetic composition of fast-growing and highly mobile tumor cells. This is because ctDNA may overrepresent DNA from “weakened” tumor cells that are more susceptible to cell death, subsequently releasing their genetic materials into the blood. Further studies are still required in this field to optimize the full use of ctDNA as a surveillance tool.

Presence of non-coding RNAs in HCC patients

Aside from genetic modifications found in genomic DNA or cDNA, ncRNAs circulating in the bloodstream can also possess diagnostic significance. MiRNAs are short ncRNAs at about 22 bases long, and their function is to regulate gene expression in cis or trans. Given their involvement in genetic regulation, profiling circulating miRNAs holds promise as a non-invasive marker for human cancers.

In a study recruiting 513 subjects, miRNA profiles were obtained by NGS. A thirteen miRNA-based biomarker panel can differentiate clearly between HBV, HCV, and HBV-positive HCC cases [151]. Two miRNA candidates, miR-375 and miR-92a, are novel identified targets as HBV-specific miRNAs. A trio biomarker miR-25, MiR-375, and let-7f can significantly discriminate HCCs from controls, where miR-375 alone has an AUC of 0.96. Another study by Chen et al. demonstrated that the dual biomarker of miRNA-30b-5p and MINPP1 can detect HBV-positive HCC [152]. The level of MINPP1 signifies the tumorigenesis of HBV-positive patients, whereas miRNA-30b-5p can regulate the expression of MINPP1.

Sometimes, a single miRNA might not differentiate between progressive liver diseases and HCC. An analysis of miRNA expression in 168 subjects revealed intriguing miRNA expression trends in patients infected with HCV. MiR-484 demonstrated a decrease in advanced fibrosis compared to mild fibrosis and HCC, but it increased HCC relative to cirrhosis [153]. In addition, miR-524-5p showed an increase in both cirrhosis and HCC, while miR-615-5p was found to be increased in the cirrhotic group relative to the control group. Notably, miR-524 displayed considerable potential in distinguishing between cirrhosis and fibrosis. These miRNAs under study may potentially be helpful in the staging and diagnosing of HCV hepatic progression, providing a significant understanding of the disease.

In a recent scientific publication, investigators presented a process that employs DNA molecular markers to convert gene expression profiles into clinical assessments [154]. Remarkably, this approach precisely categorized HCC patients and healthy individuals using only five miRNAs obtained from blood specimens, including miR-1290, miR-4370, miR-1203, miR-221-3p, and miR-4258.

Recent findings revealed that circular RNA (circRNA) is also associated with tumor development [155, 156]. A study delved into the expression patterns of circRNAs in HCC, identifying circMTO1 as a significantly downregulated circRNA with implications for patient survival [157]. The author concluded that circMTO1’s function in suppressing HCC progression positions it as a potential drug target in HCC treatment, and its decreased presence may serve as a prognostic marker for poor patient outcomes. Besides, circSETD3 is recognized as a novel tumor suppressor of HCC and is a significant prognostic biomarker [157]. CircSETD3 can suppress the growth of HCC through the MAPK signaling pathway, and its downregulation is associated with unfavorable outcomes of HCC.

LncRNA, on the other hand, has a quite different role in tumorigenesis. They are RNA molecules with more than 200 nucleotides and have no protein-coding or potentials or only peptide-coding. They interact with oncogenes or tumor suppressor genes through epigenetic regulation and transcriptional activation or as sponges to silence miRNAs. Some lncRNAs also have a role in post-transcriptional regulation or modulating signaling pathways. It is a relatively new field to use lncRNAs as biomarkers of HCC detection, but some research articles also have significant findings. A review article 2018 discussed some findings on lncRNA as a biomarker of HCC [158]. There are indeed some reports worth mentioning in recent years. For instance, Liu et al. utilized an ultrasensitive strategy, an electrochemical nucleic acid sensor, to detect the expression of a lncRNA Highly up-regulated in liver cancer (HULC) [159]. HULC is highly expressed in patients with HCC, and its level can differentiate between HCC and control individuals [160]. Its level is also different between the HBV-positive group and the control group. Besides, research is now focusing on extracellular vesicle-derived lncRNAs as biomarkers of HCC. EV-LINC00853 displayed outstanding diagnostic ability for all-stage HCC, with higher sensitivity and specificity than AFP, particularly in early-stage and AFP-negative HCC, suggesting its potential as a novel diagnostic biomarker [161]. Another study indicated that serum small EV-derived lncRNAs, specifically EV-DLEU2, EV-SNHG1, EV-MALAT1, and EV-HOTTIP, show promising diagnostic potential for initial-stage HCC, with combined panels achieving the best results [162]. With the appearance of EV-lncRNA sequencing technology, bioinformatics approaches were introduced to analyze the potential lncRNA that can be HCC detection biomarkers. A panel of eight EV-lncRNA was identified as potential biomarkers [163]. However, further experiments are needed to validate those candidates.

Due to the lack of extensive clinical validation, ncRNAs are not being used as a detection biomarker in HCC. However, it is a valuable future research direction in diagnosing cancers because miRNA is closely related to regulating genes, especially cancer-associated genes. This can provide additional insights into the genetic makeup of the potential HCC tumors in patients with liver diseases.

Altered methylation patterns related to HCC occurrence

Apart from typical genetic mutation patterns that traditional sequencing or PCR methods can detect, epigenetic regulations on the genome also have an essential role in tumor development. Methylation is a process by which methyl groups (-CH3) are added to the DNA molecule, typically at the cytosine-guanine (CpG) dinucleotide sequences. This can change the activity of a DNA segment without changing the sequence itself. The most crucial aspect of methylation in regulating gene expression is the hypermethylation of tumor suppressor genes. And hypomethylation of oncogenes. Abnormal DNA methylation patterns can contribute to the development of cancers. Therefore, the methylation status of specific genes and their significance as a cancer biomarker has been heavily studied in recent years, with the advancement of detection technology [164] (Table 2).Table 2 Summary of selected research output on detection of HCC using methylation patterns

	Marker	Blood-based	Description	Ref.	
1	RASSF1A	+	Mean rate of 30% and 65% methylation in HCV-related cirrhosis and HCC tissues respectively	[165]	
2	RASSF1A		Mean rate of 26.1% and 59.1% methylation in cirrhosis and HCC tissues respectively	[166]	
DOK1		Mean rate of 19.6% and 56.0% methylation in cirrhosis and HCC tissues respectively	
3	RASSF1A	+	Mean rate of 70% methylation on top of HCV-associated cirrhosis, with serum AFP combined to improve sensitivity	[167]	
4	RASSF1A	+	Hypermethylated sequences in 93% of HCC, 58% of HBV carriers, and 8% of the healthy individuals

High RASSF1A at diagnosis or 1-year after resection relates to poor prognosis (p < 0.01)

RASSF1A increase after cancer diagnosis (p < 0.014)

	[168]	
5	CHFR, VASH2, GRID2IP, CCNJ, F12 CpG sites	+	HCC detection sensitivity was 84.5% at 95% specificity and 0.94 AUC using the count of methylated reads on combined specific genes.	[169]	
6	WISP1	+	Hypomethylation, increased plasma soluble WISP1 improved diagnostic power combining with AFP	[170]	
7	Six hypermethylated CpGs sites		A combination of six hypermethylated HCC-specific CpGs sites has a 92% sensitivity predicting HCC, and 98% specificity differentiating from normal liver or other cancers	[171]	
8	Long interspersed element-1 (LINE-1)	+	Global hypomethylation measured in LINE-1 repeats in blood leukocytes DNA correlates with elevated risk of HCC (p = 0.004)	[172]	
9	RASSF1A sequence	+	Higher methylation in HCC (64.2%) than patients with LC (17.5%), CHB (5.0%) and healthy individuals (0).

Associated with a worse OS (p < 0.05)

	[173]	
10	CDH1, DNMT3b, ESR1 promoter	+	Higher methylation in HBV-related HCC compared with LC, CHB and NC.

Combined methylation is a better diagnostic marker than AFP.

	[174]	
11	RASSF1A, E-Cadherin, RUNX3	+	Hypermethylation in HCC higher than cirrhosis and healthy group (p < 0.001).

RASSF1A and E-Cadherin were predictors of HCC within cirrhosis cases.

	[175]	
12	Methylated p16	+	Methylated p16 is higher in HCC than CHC, cirrhosis and healthy subjects

Higher in patients with normal AFP than higher AFP

	[176]	
13	TLX1, GALR1, ZNF154	+	Multi-cancer methylation biomarkers combining three methylation markers have a sensitivity and specificity of 37.3% and 83.3% on HCC respectively.	[177]	
14	38 DNA methylation regions	+	Machine learning method for systematic analysis with a 96% of sensitivity and 98% of specificity in an independent training cohort.	[178]	
15	Enzymatic methyl sequencing	+	Sequencing utilizing enzymatic conversion of unmethylated bases as a screening model to distinguish HCC patients from non-HCC individuals	[179]	
16	TGR5	+	Hypermethylation of the TGR5 promoter is significantly higher in HCC than CHB and HCs (p < 0.01)

Increased sensitivity when combined with AFP

	[111]	
17	RASSF1A promoter		Hypermethylation of RASSF1A in HCC, but not NC. Reduced RASSF1A is related to TNM stage, metastasis, AFP, portal vein embolus, capsular infiltration, and multiple tumor nodes.	[180]	
18	UBE2Q1	+	Hypomethylation of UBE2Q1 in HCC than LC (p = 0.026), CHB (p = 0.006), and HCs (p = 0.011). Negatively associated with TNM stage. Increase sensitivity with AFP combined.	[113]	
19	SEPT9	+	Increase methylation of SEPT9 in HCC than at-risk and healthy individuals (p < 0.0001)	[181]	
20	INK4A	+	Hypermethylated INK4A in HCC than controls	[116]	
21	ELF, RASSF1A, p16, GSTP1		Hypermethylation in tumor than non-tumor tissues (p < 0.05), and also combined markers (p < 0.001). Increase sensitivity with AFP combined	[182]	
22	APC, GSTP1, FASSF1A, SFRP1	+	Hypermethylation in all four genes in HCC than normal or benign controls.

Methylated RASSF1A is a prognostic marker of overall survival.

	[183]	
23	APC		Methylation status of APC complement with AFP to predict HCC	[184]	
24	MT1M and MT1G	+	Hypermethylated MT1M and MT1G in HCC than CHB and NC group (p < 0.001), with a specificity of 94.6%.

MT1M promoter methylation positively correlates with tumor size (p < 0.001), and metastasis when combined with MT1G.

	[185]	
25	P16	+	P16 methylation increases from benign liver disease to HCC progression.	[186]	
26	HOXA1, TSPYL5, B3GALT6	+	The multi-target HCC blood test utilized three methylation markers and demonstrated high concordance (> = 97%) to predict HCC without significant interference observed.	[187]	
27	Methylation Fingerprint Panel	+	The study identified three panels: cancer-specific biomarker panels, a pan-GI panel, and a multi-cancer prediction panel, with high AUC values ranging from 0.85 to 0.98 for detecting various gastrointestinal cancers.	[118]	
28	RNF135, LDHB	+	Combined RNF135 and LDHB methylation level analysis has a sensitivity of 57% on HCC, compared with AFP at 45%. When combined with HCC, the sensitivity is 70%.	[119]	
29	SEPT9	+	A significantly higher copy number of methylated SEPT9 was observed in the HCC group than in the control group (p < 0.001)	[188]	
30	SEPT9	+	SEPT9 methylation pattern is a better predictor than serum AFP for diagnostic performance.	[189]	
31	IGFBP7	+	Frequency of serum IGFBP7 promoter methylation is higher in HCC than in CHB and HC controls (p < 0.001).	[190]	
32	GNB4, Riplet	+	Circulating tumor cells combined with methylation patterns have a sensitivity of 88.2% and an AUC value of 0.98.	[124]	
33	CCND1	+	The methylation status of the CCND1 promoter outperforms serum AFP in both AUC and specificity to predict HBV-HCC versus CHB.	[191]	
34	SOX1, VIM	+	Higher frequency of SOX and VIM promoter methylation than LC, CHB, and HC subjects (p < 0.001).	[192]	
35	LINE-1, RASSF1A	+	LINE-1 was hypomethylated in 66.7% and RASSFIA promoter was hypermethylated in 73.3% of HCC serum.

Associated with HBsAg positivity, tumor size, AFP, and lymph node metastasis.

	[193]	
36	BARD1, MAGEB3, BRUNOL5, FXYD6, TET1, TSPAN5, DPPA5, KIAA1210, and LSP1	+	Neighboring CpG sites on 9 genes are predictable for prospective HCC development from HBV-negative cirrhotic patients.

DPPA5, KIAA1210, LSP1 are hypermethylated, while BARD1, MAGEB3, BRUNOL5, FXYD6, TET1, TSPAN5 are hypomethylated, compared with controls.

	[194]	
37	EXO1		DNA methylation status in five CpG islands of the EXO1 gene was associated with the prognosis of HCC	[195]	
38	Wnt/beta-catenin signaling pathway	+	Hypermethylation of Wnt/Beta-catenin signaling pathway is correlated with tumor size, TNM stage, distant metastasis, and HBV infection (p < 0.05).	[126]	
39	SEPT9	+	Serum methylated SEPT9 test has a high diagnostic accuracy for HCC on cirrhotic patients (AUROC 0.944, p < 0.0001), and is the only variable associated with HCC diagnosis in this cohort.	[196]	
40	RASSF1A, SOCS1	+	RASSF1A and SOCS-1 methylation were detected in 40% and 38% of HCC patients. RASSF1A/SOCS-1/AFP panel detects HCC at sensitivity of 86% and specificity of 75%.	[197]	
41	CCND2	+	CCND2 methylation is significantly higher in HCC patients (p < 0.001). Advanced HCC is associated with higher CCND2 methylation and lower CCND2 mRNA levels than early-stage disease.	[198]	
42	GSTP1	+	Higher GSTP1 promoter region methylation frequency in pre-ACHBLF patients compared to CHB and HCs. Lower GSTP1 mRNA levels in pre-ACHBLF patients. Increased ACHBLF incidence in pre-ACHBLF patients with methylated GSTP1.	[199]	
43	MAGE-A1, MAGE-A3		Different methylation patterns in several CpG sites among the MAGE-A1 and MAGE-A3 promoters in HCC cells. Clinical sensitivity and specificity were 91.2% and 100%.	[200]	
44	KLHL35, PAX5, PENK, and SPDYA		These genes are significantly more highly methylated in HCC than in non-cancerous liver tissue, irrespective of the hepatitis virus status. LINE-1 hypomethylation was prevalent in HCC.	[201]	
45	A1AT, SERPINA1	+	More fully-methylated SERPINA1 promoters in control than HCC samples, and higher hemimethylation in stage I compared to stage II and III HCC. Higher AFP and A1AT levels in hemimethylated patients (p < 0.001).	[202]	
46	TFPI2		Methylation of TFPI2 gene was detected in 44.9% of primary HCC samples, 10.7% of the corresponding non-tumorous liver samples, and 5.0% of the normal liver samples. Lower expression of TFPI2 is correlated with TNM stage, and methylation is associated with poorer prognosis (p < 0.001).	[203]	
47	RUNX3, p16, RASSF1A, CDH1	+	88%, 100%, 50%, and 13% of HCC patients were detected with hypermethylation of RUNX3, p16, RASSF1A and CDH1. The inclusion of RUNX3 in the gene panel can potentiate the detection of advanced cancer.	[204]	
48	MAPK10		Methylation of MAPK10 detected in 58% of HCC cell lines, and 666% of primary HCC tissues, results in downregulated expression of MAPK10 proteins.	[205]	
49	SOX11	+	Higher methylation of SOX11 promoter in HCC patients (69.4%) compared to CHB patients (13.6%) and healthy controls (10.7%). Significant difference in SOX11 promoter methylation between HCC patients with vascular invasion and those without. SOX11 methylation demonstrates a 69% sensitivity in distinguishing HCC from CHB, higher than the 57% sensitivity of serum AFP.	[206]	
50	HCCS1	+	HCCS1 promoter methylation frequency higher in HCC patients compared to CHB patients and healthy controls (P < 0.001). HCCS1 promoter methylation associated with TNM stage (P = 0.01). 62.5% sensitivity for serum HCCS1 promoter methylation in discriminating HCC from CHB, compared to 55% for AFP alone, and sensitivity combined with AFP level is 81.7%.	[207]	
51	Sat2		Correlation between hypomethylation Sat2 with a breakpoint in chromosome 1(p < 0.001). Sat2 demethylation play a role in early stage of liver carcinogenesis.	[208]	
52	Sat2, LINE-1		Sat2 hypomethylation associated with HCC risk. LINE-1 is not associated with HCC risk by age. Decrease in Sat2 methylation and LINE-1 hypomethylation associated with increased risk of HCC for HBsAg carriers.	[209]	
53	Sat2, LINE-1	+	Negative relationship between urinary aflatoxin B albumin levels and LINE-1 and Sat2 methylation. It is associated with the risk of HCC development.	[210]	
54	SFRP2	+	SFRP2 methylation levels significantly higher in patients with HBV-HCC than in those with CHB and healthy controls (p < 0.001). SFRP2 mRNA level significantly lower in HCC group compared to the others (p < 0.05). SFRP2 methylation level showed better diagnostic value than AFP.	[211]	
55	SGIP1	+	Elevated levels of SGIP1 methylation in HCC patients associated with poorer OS, PFS, and MFS compared to those with low levels (p < 0.05).	[212]	
56	SCAND3, Myo1g	+	SCAND3 and Myo1g methylation were high in HCC cell lines and tissues, and serum SCAND3, Myo1g, and SCAND3 + Myo1g methylation values showed better detection and early detection of HCC than AFP alone. In the AFP-negative HCC group, SCAND3 and Myo1g methylation also can predict diagnosis.	[213]	
57	LZP		Methylation of LZP promoter decreases mRNA expression, and is negatively related to the HCC status.	[214]	
58	ATM		Higher ATM promoter methylation in HCC tissues, and associated with ATM expression (p < 0.001). Methylation of ATM promoter associated with better outcomes in locally advanced HCC patients who received radiotherapy	[215]	
59	IL-6	+	IL-6 promoter methylation levels lower in HCC patients than in CHB patients (p < 0.001). IL-6 promoter methylation level is an independent factor in HCC development, and its diagnostic value is superior to AFP. Combined use of AFP and IL-6 methylation level improves AUC (0.773).	[216]	
60	CDO1	+	CDO1 promoter methylation frequency higher in HBV-related HCC than in LC, CHB, and healthy controls (p < 0.001). Higher frequency of CDO1 promoter methylation in advanced stages HCC compared to early stages. Improved diagnostic value combined with serum AFP.	[217]	
61	CDH13	+	Higher methylation frequency of CDH13 promoter in HCC patients compared to NCs and CHB groups (p < 0.05). Methylation level of CDH13 promoter influenced by TBil, ALB, and AFP. Combined methylated CDH13 level and AFP level show better diagnostic score (AUC = 0.796). CDH13 methylation is an independent predictor for HCC prognosis (p < 0.05).	[218]	
62	FES		FES hypermethylation correlated with tumor size, serum AFP, and tumor differentiation (p < 0.005). Both FES hypermethylation and protein downregulation associated with PFS and OS of HCC patients.	[219]	
63	NLRP7, NLRP2, NLRP3	+	Hypomethylation of programmed-cell death genes (PRGs) including NLRP7, NLRP2, and NLRP3 in HCC tissues; NLRP3 methylation levels correlated with expression level (r = 0.51). Hypomethylated PRGs can discriminate between early HCC patients and healthy controls in cfDNA analysis (AUC = 0.94), and associated with poor HCC prognosis.	[142]	
64	DBX2, THY1	+	DBX2 and THY1 are hypomethylated in HCC. Diagnostic sensitivity and specificity of DBX2 for differentiating healthy controls and early stage HCC were 88.89% and 87.10% respectively. Diagnostic sensitivity and specificity of THY1 were 85.19% and 80.65% respectively.	[220]	
65	F-box protein 43 promoter	+	F-box protein 43 promoter methylation levels were significantly lower in HCC PBMCs than in chronic hepatitis B and healthy control PBMCs (P < 0.001). This was superior to those of AFP levels in the diagnosis of HCC. Combination of F-box protein 43 promoter methylation and AFP levels improved the AUC to 0.888 with sensitivity of 76.42% and specificity of 86.08%.	[221]	
66	RASSF1A, p16, p15	+	Abnormal methylation was found in blood samples 1 to 9 years before HCC was diagnosed. RASSF1A had the highest rate of increased methylation (70%), followed by p16 (44%) and p15 (22%). Combined risk factors and methylation markers, the accuracy of predicting HCC was 89%, with 84% sensitivity and 94% specificity	[222]	
GNB4, Riplet	+	In tissue validation, GNB4 and Riplet had an AUC of 100%, with 100% sensitivity and specificity for detecting any-stage HCC. In blood tests, this combination showed a high sensitivity of 84.39% and specificity of 91.92%, with an AUC of 92.51% for detecting any-stage HCC. The dual-marker panel was more sensitive for detecting stage I HCC than AFP. It had a high sensitivity (70.27%) for detecting a single tumour of size 3 cm or less.	[144]	

Hypermethylation of Ras Association Domain Family Member 1A (RASSF1A) is one of the most commonly identified methylation markers for HCC. RASSF1A is a tumor suppressor gene that regulates cell progression by apoptosis, microtubule stability, and cell proliferation. The CpG island of the RASSF1A promoter is usually highly methylated in HCC patients, ranging from 40 to 93%, varying from different studies [168, 197]. This hypermethylation of RASSF1A in HCC patients can be detected in both tumor tissues [166] and liquid biopsy using circulating cfDNA [168]. When combined with serum AFP, methylation of RASSF1A is a better diagnostic biomarker for HCC, especially in patients with hepatitis infection, with a sensitivity and specificity of 65.0% to 85.0% and 70.0% to 100%, respectively [167, 182]. Notably, methylation is also detected on the RASSF1A gene of cirrhotic liver tissues, but not as high as the tumor tissues [175]. Among the cirrhosis cases, RASASF1A could be considered a prediction biomarker for developing HCC [175]. A study has demonstrated that the methylation extent of RASSF1A increases during CLD development, from chronic hepatitis B to cirrhosis and finally into HCC [173]. Consistently, a cohort study with patients recruited in a cancer screening study from Zhang et al. revealed that abnormal methylation of RASSF1A can be detected as early as 1 to 9 years before HCC is diagnosed [222]. Therefore, screening RASSF1A methylation status is considered an effective measure for early detection of HCC in patients with high cancer risk, such as CLD or HBV carriers [180, 222, 223]. However, there are also challenges to validating RASSF1A hypermethylation as a cancer biomarker due to contradictory data on methylation frequency in various malignant diseases for cfDNA and gDNA. Differences in the CpG sites analyzed could cause these discrepancies, the cancer stages of the patients, and the timing of RASSF1A methylation in tumorigenesis. Furthermore, inconsistencies in the association between RASSF1A methylation and clinicopathological parameters suggest that other genes’ aberrant methylation may significantly influence tumorigenesis in some cancers [224].

Additionally, methylation of the CDKN2A, coding for the tumor suppressor protein p16, is a well-studied HCC detection biomarker. P16, a tumor suppressor protein, is vital for controlling the cell cycle by blocking the actions of CDKs. By inhibiting these enzymes, p16 helps avert uncontrolled cell growth and division, which could lead to tumor formation. Hypermethylation of CDKN2A results in a lower level of p16, which is more prevalent in patients with HCC than in chronic hepatic cirrhosis and healthy control people [176]. The levels of p16 increase with HCC progression from benign liver disease [186]. It is also a potent marker as it can help differentiate HCC among patients with normal AFP than higher AFP levels [176]. Like RASSF1A, p16 methylation was found in 44% of patients before HCC diagnosis [222].

The septin 9 (SEPT9) gene, a crucial regulator of cell division, functions as a tumor suppressor. Its excessive methylation is associated with the progression of liver cancer [225, 226]. The SEPT9 gene is expressed in all healthy tissues, but its expression is reduced or silenced due to abnormal promoter hypermethylation in liver cancer [227]. An extensive epigenome analysis of 304 liver cancer tissue specimens identified SEPT9 as a crucial epi-driver gene in liver cancer development, primarily due to the hypermethylation of the SEPT9-promoter [225]. Increased methylation of SEPT9 is found in HCC patients than in healthy individuals [181], and it’s a better predictor than serum AFP for diagnosis of HCC. It is also reported that a higher copy number of SEPT9 methylation was presented in HCC than in control individuals [188].

Glutathione S-transferase pi 1 (GSTP1) is a protein detoxifying harmful substances, and its hypermethylation is often observed in HCC. This hypermethylation reduces the GSTP1 enzyme’s production, impairing detoxification processes and potentially contributing to HCC development and progression [228]. GSTP1 hypermethylation and AFP level can be a high-sensitivity biomarker for detecting HCC at 93.55% sensitivity [182]. It is also consistent with RASSF1A and is hypermethylated in tumors compared to benign control groups [183]. In patients with acute-on-chronic hepatitis B liver failure (ACHBLF), which is a condition of acute regression of liver function due to CLDs such as HBV infection, GSTP1 methylation frequency was significantly higher than in chronic hepatitis B patients and healthy individuals [199]. The higher methylation and lower expression of GSTP1 are associated with ACHBLF incidence.

A repetitive DNA sequence known as a retrotransposon, long interspersed nuclear element-1 (LINE-1), is found in the genome. In the case of HCC, LINE-1 exhibits overexpression and hypomethylation. This hypomethylation in LINE-1 elements can result in genomic instability, higher mutation rates, and changes in gene expression, which can all contribute to the development and progression of cancer. Research has demonstrated a connection between LINE-1 hypomethylation and unfavorable outcomes in individuals with liver cancer. More than 50% of HCC patients demonstrate an overall hypomethylation in LINC-1 [201]. This pattern is also observed in cfDNA, ctDNA, and blood leukocyte DNA [172, 193]. Additionally, satellite 2 DNA (Sat2), located in the 1q12 pericentromeric region, is a sequence with reduced methylation in cancer cells and contributes to chromosomal instability [229]. Recent research has revealed that Sat2 and similar heterochromatic regions can generate ncRNAs [230], which might have a role in responding to stress and facilitating heterochromatin reformation. Nevertheless, the influence of DNA hypomethylation on Sat2 expression remains uncertain, as different studies have produced inconsistent results. Nonetheless, several studies have reported that Sat2 hypomethylation is associated with HCC risk. A significant relationship has been identified between Sat2 sequences with reduced methylation and increased 1q copies having a 1q12 breakpoint. This decrease in methylation is thought to change how CpG-rich satellite DNA interacts with chromatin proteins, causing heterochromatin to decondense, break, and form 1q abnormally. This implies that the demethylation of Sat2 could be involved in the initial phases of the development of liver cancer [208]. Meanwhile, aflatoxin is a well-described carcinogen leading to HCC. Aflatoxin B1 albumin is a metabolite under aflatoxin exposure and can be excreted through urine. A cohort study with 1140 cancer-free participants revealed a reverse association between the aflatoxin concentration and global LINE-1 and Sat2 methylation [210]. This demonstrates that there may be an epigenetic regulation effect of aflatoxin, which results in HCC development. Urinary aflatoxin metabolite level and DNA methylation can be a biomarker of potential HCC occurrence. On the other hand, a prospective case-control study measuring methylation levels in leukocyte DNA suggested that Sat2 hypomethylation is associated with the risk of HCC, but LINE-1 is not associated with HCC risk by age [209]. The association is stronger within HBsAg carrier between Sat2 and LINE-1 hypomethylation and the risk of HCC.

Other reported methylated genes that can be potentially regarded as biomarkers of HCC are listed in Table 2.

Presence of tumor-derived vesicles in the circulation

Extracellular vesicles (EVs) are tiny, membrane-bound capsules containing various organ components [231]. There are three main types of EVs: microvesicles, exosomes, and apoptotic bodies, each varying in size and composition and released from cells in different ways [232]. EVs contain various cellular components such as proteins, DNA, RNA, and lipids [233]. It plays a crucial role in cell-to-cell communication and is involved in essential biological processes like inflammation and tissue remodeling [234]. Various liver cells, such as hepatocytes, hepatic stellate cells, and endothelial cells, are released into the bloodstream. The EVs released by the tumor cells are tumor-derived vesicles [235]. LncRNAs, which regulate biological and genetic functions, have been found in EVs and linked to numerous diseases. The composition of EVs can change in response to different stimuli, making them potential biomarkers for HCC. Liquid biopsy methods are now widely used to detect the presence of EVs, providing valuable information about the occurrence and progression of HCC [235].

Change in viral load in viral hepatitis-related HCC patients

Pre-treatment serological data were analyzed in a study of 125 HBV-positive HCC patients with chemotherapy. Upon analyzing the virological data alongside conventional clinical variables, factors such as high total bilirubin, HCV infection, and elevated HBV DNA levels significantly influenced survival outcomes [236]. Notably, an exploratory analysis revealed a higher incidence of severe hepatitis during chemotherapy in patients with high pretreatment HBV DNA levels. On the other hand, Choi and the others reported that the association of viral load on patients with HBV but not cirrhosis, with or without prior anti-viral treatment, is non-linear [237, 238]. The risk of developing into HCC is the highest at around 6 to 7 logIU/mL. The risk decreases with increasing baseline viral load. It is worth mentioning that CLDs with viral infection are alone the dangerous risk factor leading to HCC. Therefore, the clinical importance of checking the viral load as a potential prognostic biomarker is crucial. Several viral factors contributing to HCC, including HBsAg, HBeAg, viral DNA levels, viral genotypes, and viral mutations, may be considered integratively and provide essential information for surveillance program development [239].

Potential metabolomics clues for HCC diagnosis

On the other hand, metabolic profiling is also an emerging research direction in the biomarkers of HCC diagnosis. With the advancement of Omics technology, metabolic profiles from hepatitis patients and HCC patients were characterized and compared. High classification accuracy models could be derived from these multi-omics data [76]. “Omics” technologies, which include genomics, transcriptomics, proteomics, and metabolomics, provide an in-depth molecular and biochemical analysis of a biological entity, whether it’s an organism, tissue, or specific cell type. Metabolomics, which pertains to the exhaustive study of lightweight metabolites within a biological sample, holds several unique advantages. It is more closely aligned with the phenotype, is not restricted to specific species, and involves fewer molecules than other omics technologies. The metabolite profile serves as a comprehensive summary of the preceding omics profiles, which makes it particularly effective in identifying minor alterations in metabolic pathways and shifts from homeostasis [240]. Techniques such as MS and nuclear magnetic resonance (NMR) spectroscopy have been effectively used in metabolomic analysis.

Gas chromatography (GC)-MS-based metabolomics is commonly used to analyze patients’ serum. In a study involving 20 HCC patients and 20 normal subjects, serum metabolome was analyzed. Metabolites, including butanoic acid, L-valine, glycerol, etc., significantly differentiate the two groups. The specificity is 100%, and the total accuracy is 75% [241]. The same group also investigated using urine metabolomics via GC/MS, yielding an AUC of 0.9275 for detecting HCC from control groups combined with AFP [242]. Another metabolic profiling study unveiled 43 serum metabolites and 31 urinary metabolites in HCC patients, which impact crucial metabolic pathways [243]. Specific metabolites, including bile acids, histidine, and inosine, exhibited notable statistical variances and considerable fold changes, hinting at their prospective utility as HCC biomarkers. Nonetheless, it was observed that irregular levels of specific bile acids were linked with conditions such as liver cirrhosis and hepatitis. The research also distinguished HCC patients with low AFP values from healthy subjects, utilizing a set of metabolite markers. Moreover, membrane phospholipids, measured by LC-MS/MS, were shown to discriminate HCC from adjacent liver tissues with an AUC of 0.963 [243].

Although the technology has matured for more than a decade already, the detailed metabolic profiles of HCC patients have not yet been well characterized due to the heterogeneity of this disease. The training and validation cohort have not been large enough to validate the power of specific metabolic panels for HCC diagnosis. With the advancement of analytical tools, the omics approach is inevitably essential to precision medicine.

Omics approach to identify novel biomarkers

The general approach of using omics technologies to diagnose HCC involves analyzing an array of biological molecules, such as proteins, metabolites, and modified RNA sites, to identify specific biomarkers and molecular profiles associated with the disease [244]. This comprehensive and integrative method allows for early detection and improved understanding of HCC pathogenesis, ultimately leading to better patient outcomes and targeted treatment options [245]. By overcoming challenges in data analysis, identification, and accessibility, omics technologies can revolutionize the field of HCC diagnosis and management. Mass spectrometry (MS)-based omics technologies have the potential to diagnose HCC by analyzing biological molecules related to disease development, such as proteomics techniques that identify specific serum protein panels [246]. However, there are challenges to overcome, such as the rapid identification of metabolites, proteins, and modified RNA sites and the development of feasible in-house databases and powerful bioinformatics tools [247, 248]. Addressing these challenges and making multi-omic strategies accessible to non-specialist groups could lead to a better understanding of HCC pathogenesis and improved human health outcomes.

Additionally, employing bioinformatics analysis on the current dataset is a valuable method for the secondary discovery of potential targets. Establishing prediction models based on cfDNA, methylation profiling, and somatic copy number aberrations data is a viable strategy [102, 249–251]. In recent years, the integration of machine learning algorithms has substantially advanced the field of biomarker discovery [178, 252]. Besides the bioinformatics approach to the studies of epigenetics and ncRNAs [253, 254], spatial proteomics, or transcriptomics [253, 254] can also contribute to the disease prognosis and management. However, it is crucial to recognize that bioinformatics should be utilized as a supplementary tool in biomarker research rather than a primary source due to the absence of experimental evidence. Consequently, further experimental and clinical validations must be conducted to ensure the efficacy of the identified biomarkers.

Taken together, many promising targets can be considered as new liquid biopsy biomarkers for detecting HCC. However, there is still a long way to look for a new universal serological HCC detection biomarker using liquid biopsy to replace AFP completely.

Biomarkers for treatment options and therapeutic response

Some recent review articles have discussed the representative findings of molecular biomarkers to predict HCC prognosis and the current staging system to predict HCC prognosis [32, 35, 255, 256]. The following part highlights the current understanding of biomarkers that can provide insights into treatment options and therapeutic responses (Fig. 2).Fig. 2 Biomarkers for therapeutic options. To facilitate the decision on the best treatment for HCC patients, biomarkers predicting therapeutic response to different treatments, including surgical resection, TACE, HAIC, liver transplantation, targeted therapies, and immunotherapies, are being investigated. Some of the significant aspects of the studies are highlighted in the illustration, and the predicted response and correlated clinical outcomes are drawn on the diagram

Biomarkers related to surgical resection

While the surgical resection guidelines are beyond this review’s scope, we will discuss biomarkers for postoperative monitoring and prediction of recurrence. A recent study revealed that serum AFP level greater than 400 ng/mL is a risk factor for OS and recurrence-free survival (RFS) (HR: 1.512) [257], which is consistent with previous studies that AFP decrease after surgery is an excellent prognostic indicator [258, 259]. Another study has combined the level of sulfite oxidase with AFP, which can predict postoperative outcomes and recurrence risk at sensitivity and specificity of 93.8% and 95.2%, respectively [260].

On the other hand, Yamamoto et al. compared the predictive values of AFP, AFP-L3%, DCP, and GP73 in postoperative patients [261]. It was found that DCP is the best prognostic marker for HCC development, but AFP-L3% may be more significant for early recognition of tumor recurrence. Another study investigating the significance of combining these three tumor markers found that the number of elevated markers post-surgery predicts survival and recurrence [262]. A multivariable analysis using large-scale clinical data has identified that males, large tumors, multi-nodules, high albumin-bilirubin, and high serum AFP are the predictors of early recurrence after hepatectomy [263].

It was shown that GPC3-positive patients with HCC have worse survival than GPC3-negative patients [264]. In general, higher GPC3 expression is associated with poorer prognosis in HCC patients, no matter who is HBV-related, post-operative, or not [265–267]. Similar results were observed for serum GPC3, in which a higher level signifies a shorter OS and disease-free survival (DFS) after surgical treatment [268, 269], although there are also controversial results [270]. Consequently, GPC3 is being investigated for its potential when combined with other biomarkers for the prognostic indication. The expression of GPC3 and OPN in HCC tissue was a negative predictor for patients with HBV-related small HCC tumors who have undergone surgical resection [271]. On the other hand, Feng et al. discovered a link between the expression of GPC3 and CK-19 in HCC tissue and local recurrence in patients with post-surgical resection for HCC [272].

Apart from the conventional serological markers, there are also reports of other potential biomarkers. A study found that platelet count (PLT) and five platelet-related factors can predict HCC recurrence, especially late recurrence, in non-cirrhotic patients [263]. Ascites, PLT levels, alkaline phosphatase levels, and tumor sizes were independently associated with the risk of HCC recurrence. However, larger cohorts are needed to validate these findings. NcRNAs are also within the research scope. The HCCseek-23 panel with eight miRNA showed 81% sensitivity and 83% specificity for early-stage HCC diagnosis and 93% sensitivity for identifying AFP-negative HCC. Combined with serum biomarkers, they were significantly associated with DFS. Furthermore, lncRNA MVIH has also been reported to be a predictor. Overexpression of MVIH is correlated with poor RFS (p < 0.001) and OS (p = 0.007) of postoperative HCC patients [273]. One study found that circFOXK2 is highly expressed in HCC tissues and correlates with poor outcomes in patients undergoing radical hepatectomy (p = 0.0005) [274]. The research revealed that circFOXK2 promotes HCC progression and activates the Warburg effect by upregulating specific proteins and miRNA sponges, making it a potential prognostic marker and drug target for HCC.

Identifying CTCs with specific genes can also help healthcare providers predict patients’ responses to treatment. For instance, MAGE3, surviving, and CEA could be used to indicate the effectiveness of cryosurgery on unresectable HCC [275]. CTCs are associated with tumor diffusion and thrombosis, and the presence and number of CTCs are associated with worse survival [79]. A study focusing on the EMT properties of CTCs found that CTC count and mesenchymal characteristics of CTCs are associated with early recurrence or postoperative DFS [80]. During the process of EMT, the expression of EpCAM is usually down-regulated, and it becomes no longer the only reliable marker for the enrichment of CTCs [276]. Another study has shown consistent results that CTCs with high EMT phenotypes are more likely to be metastatic. More epithelial markers, such as CD133, vimentin, HER2, and PSMA, are provided for the positive enrichment of these stem-like CTCs [277]. Additionally, HCC patients with CTCs detected are associated with vascular invasion, elevated AFP levels, disease progression, recurrence, and poorer prognosis [278–280].

On the other hand, Chen and others performed the unique molecular identifier target sequencing on plasma and PBMCs from HCC patients [107]. They found that mutation variant frequency changes (MVFCs) correlate with shorter RFS, thus suggesting minimum residual disease (MRD). MRD refers to the small number of tumor cells that remain in the primary site after treatment, usually surgical resection. That tiny tumor volume is not generally detectable by conventional detection strategies, such as ultrasound, imaging, or serological tests. MRD is a condition in which patients are susceptible to recurrence before average time and is usually accompanied by shorter RFS and OS. Chen defined the MRD-positive patients as MVFC mutations favorable in ctDNA. The prognostic evaluation is greatly improved when combined with serum AFP and DCP (p < 0.0001). The design of their platform is also compatible with different gene panels, so it is theoretically applicable to other samples or diseases.

Biomarkers related to transarterial chemoembolization and hepatic arterial infusion chemotherapy

Transarterial Chemoembolization (TACE) is a medical process where a catheter is used to directly administer chemotherapy, typically doxorubicin, into the tumor’s feeding arteries. This is then followed by blocking these arteries [281]. This procedure has a relatively low mortality rate related to treatment, which is less than 5%, and it has been found to extend the median survival rate to somewhere between 11 and 20 months [282]. Notably, this treatment does not yield practical results for over 40% of patients who are left to depend on less potent systemic therapies [283]. Hence, discovering predictive biomarkers for TACE treatment response could greatly benefit patients. This would enable them to transition to alternative therapies promptly without unnecessary delay. Pyruvate kinase muscle isozyme M2 (PKM2) is reported to be associated with resistance (p < 0.01) and survival to TACE (27.5 m vs. undefined, p < 0.0001) [284]. Elevated PKM2 predicts a poor therapeutic outcome. Furthermore, cfDNA and ctDNA levels are also suggested to be associated with the failure of the TACE procedure, with a sensitivity of 80% and a specificity of 95.6% [285]. A recent study on 132 patients showed that DNA-dependent protein kinase (DNA-PKcs) is associated with poorer survival (4.5 vs. 16.9 m, p = 0.011) [286]. The expression of DNA-PKcs is related to doxorubicin resistance.

Like TACE, Hepatic arterial infusion chemotherapy (HAIC) delivers the chemotherapies into the liver, but instead of the arteries, the vein leading to nearby organs will be blocked. A study found that serum VEGF levels in advanced HCC patients can predict the therapeutic response and survival for receiving cisplatin and 5-FU via HAIC [287]. In a recent Phase III clinical trial testing the efficacy of HAIC-oxaliplatin plus fluorouracil (HAIC-FO), a 15-gene mutation panel was discovered that can predict the responsiveness to the treatment. 83% of patients were identified to have a longer OS (19.3 vs. 10.6 months, p = 0.002) [288].

Biomarkers related to local ablation

Local ablation involves using electrical equipment to heat and destroy tumor tissues at the local site, typically through radiofrequency. At temperatures exceeding 60 °C, the probe burns the tumor tissues and adjacent inoperable or metastatic tissues. This procedure is sometimes performed via endoscopy, or in the case of larger tumors, a laparotomy may be required. The decision to utilize local ablation for HCC treatment primarily depends on tumor size, ascertained through CT or MRI. The Child–Pugh score is also occasionally considered, with only patients classified as grade A or B deemed suitable for ablation therapies [289]. AFP level is perceived as an indicator of whether patients will experience recurrence following ablation [290]. A comprehensive retrospective study involving nearly 3,000 patients who underwent tumor ablation revealed that additional biomarkers, including tumor size and numbers, serum DCP, platelet counts, Child-Pugh score, and HCV viral load, are associated with distant recurrence [291]. An Italian survey corroborated these findings, reporting that advanced age is an independent predictor of poor OS apart from AFP levels, while ALT can prognosticate recurrence [292]. More studies suggest AFP-L3%, DCP, neutrophil to lymphocyte ratio, ferritin, and specific miRNAs correlate with the OS and DFS after ablation, but further research is awaited to confirm their clinical significance [293].

Biomarkers related to liver transplantation

Liver Transplantation is considered when patients have unresectable HCC tumors by conventional surgery, but the tumors are still not widespread, usually at T1. Patients have to have good health conditions and normal liver function. As liver transplantation involves the donation of liver tissues from another individual and is a complicated procedure, it is precious. It requires special attention before the clinician and surgeon decide to operate on the patient. Therefore, reliable biomarkers are needed to help determine if a patient is suitable for transplantation and the predicted prognosis after the surgery. AFP levels are usually considered only in current clinical guidelines for therapeutic options. For example, patients with AFP levels above 1000 ng/mL are not considered for liver transplantation due to poor predicted prognosis after operation [46, 294, 295]. Although AFP is one of the most widely used biomarkers for HCC diagnosis, its stability as an indicator of disease progression and the reference range has been controversial. Studies report a positive correlation between AFP mRNA level and tumor size, circulating malignant hepatocytes, and metastases. However, controversial studies have also been reported [296–299], limiting its significance as a prognostic marker for HCC.

Parameters, including tumor sizes, numbers, serum AFP levels, and tumor uptake on FDG PET/CT, are recognized post-transplantation predictors of tumor recurrence in HCC patients [300–303]. A combined set of criteria, including tumor sizes, numbers, serum AFP levels, and maximum tumor-to-background ratio, is the most effective way to predict post-transplant recurrence and select candidates for living donor liver transplantation compared to conventional criteria sets [304]. A study of 103 patients with HCC found that poorly differentiated tumors and high AFP levels were linked with poorer survival (p < 0.05) and higher recurrence (p < 0.05) after liver transplantation [305]. The research suggests that these tumor biological characteristics should be taken into account before performing the procedure for patients with HBV-associated HCC. This information can help assess HCC patient survival time after liver transplantation. A 30-year comprehensive study calculated the recurrence rate of 865 HCC patients receiving liver transplantation. Multivariate factors predicting recurrence were developed, including tumor grade, macrovascular and microvascular invasion, tumors outside Milan criteria, radiographic maximum diameter, and specific pre-transplant neutrophil-to-lymphocyte ratios [281]. The situation is highly individual and requires more clinical information to help make decisions.

Biomarkers related to targeted therapies

For patients who have unresectable HCC tumors and who are also not suitable for liver transplantation, systemic therapies are the first-line treatment. Sorafenib is the most commonly used first-line drug, but the development of sorafenib resistance is usually observed. The study of sorafenib resistance is a hot topic, and many molecular mechanisms leading to sorafenib resistance have been discovered [306]. Therefore, it is crucial to predict the drug response to systemic therapies in HCC patients [307]. In a study using data from the SORAMIC study, researchers utilized EV-based proteomics to predict treatment response [308]. Low GPX3 and high ARHGAP1 in plasma predicted better treatment response to sorafenib with AUC 0.97. From another phase III SHARP trial, the plasma Tregs and CD56Dim NK cells are correlated with shorter OS for patients receiving sorafenib (p < 0.05) [309]. When sorafenib is combined with mFOLFOX, plasma sVEGFR21 is associated with shorter time-to-progression in HCC patients. Consistent results were observed that VEGF and HIF in HCC have poor predicted treatment outcomes (p < 0.001) and OS (p < 0.001) [310]. Apart from typical serological markers, ncRNAs are also at the hot spot. For instance, the lncRNA Linc01056 is found to be downregulated in HCC tumors, where its expression level is related to sorafenib sensitivity [311]. Besides, from a genomic study using patient-derived tissues, a sub-type of β‐Catenin with high Male predominance has low miRNA expression and is sensitive to sorafenib [312]. Similarly, the circulating level of another miRNA, miR-518d-5p, is reported to be a potential sorafenib resistance biomarker in BCLC-C HCC patients [313]. On the other hand, the immune microenvironment also affects systemic drugs’ therapeutic effect. A study showed that high CD4+ T effector/Treg ratios and IFN-γ production by CD8+Ki67+ T cells are potential biomarkers for improved survival and response to sorafenib therapy [310]. Similarly, pERK+/pAkt- CTCs were discovered to be correlated with better prognosis in HCC patients receiving sorafenib treatment [314].

Lenvatinib is sometimes regarded as the second-line therapy after sorafenib resistance has arisen. High expression of FAT1 and LRP1B genes in ctDNA is associated with poor PFS and a higher recurrence rate [315]. Also, serum ST6GAL1, a tumor-secreted protein, is positively correlated with better survival of Lenvatinib [316]. Likewise, a higher level of circMED27 in the serum of HCC patients also correlates with worse prognosis and clinical outcomes when treated with Lenvatinib [317]. Some other biomarkers related to treating HCC with targeted therapies are reviewed in some recent articles [7, 318, 319].

Biomarkers related to immunotherapies

The immune-suppressive environment is one of the reasons for the poor treatment response of HCC. A recent clinical study measured the serum AFP and CRP levels from patients with HCC treated with anti-PD-(L)-1 therapies. The two parameters were identified as independent predictive markers and developed as the CRAFITY score. The CRAFITY score is associated with survival and therapeutic response in those HCC patients [320]. In 2024, a different study examined the significance of AFP trends in forecasting responses to systemic treatment in HCC patients undergoing bevacizumab combined with immunotherapy [321]. The retrospective evaluation of 536 HCC individuals revealed three unique AFP patterns in both AFP-low and AFP-high groups, with a quick decrease in AFP following treatment associated with improved patient outcomes (HR: 0.2 in AFP-low, and 0.04 in AFP-high class). These results highlight the possibility of using AFP trends as an independent biomarker for predicting clinical results, offering a dynamic prediction tool for systemic therapy prognosis in HCC patients and assisting in clinical decision-making. Weng et al. discovered that SLAMF7 deficiency-caused CCL2 signaling can modulate macrophage repolarization and result in an immunosuppressive response (p = 0.00034) [322]. SLAMF7 could be used as a biomarker and drug target to predict patient immunotherapy response. Winograd et al. also found that PD-L1+ CTCs could help identify HCC patients likely to respond to immunotherapy [323].

A detailed molecular analysis was carried out on tumor biopsy samples from 60 HCC patients insensitive to sorafenib treatment to understand better the genomic characteristics of HCC patients treating anti-PD-1 [324]. The research found a 10% overall response rate to the therapy, with key contributing factors including female gender, PD-L1 positivity, and a low neutrophil-to-lymphocyte ratio. Notably, CTNNB1 mutations and up-regulation of MET were only detected in those who did not respond to treatment, underscoring their potential as predictive biomarkers. Therefore, these biomarkers merit further exploration to improve our knowledge of their potential clinical application in managing HCC patients receiving immunotherapy. Non-coding RNAs such as RNA methylation and circRNA can also serve as biomarkers to predict the effectiveness of immunotherapies in HCC [325]. For instance, the circuit can inhibit the immune response to HCC tumors and stimulate tumor growth via the Snail/DPP4/CXCL10 axis [326].

Notably, atezolizumab (Anti-PD-L1) combined with bevacizumab (Anti-VEGF) (AtezoBev) is one of the standard therapeutic options for unresectable HCC. However, an integrated molecular analysis from samples of patients enrolled in a clinical trial demonstrated that the pre-existing immunity population, with CD274 expression (p = 0.0011), T effector signature (p = 0.0035), and density of intratumoral CD8+ T cells (p = 0.053) as the predictors of better therapeutic response to this combination therapy [327]. Conversely, a high Treg to effector T cells ratio and expression of GPC3 and AFP worsen the clinical benefit. The serum AFP and albumin-bilirubin (ALBI) levels can be biomarkers to predict the response to AtezoBev [328]. The multivariate analysis established an independent correlation between OS and the ALBI-AFP combination, where patients in the ALBI2-AFP non-responders category exhibited the poorest prognosis.

A stage-specific immune classifier was developed by Shi et al. based on patients’ samples [329]. This panel of markers can detect early-stage HCC with a performance superior to serum AFP. It also provides information about whether the patients are resistant to anti-PD-1 monotherapies. Similarly, another study reported that β-catenin activation can result in immune escape of the HCC tumor, and the patients will be more resistant to anti-PD-1 immunotherapies [330]. Bioinformatics analysis also provides potential prognostic biomarkers and therapeutic targets for HCC [331]. Research on novel biomarkers for predicting immunotherapy responses is emerging, and it is anticipated that a more precise understanding will be attained through advanced technologies that analyze the tumor immune landscape, such as single-cell RNA sequencing (scRNA-seq), spatial transcriptomics and multi-omics approaches.

With the help of scRNA-seq, the immunosuppressive microenvironment can be well characterized, and more insight into the interaction between the immune cells can be illustrated. For instance, He et al. utilized the multi-dimensional scRNA-seq to analyze samples from AFP-positive and AFP-negative HCC and adjacent normal tissues [332]. The sequencing results showed that APC-positive tumors are associated with multifaceted immune distortion, including T cell exhaustion and tumor-associated macrophages (TAMs) elevation. When looking further into details, SPP1+ TAMs are responsible for the T cell suppression. On the other hand, the CTCs are also regulating the immune microenvironment through intercellular signaling. CCL5 overexpression in CTCs can recruit regulatory T cells, which help the HCC tumor escape from immune response and metastasis [332]. Furthermore, scRNA-seq has offered insights demonstrating that patients showing PR or SD experienced immune shifts toward cytotoxic T cells. In contrast, patients with PD showed increased numbers of CD14+ and CD16+ monocytes and the upregulation of neutrophil-associated pathways[324]. These observations imply that cytotoxic T cell infiltration, increased activated CD8+ T cells during anti-PD-1 treatment, and the suppression of neutrophil-associated markers could be critical markers for predicting and enhancing response to anti-PD-1 therapy in HCC patients.

The microbiome, defined as the collective genomes of the microbiota within a host, is increasingly acknowledged for its role in immune regulation and responses to various cancer treatments [333, 334]. Significantly, the gut microbiome and the liver interact bidirectionally through the gut-liver axis, enabling gut microbiota and their byproducts to both directly and indirectly impact gene expression in hepatocytes, tumor cells, and non-tumor cells, including immune cells [335–337]. A metagenomic sequencing research study revealed that fecal samples from immunotherapy responders exhibited higher taxa richness and gene counts [338]. It concludes that gut microbiome variations could significantly influence the responses of HCC patients to anti-PD-1 immunotherapy. Interestingly, a meta-analysis involving 1,056 HCC patients revealed that antibiotic-induced reduction in microbiota diversity does not affect OS in HCC patients on ICIs. However, more extensive and better-controlled studies are warranted [339]. A prospective clinical study explores the relationship between the gut microbiome and combined immunotherapy in patients with HCC [340]. Initial findings showed higher gut microbiome diversity in immunotherapy responders, but this difference faded by week 6 of treatment, while certain gut bacteria showed correlations with specific serum metabolites. The study suggests that gut microbiome biomarkers and serum metabolites could help identify HCC patients who would benefit from immunotherapy. Another study reported that antibiotic exposure around the time of treatment initiation has been associated with adverse prognostic implications in patients receiving AtezoBev [341].

In addition to the microbiome, gut metabolites have also been associated with immunotherapeutic responses. In a recent study investigating the connection between gut microbiota and metabolites in predicting outcomes for unresectable HCC patients undergoing treatment with ICIs, researchers discovered significant differences in fecal bacteria between patients with objective response (OR) and those with progressive disease (PD) before starting immunotherapy [342]. The study emphasizes the relationship between fecal microbiota, bile acids, and immunotherapy outcomes for HCC. It showcases the potential of gut microbiota and metabolites as biomarkers for predicting treatment outcomes in ICI-treated HCC patients. Research exploring the impact of the microbiome on immunotherapy responses in HCC patients is still in its early stages. The current consensus suggests that the microbiome modulates the immune environment and response. However, the complex mechanisms that drive this interaction and the potential association between diversity and sensitivity remain unexplored.

Candidate drug targets in HCC and recent clinical trials

Despite ongoing improvements in disease diagnostic platforms, it is crucial that treatment options concurrently evolve to enhance patient prognosis. Notably, conventional targeted drugs, such as sorafenib, Lenvatinib, and regorafenib, have been associated with the rapid development of drug resistance. To combat this, current research in systemic therapies for HCC primarily focuses on combination therapies supplemented with additional targeted inhibitors [343]. Research is exploring the inhibition of multiple molecular targets to boost therapeutic efficacy and longevity, potentially broadening the applicable patient demographic [344]. For example, CD147 is a glycoprotein reported to be highly expressed, and its presence enhances the malignancy of HCC [345, 346]. The signaling machinery involving CD147 is related to the tumor cell properties [346, 347], but efforts have been made to target CD147 using antibodies [348]. On the other hand, GC33 demonstrated anti-tumor activity in both animal models and phase I clinical trials, believed to regulate GPC3 expression in HCC, thus potentially benefiting HCC patients [349]. It was thought to control the GPC3 expression in HCC and has the potential clinical benefit to HCC patients. However, subsequent phase Ib and II studies revealed no clinical benefits within the HCC population, even with concurrent sorafenib treatment [350, 351]. In response to these findings, recent clinical trials have commenced investigations into combinatorial treatments involving other molecular inhibitors alongside targeted drugs. In one phase II trial (NCT01246986), TGF-βRI inhibitor LY2157299 was administered with sorafenib or ramucirumab, a VEGFA inhibitor [352]. The results indicated a correlation between lower TGF-β1 levels and extended survival in HCC patients. Another avenue of exploration is the ICI AK104 (PD-1/CTLA-4 bispecific antibody), which, when combined with Lenvatinib as a first-line treatment for unresectable HCC patients in a Phase II study (NCT04444167), exhibited promising anti-tumor activity. No toxicities or unforeseen safety issues were reported, suggesting a promising direction for future HCC treatment strategies [353]. Additionally, apart from being the conventional HCC biomarkers, T-cell receptors specific for AFP peptide are also engineered to be tested in clinical trials [354–356]. However, the studies are still in the early stages, and there is yet to validate the safety and efficacy of this TCR-gene transfer therapy.

Indeed, AtezoBev has become a significant focus in HCC research. Numerous recent clinical trials across various phases are investigating the potential of AtezoBev for treating different sub-categories of HCC. In contrast to anti-PD-1 monotherapy, the combination of atezolizumab and bevacizumab has shown promising responses in intrahepatic lesions, similar to those observed in extrahepatic lesions. This combination may potentially overcome the immune-tolerant hepatic microenvironment in patients with advanced HCC, offering a new avenue for treatment and improved outcomes. Ongoing clinical trials are also examining the application of AtezoBev in different contexts. For example, the Kirros trial (NCT06096779) investigates the impact of Bevacizumab within the AtezoBev combination on patients with advanced or metastatic HCC accompanied by cirrhosis. Moreover, the CCGLC-001 trial (NCT05713994) evaluates the efficacy of AtezoBev in HAIC. In contrast, the CCGLC-008 trial (NCT05717738) investigates the combined therapy of TACE, anti-VEGF antibodies or pan-target anti-angiogenic drugs, and anti-PD-1/PD-L1 antibodies for advanced HCC patients who are not suitable for radical treatment, resection, transplantation, or ablation. Examining AtezoBev in these clinical settings underscores its potential as a promising treatment option for HCC patients, expanding the range of therapeutic approaches and possibly improving patient outcomes. More recent completed and ongoing clinical trials testing on targeted therapies are listed in Table 3.Table 3 Recent clinical trials on targeted drugs from 2020

	Interventions	Trial Name/Identifier	Patient no.	Study Type	Primary Endpoint	Study Status	Ref.	
1	SHR-1210 (Anti-PD-1), Apatinib	RESCUE / NCT03463876	190	Phase II	ORR: 34.3%, median PFS: 5.7 m	Completed	[357]	
2	Pembrolizumab, MTL-CEBPA (C/EBPα small activating RNA)	TIMEPOINT / NCT04105335	108	Phase I	No AE reported, Anti-tumor activity in 26.7%	Completed	[358]	
3	FGF401 (FGFR4 inhibitor), PDR001 (anti-PD1 IgG4 antibody)	NCT02325739	172	Phase I/II	DLT: 8.6%, TTP: 2.63 m (Phase I), ORR: 11.4%	Completed	[359]	
4	TACE (Sorafenib)	NCT02504983	200	Phase IV	Time to CR: 14.4 m (TACE + Sora) vs. not reach (TACE only)	Completed	[360]	
5	BLU-554 (FGFR4 inhibitor), CS1001 (Anti-PD-1)	NCT04194801	26	Phase Ib/II	ORR: 20%	Completed	[361]	
6	Dovitinib	EU-CTR 2011-002445-36	25	Phase II	ORR: 48%	Completed	[362]	
7	Tivozanib	NCT01835223	33	Phase Ib/II	PFS: 24 wk,

OS: 9 m

	Completed	[363]	
8	LY2157299 (TGF-βRI inhibitor), Sorafenib, Ramucirumab	NCT01246986	204	Phase II	OS: 7.3–16.8 m

TTP: 2.7–4.2 m

	Completed	[364]	
9	Cabozantinib	CELESTIAL / NCT01908426	707	Phase III	OS: 10.2 m vs. 8 m (placebo)	Completed	[365]	
10	Nivolumab, BMS-813160 (CCR2/5-inhibitor), BMS-986253 (anti-IL-8)	NCT04123379	48	Phase II	STN: 8.3%	Completed	[366]	
11	Donafenib, Tislelizumab	NCT06232759	56	Phase II	ORR: 80.4%,

DCR: 90.2%

	Completed	[367]	
12	AK104 (Anti-PD-1/CTLA-4), Lenvatinib	NCT04444167	59	Phase II	ORR: 35.5–35.7%,

DOR 13.6–13.67 m,

PFS: 8.6–9.8 m,

OS: 27.1 m

	Completed	[353]	
13	AtezoBev	NCT04862949	124	Observational	ORR: 29.8%	Completed	[368]	
14	TACE: PD-1/PD-L1 inhibitors + VEGF-TKI/bevacizumab	CHANCE2201 / NCT05332821	474	Observational	OS: 15.9–22.6 m,

PFS: 7.4–9.9 m,

ORR: 22.9–41.2%

	Completed	[352]	
15	Atezolizumab, Bevacizumab, UCPVax (anti-telomerase vaccine)	TERTIO / NCT05528952	105	Phase II	ORR	On-going	[369]	
16	Chidamide (Histone deacetylase inhibitor), Regorafenib	NCT05770882	46	Phase Ib/II	AE, ORR, PFS	Ongoing	[370]	
17	Cabozantinib	CaPture / NCT04767906	40	Phase II	TT	Ongoing	[371]	
18	Anti-PD-1 antibody, Lenvatinib	NCT06311929	300	Phase IV	DFS	Ongoing	[372]	
19	PTX-9908 (CXCR4 inhibitor)	NCT03812874	50	Phase I/II	AE, DLT	Ongoing	[373]	
20	Budigalimab, Livmoniplimab, Lenvatinib, Sorafenib	LIVIGNO-1 / NCT05822752	120	Phase II	BOR	Ongoing	[374]	
21	Serplulimab, Bevacizumab	NCT06370065	35	Phase II	ORR	Ongoing	[375]	
22	TACE: PD-1/PD-L1 inhibitors + VEGF-TKI/bevacizumab	CHANCE2202 / NCT05332496	220	Observational	PFS, OS	Ongoing	[376]	
23	Zabadinostat (class I HDAC inhibitor), Geptanolimab, Lenvatinib, Sorafenib	NCT05873244	44	Phase II	PFS	Ongoing	[377]	
24	ETN101 (mTKI)	NCT06326502	50	Phase I	DLT	Ongoing	[378]	
25	Anlotinib hydrochloride, Penpulimab	NCT05862337	480	Phase III	RFS	Ongoing	[379]	
26	Camrelizumab, Lenvatinib	NCT04443309	53	Phase I/II	ORR	Ongoing	[380]	
27	Ablation: Lenvatinib + anti-PD-1	NCT05803928	70	Phase I	RFS	Ongoing	[381]	
28	Cryoablation: Tislelizumab, Lenvatinib	CASTLE-10 / NCT05897268	25	Phase II	ORR	Ongoing	[382]	
29	TACE: Lenvatinib, iodion-125	NCT04967495	171	Phase I	OS	Ongoing	[383]	
30	SBRT: AtezoBev	NCT05488522	18	Phase I	DLT	Ongoing	[384]	
31	Liver transplantation: Anti-PD-1 inhibitors	NCT05475613	59	Phase II	PFS	Ongoing	[385]	
32	Tislelizumab, Sitravatinib	NCT05407519	40	Phase II	RFS	Ongoing	[386]	
33	Penpulimab, TQB2618 (TIM-3 inhibitor), Anlotinib Hydrochloride	NCT05975645	40	Phase I	ORR	Ongoing	[387]	
34	Tislelizumab, regorafenib	NCT04183088	125	Phase II	AE, ORR, PFS	Ongoing	[388]	
35	Adebrelimab, Lenvatinib	HSBRT2401 / NCT06261125	60	Phase II	PFS	Ongoing	[389]	
36	Lenvatinib, VIC1911 (Aurora kinase A inhibitor)	NCT05718882	30	Phase II	PFS	Ongoing	[390]	
37	Pembrolizumab, Lenvatinib	PLENTY202001 / NCT04425226	192	Phase II	RFS	Ongoing	[391]	
38	iNKT Cells, Anti-PD-1, Regorafenib	NCT05962450	84	Phase II	PFS	Ongoing	[392]	
39	Oncorine (H101), Tislelizumab, Lenvatinib	NCT05675462	25	Phase I	DLT, MTD, AE	Ongoing	[393]	
40	Durvalumab, Tremelimumab	NCT05809869	25	Phase II	BOR, RAE	Ongoing	[394]	
41	Regorafenib, ICIs	NCT05573282	50	Observational	OS, PFS	Ongoing	[395]	
42	Regorafenib, PD-1 inhibitor	NCT05048017	20	Phase II	PFS	Ongoing	[396]	
43	TACE: TKIs	CHANCE-CHESS 2302 / NCT05704192	373	Observational	OS	Ongoing	[397]	
44	SBRT: Durvalumab	NCT04913480	37	Phase II	PFS	Ongoing	[398]	
45	AtezoBev	Kirros / NCT06096779	120	Phase II	AE	Ongoing	[399]	
46	Ipilimumab, Pembrolizumab, Durvalumab, Idarubicin, Bevacizumab	NCT06482801	90	Phase II	AE, PFS, ORR, DOR	Ongoing	[400]	
47	Palbociclib	NCT06478927	22	/	PFS	Ongoing	[401]	
48	OTX-2002 (mRNA MYC inhibitor), TKIs, ICI	MYCHELANGELO I / NCT05497453	190	Phase I/II	DLT, MTD, AE, ORR, DOR	Ongoing	[402]	
49	Atezolizumab, Cabozantinib, Lenvatinib	NCT05168163	122	Phase II	OS, PFS	Ongoing	[403]	
50	Tegavivint (TBL1 inhibitor), Pembrolizumab	NCT05797805	108	Phase I/II	AE, DLT,	Ongoing	[404]	
51	Toripalimab plus Lenvatinib	NCT04368078	76	Phase II	ORR	Ongoing	[405]	
52	Donafenib + Envafolimab	NCT06498622	45	Phase II	RFS	Ongoing	[406]	
53	TACE: Sintilimab (IBI308)	NCT04297280	25	Phase II	ORR	Ongoing	[407]	
54	HAIC: Tremelimumab + Durvalumab, Lenvatinib	NCT06364007	20	Phase II	ORR	Ongoing	[408]	
55	HAIC: Camrelizumab, TKIs	NCT05135364	48	Phase II	PFS	Ongoing	[409]	
56	HAIC: AtezoBev, Bevacizumab Biosimilar IBI305 + Sintilimab	CCGLC-001 / NCT05713994	300	Observational	Number of Patients Amendable to Curative Surgical Interventions	Ongoing	[410]	
57	Futibatinib, Pembrolizumab	NCT04828486	25	Phase II	PFS	Ongoing	[411]	
58	Lenvatinib	NCT05103904	19	Phase II	ORR	Ongoing	[412]	
59	Atezolizumab, Bevacizumab, Durvalumab, Tremelimumab	REFINE-IO / NCT06117891	300	Observational	OS	Ongoing	[413]	
60	TACE: Lenvatinib, Anti-PD-1 antibody, Bevacizumab Biosimilar IBI305 plus sintilimab, AtezoBev, apatinib plus camrelizumab, Sorafenib, Donafenib, Regorafenib	CCGLC-008 / NCT05717738	300	Observational	Number of Patients Amendable to Curative Surgical Interventions	Ongoing	[414]	
61	Radiotherapy: TKIs, Anti-PD-1	NCT06061445	22	/	OS, ORR	Ongoing	[415]	
62	DNAJB1-PRKACA peptide vaccine, Nivolumab, Ipilimumab	NCT04248569	56	Phase I	AE, CD4/CD8 interferon production	Ongoing	[416]	
63	HAIC: Lenvatinib, Tislelizumab, Toripalimab, Sintilimab, Camrelizumab	NCT06333561	300	Observational	OS	Ongoing	[417]	
64	Durvalumab, Lenvatinib	Dulect2020-1 / NCT04443322	20	/	PFS, RFS	Ongoing	[418]	
65	Trametinib (MEK inhibitor), Everolimus (mTOR inhibitor), Lenvatinib	NCT04803318	100	Phase II	AE	Ongoing	[419]	
66	Bevacizumab, Atezolizumab, Tislelizumab, Toripalimab, Sintilimab, Camrelizumab	NCT06323382	240	Observational	PFS	Ongoing	[420]	
67	Radiation: Durvalumab, Tremelimumab	NCT04430452	21	Phase II	ORR	Ongoing	[421]	
68	Microspheres: Chemodrug, IL2, PD1, CTLA4, VEGF antibodies	NCT04770207	100	Phase II	AE	Ongoing	[422]	
69	Tislelizumab	HESTIA / NCT05622071	50	Phase II	ORR	Ongoing	[423]	
70	Q702 (TKI), Pembrolizumab	NCT05438420	120	Phase I/II	AE, Tumor response	Ongoing	[424]	
71	Cabozantinib	NCT04204850	20	Phase II	DCR	Ongoing	[425]	
73	Anlotinib hydrochloride, TQB2450 (anti-PD-L1)	NCT04888546	20	Phase I/II	pCR, ORR	Ongoing	[426]	
Estimated numbers

AE Adverse Events, BOR Best Overall Response, DCR Disease Control Rate, DFS Disease-Free Survival, DLT Dose Limiting Toxicity, DOR Duration of remission, m month, MPR Major Pathologic Response, MTD Maximum Tolerated Dose, mTKI multiple Tyrosine Kinase Inhibitor, OSRR Organ-Specific Response Rate, pCR pathological Complete Response Rate, RAE Rate of Abscopal Effect, RFS Recurrence-Free Survival, STN Significant Tumor Necrosis, TT Time on Treatment, TTP Time to Progression

In conclusion, exploring combination therapies represents a promising future in advancing HCC treatment strategies. As research in this field continues to evolve, it holds the potential to substantially improve patient prognosis and redefine the therapeutic landscape for HCC.

Discussions and perspectives

As the prevalence of non-heritable risk factors for HCC continues to increase, it is anticipated that HCC will become more widespread in the coming decades. Despite advancements in targeted drug therapies, the predicted survival rate for HCC patients has not improved significantly. This presents a substantial burden for both the medical and social communities. It is not feasible to perform hepatic CT or MRI for every individual with CLDs or poor lifestyle habits. Consequently, there is an urgent need to identify easily quantifiable biomarkers for early detection or therapeutic indicators through liquid biopsy. This review highlights and discusses significant and recent research findings in studying HCC biomarkers.

As medical knowledge advances, the heterogeneity of HCC has become increasingly apparent to healthcare professionals. It is now widely understood that there is no universal cure for all cancers; instead, personalized medicine is the key to successful treatment. To design the most effective therapeutic regimen for each patient, it is essential to accurately identify their genetic alterations, tumor phenotypes, and immune microenvironment makeup. Ideally, comprehensive diagnostic and monitoring information could be obtained from a single blood sample, significantly reducing the need for invasive procedures such as tissue biopsy. This non-invasive approach would greatly benefit patients, eliminating unnecessary discomfort and potential complications associated with more invasive diagnostic methods.

This review does not intend to offer specific clinical recommendations to clinicians; instead, it aims to provide insights into the current research directions of biomarkers that may contribute to patients’ well-being. By showcasing the latest findings in biomarker detection using liquid biopsy, we aim to promote a deeper understanding of these innovative techniques and their implications for the future of HCC diagnosis and treatment. Furthermore, continued research and collaboration in this field will be instrumental in advancing personalized medicine and ultimately improving patient outcomes. As our understanding of HCC biomarkers evolves, we anticipate that these advancements will significantly impact the way healthcare professionals approach the management of this complex disease.

Artificial intelligence (AI) is the most promising technological advance in the 21st century. AI and machine learning have been widely applied to nearly every aspect of R&D. In terms of the research in HCC, with improved computing power, the deep learning models can integrate vast amounts of data, including patients’ healthcare records, biochemical test results, imaging, biomarkers, and corresponding clinical outcomes, that are impossible to be analyzed as a whole before. Combining AI-predicted models and histochemical morphological analysis can accurately detect the disease and predict the prognosis and treatment response [427, 428]. Future directions will include validating the stability and interpretability of the AI-generated results and extending the database to a more extensive collection to generate general diagnostic standards.

In conclusion, identifying and validating reliable and easily quantifiable biomarkers for HCC are crucial in addressing the increasing burden of this disease. Using liquid biopsy techniques for detecting these biomarkers offers a non-invasive, cost-effective, and efficient alternative to traditional diagnostic methods. Moreover, understanding the complex interplay between genetic alterations, tumor phenotypes, and immune microenvironments will be essential for developing personalized treatment strategies to improve patient outcomes significantly. As research into HCC biomarkers continues to progress, it is imperative that we also investigate novel technologies and methodologies to enhance the sensitivity and specificity of these diagnostic tools. This includes exploring the potential of combining multiple biomarkers to improve diagnostic accuracy or using advanced computational methods to analyze complex datasets to identify new biomarkers. By working together, we can overcome the challenges posed by HCC and significantly improve the lives of patients affected by this devastating disease.

Authors’ contributions

YT.C. conceptualized the study, collected literature, prepared the figures and drafted the manuscript; C.Z. edited the manuscript and figures; J.W., P.L., L.X., H.Y., Y.F. edited the manuscript; ZC.C. and N.W. conceived the idea, design the study, drafted the manuscript.

Funding

This work is financially supported by the University Research Committee of The University of Hong Kong (Project Code: 109000349), the Research Grant Committee of Hong Kong (Project Code: 17119621 and 17111424), The Health and Medical Research Fund (Project Code: 21222151, 19201591 and 15162961) and Innovation and Technology Fund (Project Code: PRP/028/22FX).

Availability of data and materials

This published article and its supplementary information files include all data generated or analyzed during this study.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Bianco C Jamialahmadi O Pelusi S Baselli G Dongiovanni P Zanoni I Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores J Hepatol 2021 74 4 775 782 10.1016/j.jhep.2020.11.024 33248170
Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I, et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol. 2021;74(4):775–82.33248170 10.1016/j.jhep.2020.11.024
2. Toh MR Wong EYT Wong SH Ng AWT Loo L-H Chow PK-H Global epidemiology and genetics of hepatocellular carcinoma Gastroenterology 2023 164 5 766 82 10.1053/j.gastro.2023.01.033 36738977
Toh MR, Wong EYT, Wong SH, Ng AWT, Loo L-H, Chow PK-H, et al. Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology. 2023;164(5):766–82.36738977 10.1053/j.gastro.2023.01.033
3. Fujiwara N Kubota N Crouchet E Koneru B Marquez CA Jajoriya AK Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease Sci Transl Med 2022 14 650 eabo4474 10.1126/scitranslmed.abo4474 35731891
Fujiwara N, Kubota N, Crouchet E, Koneru B, Marquez CA, Jajoriya AK, et al. Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. Sci Transl Med. 2022;14(650):eabo4474.35731891 10.1126/scitranslmed.abo4474
4. Li L Wang H Heterogeneity of liver cancer and personalized therapy Cancer Lett 2016 379 2 191 197 10.1016/j.canlet.2015.07.018 26213370
Li L, Wang H. Heterogeneity of liver cancer and personalized therapy. Cancer Lett. 2016;379(2):191–7.26213370 10.1016/j.canlet.2015.07.018
5. Whitfield JB Schwantes-An TH Darlay R Aithal GP Atkinson SR Bataller R A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers J Hepatol 2022 76 2 275 282 10.1016/j.jhep.2021.10.005 34656649
Whitfield JB, Schwantes-An TH, Darlay R, Aithal GP, Atkinson SR, Bataller R, et al. A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. J Hepatol. 2022;76(2):275–82.34656649 10.1016/j.jhep.2021.10.005
6. Nahon P Bamba-Funck J Layese R Trépo E Zucman-Rossi J Cagnot C Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis J Hepatol 2023 78 3 584 595 10.1016/j.jhep.2022.11.003 36427656
Nahon P, Bamba-Funck J, Layese R, Trépo E, Zucman-Rossi J, Cagnot C, et al. Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis. J Hepatol. 2023;78(3):584–95.36427656 10.1016/j.jhep.2022.11.003
7. Llovet JM Pinyol R Kelley RK El-Khoueiry A Reeves HL Wang XW Molecular pathogenesis and systemic therapies for hepatocellular carcinoma Nat Cancer 2022 3 4 386 401 10.1038/s43018-022-00357-2 35484418
Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022;3(4):386–401.35484418 10.1038/s43018-022-00357-2
8. Singal AG Zhang E Narasimman M Rich NE Waljee AK Hoshida Y HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis J Hepatol 2022 77 1 128 139 10.1016/j.jhep.2022.01.023 35139400
Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;77(1):128–39.35139400 10.1016/j.jhep.2022.01.023
9. Kansagara D Papak J Pasha AS O’Neil M Freeman M Relevo R Screening for hepatocellular carcinoma in chronic liver disease: a systematic review Ann Intern Med 2014 161 4 261 269 10.7326/M14-0558 24934699
Kansagara D, Papak J, Pasha AS, O’Neil M, Freeman M, Relevo R, et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Ann Intern Med. 2014;161(4):261–9.24934699 10.7326/M14-0558
10. Jiang HY Chen J Xia CC Cao LK Duan T Song B Noninvasive imaging of hepatocellular carcinoma: from diagnosis to prognosis World J Gastroenterol 2018 24 22 2348 2362 10.3748/wjg.v24.i22.2348 29904242
Jiang HY, Chen J, Xia CC, Cao LK, Duan T, Song B. Noninvasive imaging of hepatocellular carcinoma: from diagnosis to prognosis. World J Gastroenterol. 2018;24(22):2348–62.29904242 10.3748/wjg.v24.i22.2348
11. Li L Hu Y Han J Li Q Peng C Zhou J Clinical application of liver imaging reporting and data system for characterizing liver neoplasms: a meta-analysis Diagnostics (Basel) 2021 11 2 323 10.3390/diagnostics11020323 33671158
Li L, Hu Y, Han J, Li Q, Peng C, Zhou J. Clinical application of liver imaging reporting and data system for characterizing liver neoplasms: a meta-analysis. Diagnostics (Basel). 2021;11(2):323.33671158 10.3390/diagnostics11020323
12. Villanueva A Hepatocellular carcinoma N Engl J Med 2019 380 15 1450 1462 10.1056/NEJMra1713263 30970190
Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–62.30970190 10.1056/NEJMra1713263
13. Brown ZJ Tsilimigras DI Ruff SM Mohseni A Kamel IR Cloyd JM Management of hepatocellular carcinoma: a review JAMA Surg 2023 158 4 410 420 10.1001/jamasurg.2022.7989 36790767
Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM, et al. Management of hepatocellular carcinoma: a review. JAMA Surg. 2023;158(4):410–20.36790767 10.1001/jamasurg.2022.7989
14. Marrero JA Kulik LM Sirlin CB Zhu AX Finn RS Abecassis MM Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases Hepatology 2018 68 2 723 750 10.1002/hep.29913 29624699
Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–50.29624699 10.1002/hep.29913
15. Tzartzeva K Obi J Rich NE Parikh ND Marrero JA Yopp A Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis Gastroenterology 2018 154 6 1706 18.e1 10.1053/j.gastro.2018.01.064 29425931
Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706-18.e1.29425931 10.1053/j.gastro.2018.01.064
16. Terzi E Ayuso C Piscaglia F Bruix J Liver imaging reporting and data system: review of pros and cons Semin Liver Dis 2022 42 1 104 111 10.1055/s-0041-1732356 34298576
Terzi E, Ayuso C, Piscaglia F, Bruix J. Liver imaging reporting and data system: review of pros and cons. Semin Liver Dis. 2022;42(1):104–11.34298576 10.1055/s-0041-1732356
17. Sørensen JB Klee M Palshof T Hansen HH Performance status assessment in cancer patients. An inter-observer variability study Br J Cancer 1993 67 4 773 5 10.1038/bjc.1993.140 8471434
Sørensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer. 1993;67(4):773–5.8471434 10.1038/bjc.1993.140
18. Child CG Turcotte JG Surgery and portal hypertension Major Probl Clin Surg 1964 1 1 85 4950264
Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1–85.4950264
19. Pugh RNH Murray-Lyon IM Dawson JL Pietroni MC Williams R Transection of the oesophagus for bleeding oesophageal varices Br J Surg 2005 60 8 646 649 10.1002/bjs.1800600817
Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 2005;60(8):646–9.10.1002/bjs.1800600817
20. Kumada T Toyoda H Tada T Yasuda S Tanaka J Changes in background liver function in patients with hepatocellular carcinoma over 30 years: comparison of Child-Pugh classification and albumin bilirubin grade Liver Cancer 2020 9 5 518 528 10.1159/000507933 33083278
Kumada T, Toyoda H, Tada T, Yasuda S, Tanaka J. Changes in background liver function in patients with hepatocellular carcinoma over 30 years: comparison of Child-Pugh classification and albumin bilirubin grade. Liver Cancer. 2020;9(5):518–28.33083278 10.1159/000507933
21. Dominguez DA Wong P Melstrom LG Existing and emerging biomarkers in hepatocellular carcinoma: relevance in staging, determination of minimal residual disease, and monitoring treatment response: a narrative review Hepatobil Surg Nutr 2023 13 1 39 55 10.21037/hbsn-22-526
Dominguez DA, Wong P, Melstrom LG. Existing and emerging biomarkers in hepatocellular carcinoma: relevance in staging, determination of minimal residual disease, and monitoring treatment response: a narrative review. Hepatobil Surg Nutr. 2023;13(1):39–55.10.21037/hbsn-22-526
22. Tateishi R Uchino K Fujiwara N Takehara T Okanoue T Seike M A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update J Gastroenterol 2019 54 4 367 376 10.1007/s00535-018-1532-5 30498904
Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update. J Gastroenterol. 2019;54(4):367–76.30498904 10.1007/s00535-018-1532-5
23. Johnson PJ Berhane S Kagebayashi C Satomura S Teng M Reeves HL Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade J Clin Oncol 2015 33 6 550 558 10.1200/JCO.2014.57.9151 25512453
Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–8.25512453 10.1200/JCO.2014.57.9151
24. Kuo YH Wang JH Hung CH Rau KM Wu IP Chen CH Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use J Gastroenterol Hepatol 2017 32 12 1975 1981 10.1111/jgh.13783 28295594
Kuo YH, Wang JH, Hung CH, Rau KM, Wu IP, Chen CH, et al. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. J Gastroenterol Hepatol. 2017;32(12):1975–81.28295594 10.1111/jgh.13783
25. Pinato DJ Sharma R Allara E Yen C Arizumi T Kubota K The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma J Hepatol 2017 66 2 338 346 10.1016/j.jhep.2016.09.008 27677714
Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2017;66(2):338–46.27677714 10.1016/j.jhep.2016.09.008
26. Reig M Forner A Rimola J Ferrer-Fàbrega J Burrel M Garcia-Criado Á BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update J Hepatol 2022 76 3 681 693 10.1016/j.jhep.2021.11.018 34801630
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–93.34801630 10.1016/j.jhep.2021.11.018
27. Hackl C Schlitt HJ Renner P Lang SA Liver surgery in cirrhosis and portal hypertension World J Gastroenterol 2016 22 9 2725 2735 10.3748/wjg.v22.i9.2725 26973411
Hackl C, Schlitt HJ, Renner P, Lang SA. Liver surgery in cirrhosis and portal hypertension. World J Gastroenterol. 2016;22(9):2725–35.26973411 10.3748/wjg.v22.i9.2725
28. Berardi G Morise Z Sposito C Igarashi K Panetta V Simonelli I Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis J Hepatol 2020 72 1 75 84 10.1016/j.jhep.2019.08.032 31499131
Berardi G, Morise Z, Sposito C, Igarashi K, Panetta V, Simonelli I, et al. Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis. J Hepatol. 2020;72(1):75–84.31499131 10.1016/j.jhep.2019.08.032
29. European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma J Hepatol 2018 69 1 182 236 10.1016/j.jhep.2018.03.019 29628281
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. 10.1016/j.jhep.2018.03.019.29628281 10.1016/j.jhep.2018.03.019
30. Vogel A Cervantes A Chau I Daniele B Llovet JM Meyer T Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2018 29 Suppl 4 iv238 iv55 10.1093/annonc/mdy308 30285213
Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv238–55.30285213 10.1093/annonc/mdy308
31. Szpakowski JL Drasin TE Lyon LL Rate of seeding with biopsies and ablations of hepatocellular carcinoma: a retrospective cohort study Hepatol Commun 2017 1 9 841 851 10.1002/hep4.1089 29404497
Szpakowski JL, Drasin TE, Lyon LL. Rate of seeding with biopsies and ablations of hepatocellular carcinoma: a retrospective cohort study. Hepatol Commun. 2017;1(9):841–51.29404497 10.1002/hep4.1089
32. Lee YT Fujiwara N Yang JD Hoshida Y Risk stratification and early detection biomarkers for precision HCC screening Hepatology 2023 78 1 319 362 36082510
Lee YT, Fujiwara N, Yang JD, Hoshida Y. Risk stratification and early detection biomarkers for precision HCC screening. Hepatology. 2023;78(1):319–62.36082510
33. Johnson P Zhou Q Dao DY Lo YMD Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma Nat Rev Gastroenterol Hepatol 2022 19 10 670 681 10.1038/s41575-022-00620-y 35676420
Johnson P, Zhou Q, Dao DY, Lo YMD. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2022;19(10):670–81.35676420 10.1038/s41575-022-00620-y
34. Ye Q Ling S Zheng S Xu X Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA Mol Cancer 2019 18 1 114 10.1186/s12943-019-1043-x 31269959
Ye Q, Ling S, Zheng S, Xu X. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer. 2019;18(1):114.31269959 10.1186/s12943-019-1043-x
35. Li J Han X Yu XN Xu ZZ Yang GS Liu BQ Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA J Exp Clin Cancer Res 2018 37 1 213 10.1186/s13046-018-0893-1 30176913
Li J, Han X, Yu XN, Xu ZZ, Yang GS, Liu BQ, et al. Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. J Exp Clin Cancer Res. 2018;37(1):213.30176913 10.1186/s13046-018-0893-1
36. Galle PR Foerster F Kudo M Chan SL Llovet JM Qin S Biology and significance of alpha-fetoprotein in hepatocellular carcinoma Liver Int 2019 39 12 2214 2229 10.1111/liv.14223 31436873
Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39(12):2214–29.31436873 10.1111/liv.14223
37. Lok AS Lai CL alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma Hepatology 1989 9 1 110 115 10.1002/hep.1840090119 2461890
Lok AS, Lai CL. alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology. 1989;9(1):110–5.2461890 10.1002/hep.1840090119
38. Collier J Sherman M Screening for hepatocellular carcinoma Hepatology 1998 27 1 273 278 10.1002/hep.510270140 9425947
Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998;27(1):273–8.9425947 10.1002/hep.510270140
39. Hanif H Ali MJ Susheela AT Khan IW Luna-Cuadros MA Khan MM Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma World J Gastroenterol 2022 28 2 216 229 10.3748/wjg.v28.i2.216 35110946
Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol. 2022;28(2):216–29.35110946 10.3748/wjg.v28.i2.216
40. Gambarin-Gelwan M Wolf DC Shapiro R Schwartz ME Min AD Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation Am J Gastroenterol 2000 95 6 1535 1538 10.1111/j.1572-0241.2000.02091.x 10894592
Gambarin-Gelwan M, Wolf DC, Shapiro R, Schwartz ME, Min AD. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol. 2000;95(6):1535–8.10894592 10.1111/j.1572-0241.2000.02091.x
41. Trevisani F D’Intino PE Morselli-Labate AM Mazzella G Accogli E Caraceni P Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status J Hepatol 2001 34 4 570 575 10.1016/S0168-8278(00)00053-2 11394657
Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34(4):570–5.11394657 10.1016/S0168-8278(00)00053-2
42. Singal A Volk ML Waljee A Salgia R Higgins P Rogers MA Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis Aliment Pharmacol Ther 2009 30 1 37 47 10.1111/j.1365-2036.2009.04014.x 19392863
Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47.19392863 10.1111/j.1365-2036.2009.04014.x
43. Lok AS Sterling RK Everhart JE Wright EC Hoefs JC Di Bisceglie AM Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma Gastroenterology 2010 138 2 493 502 10.1053/j.gastro.2009.10.031 19852963
Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138(2):493–502.19852963 10.1053/j.gastro.2009.10.031
44. Di Bisceglie AM Hoofnagle JH Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B Cancer 1989 64 10 2117 2120 10.1002/1097-0142(19891115)64:10<2117::AID-CNCR2820641024>3.0.CO;2-7 2478280
Di Bisceglie AM, Hoofnagle JH. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer. 1989;64(10):2117–20.2478280 10.1002/1097-0142(19891115)64:10<2117::AID-CNCR2820641024>3.0.CO;2-7
45. Chen J Wu M Gong J Liu Z He G Zhu H Influence of alanine transaminase levels on alpha-fetoprotein for predicting hepatocellular carcinoma in patients with hepatitis B infection Biomed Res Int 2020 2020 2043715 10.1155/2020/2043715 33490235
Chen J, Wu M, Gong J, Liu Z, He G, Zhu H, et al. Influence of alanine transaminase levels on alpha-fetoprotein for predicting hepatocellular carcinoma in patients with hepatitis B infection. Biomed Res Int. 2020;2020:2043715.33490235 10.1155/2020/2043715
46. Heimbach JK Kulik LM Finn RS Sirlin CB Abecassis MM Roberts LR AASLD guidelines for the treatment of hepatocellular carcinoma Hepatology 2018 67 1 358 380 10.1002/hep.29086 28130846
Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.28130846 10.1002/hep.29086
47. Sterling RK Jeffers L Gordon F Venook AP Reddy KR Satomura S Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma Clin Gastroenterol Hepatol 2009 7 1 104 113 10.1016/j.cgh.2008.08.041 18849011
Sterling RK, Jeffers L, Gordon F, Venook AP, Reddy KR, Satomura S, et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2009;7(1):104–13.18849011 10.1016/j.cgh.2008.08.041
48. Liu S Sun L Yao L Zhu H Diao Y Wang M Diagnostic performance of AFP, AFP-L3, or PIVKA-II for hepatitis C virus-associated hepatocellular carcinoma: a multicenter analysis J Clin Med 2022 11 17 5075 10.3390/jcm11175075 36079006
Liu S, Sun L, Yao L, Zhu H, Diao Y, Wang M, et al. Diagnostic performance of AFP, AFP-L3, or PIVKA-II for hepatitis C virus-associated hepatocellular carcinoma: a multicenter analysis. J Clin Med. 2022;11(17):5075.36079006 10.3390/jcm11175075
49. Weitz IC Liebman HA Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review Hepatology 1993 18 4 990 997 10.1002/hep.1840180434 8406374
Weitz IC, Liebman HA. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology. 1993;18(4):990–7.8406374 10.1002/hep.1840180434
50. Kim DY Toan BN Tan CK Hasan I Setiawan L Yu ML Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region Clin Mol Hepatol 2023 29 2 277 292 10.3350/cmh.2022.0212 36710606
Kim DY, Toan BN, Tan CK, Hasan I, Setiawan L, Yu ML, et al. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region. Clin Mol Hepatol. 2023;29(2):277–92.36710606 10.3350/cmh.2022.0212
51. Seo SI Kim HS Kim WJ Shin WG Kim DJ Kim KH Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma World J Gastroenterol 2015 21 13 3928 3935 10.3748/wjg.v21.i13.3928 25852278
Seo SI, Kim HS, Kim WJ, Shin WG, Kim DJ, Kim KH, et al. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2015;21(13):3928–35.25852278 10.3748/wjg.v21.i13.3928
52. Wang AE Leven EA Grinspan LT Villanueva A Novel biomarkers and strategies for HCC diagnosis and care Clin Liver Dis (Hoboken) 2024 23 1 e0152 38707238
Wang AE, Leven EA, Grinspan LT, Villanueva A. Novel biomarkers and strategies for HCC diagnosis and care. Clin Liver Dis (Hoboken). 2024;23(1):e0152.38707238
53. Johnson PJ Pirrie SJ Cox TF Berhane S Teng M Palmer D The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers Cancer Epidemiol Biomark Prev 2014 23 1 144 153 10.1158/1055-9965.EPI-13-0870
Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomark Prev. 2014;23(1):144–53.10.1158/1055-9965.EPI-13-0870
54. Singal AG Tayob N Mehta A Marrero JA El-Serag H Jin Q GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis Hepatology 2022 75 3 541 549 10.1002/hep.32185 34618932
Singal AG, Tayob N, Mehta A, Marrero JA, El-Serag H, Jin Q, et al. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology. 2022;75(3):541–9.34618932 10.1002/hep.32185
55. El-Serag HB Kanwal F Davila JA Kramer J Richardson P A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis Gastroenterology 2014 146 5 1249 55.e1 10.1053/j.gastro.2014.01.045 24462733
El-Serag HB, Kanwal F, Davila JA, Kramer J, Richardson P. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology. 2014;146(5):1249-55.e1.24462733 10.1053/j.gastro.2014.01.045
56. Capurro M Wanless IR Sherman M Deboer G Shi W Miyoshi E Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma Gastroenterology 2003 125 1 89 97 10.1016/S0016-5085(03)00689-9 12851874
Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125(1):89–97.12851874 10.1016/S0016-5085(03)00689-9
57. Llovet JM Chen Y Wurmbach E Roayaie S Fiel MI Schwartz M A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis Gastroenterology 2006 131 6 1758 1767 10.1053/j.gastro.2006.09.014 17087938
Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology. 2006;131(6):1758–67.17087938 10.1053/j.gastro.2006.09.014
58. Wang XY Degos F Dubois S Tessiore S Allegretta M Guttmann RD Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas Hum Pathol 2006 37 11 1435 1441 10.1016/j.humpath.2006.05.016 16949914
Wang XY, Degos F, Dubois S, Tessiore S, Allegretta M, Guttmann RD, et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol. 2006;37(11):1435–41.16949914 10.1016/j.humpath.2006.05.016
59. Saber MA AbdelHafiz SM Khorshed FE Aboushousha TS Hamdy HE Seleem MI Differential expression of Glypican-3 and Insulin-Like growth factor-II mRNAs and Alpha-Fetoprotein and Ki-67 markers in HCV related hepatocellular carcinomas in Egyptian patients Asian Pac J Cancer Prev 2017 18 1 121 28240019
Saber MA, AbdelHafiz SM, Khorshed FE, Aboushousha TS, Hamdy HE, Seleem MI, et al. Differential expression of Glypican-3 and Insulin-Like growth factor-II mRNAs and Alpha-Fetoprotein and Ki-67 markers in HCV related hepatocellular carcinomas in Egyptian patients. Asian Pac J Cancer Prev. 2017;18(1):121.28240019
60. Wang W Zhao L-J Wang Y Tao Q-Y Feitelson MA Zhao P Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC Cancer Biomark 2012 11 1 29 39 10.3233/CBM-2012-0261
Wang W, Zhao L-J, Wang Y, Tao Q-Y, Feitelson MA, Zhao P, et al. Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC. Cancer Biomark. 2012;11(1):29–39.10.3233/CBM-2012-0261
61. Abdelgawad IA Mossallam GI Radwan NH Elzawahry HM Elhifnawy NM Can Glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients? Asian Pac J Cancer Prev 2013 14 12 7345 7349 10.7314/APJCP.2013.14.12.7345 24460300
Abdelgawad IA, Mossallam GI, Radwan NH, Elzawahry HM, Elhifnawy NM. Can Glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients? Asian Pac J Cancer Prev. 2013;14(12):7345–9.24460300 10.7314/APJCP.2013.14.12.7345
62. Nault JC Guyot E Laguillier C Chevret S Ganne-Carrie N N’Kontchou G Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis Cancer Epidemiol Biomarkers Prev 2013 22 8 1343 1352 10.1158/1055-9965.EPI-13-0179 23780836
Nault JC, Guyot E, Laguillier C, Chevret S, Ganne-Carrie N, N’Kontchou G, et al. Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis. Cancer Epidemiol Biomarkers Prev. 2013;22(8):1343–52.23780836 10.1158/1055-9965.EPI-13-0179
63. Wen Y Jeong S Xia Q Kong X Role of osteopontin in liver diseases Int J Biol Sci 2016 12 9 1121 1128 10.7150/ijbs.16445 27570486
Wen Y, Jeong S, Xia Q, Kong X. Role of osteopontin in liver diseases. Int J Biol Sci. 2016;12(9):1121–8.27570486 10.7150/ijbs.16445
64. Morales-Ibanez O Domínguez M Ki SH Marcos M Chaves JF Nguyen-Khac E Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis Hepatology 2013 58 5 1742 1756 10.1002/hep.26521 23729174
Morales-Ibanez O, Domínguez M, Ki SH, Marcos M, Chaves JF, Nguyen-Khac E, et al. Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. Hepatology. 2013;58(5):1742–56.23729174 10.1002/hep.26521
65. Abu El Makarem MA Abdel-Aleem A Ali A Saber R Shatat M Rahem DA Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma Ann Hepatol 2011 10 3 296 305 10.1016/S1665-2681(19)31541-8 21677331
Abu El Makarem MA, Abdel-Aleem A, Ali A, Saber R, Shatat M, Rahem DA, et al. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Ann Hepatol. 2011;10(3):296–305.21677331 10.1016/S1665-2681(19)31541-8
66. Shen Q Fan J Yang XR Tan Y Zhao W Xu Y Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study Lancet Oncol 2012 13 8 817 826 10.1016/S1470-2045(12)70233-4 22738799
Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13(8):817–26.22738799 10.1016/S1470-2045(12)70233-4
67. Zhu M Zheng J Wu F Kang B Liang J Heskia F OPN is a promising serological biomarker for hepatocellular carcinoma diagnosis J Med Virol 2020 92 12 3596 3603 10.1002/jmv.25704 32043608
Zhu M, Zheng J, Wu F, Kang B, Liang J, Heskia F, et al. OPN is a promising serological biomarker for hepatocellular carcinoma diagnosis. J Med Virol. 2020;92(12):3596–603.32043608 10.1002/jmv.25704
68. Gehrmann M Cervello M Montalto G Cappello F Gulino A Knape C Heat shock protein 70 serum levels differ significantly in patients with chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma Front Immunol 2014 5 307 10.3389/fimmu.2014.00307 25071768
Gehrmann M, Cervello M, Montalto G, Cappello F, Gulino A, Knape C, et al. Heat shock protein 70 serum levels differ significantly in patients with chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Front Immunol. 2014;5:307.25071768 10.3389/fimmu.2014.00307
69. Wang B Lan T Xiao H Chen Z-H Wei C Chen L-F The expression profiles and prognostic values of HSP70s in hepatocellular carcinoma Cancer Cell Int 2021 21 1 286 10.1186/s12935-021-01987-9 34059060
Wang B, Lan T, Xiao H, Chen Z-H, Wei C, Chen L-F, et al. The expression profiles and prognostic values of HSP70s in hepatocellular carcinoma. Cancer Cell Int. 2021;21(1):286.34059060 10.1186/s12935-021-01987-9
70. Chuma M Sakamoto M Yamazaki K Ohta T Ohki M Asaka M Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma Hepatology 2003 37 1 198 207 10.1053/jhep.2003.50022 12500205
Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M, et al. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology. 2003;37(1):198–207.12500205 10.1053/jhep.2003.50022
71. Mohamed SA Tealeb A-SMI The role of heat shock protein 70 and glypican 3 expression in early diagnosis of hepatocellular carcinoma Egypt J Pathol 2022 42 2 112 6 10.4103/egjp.egjp_21_22
Mohamed SA, Tealeb A-SMI. The role of heat shock protein 70 and glypican 3 expression in early diagnosis of hepatocellular carcinoma. Egypt J Pathol. 2022;42(2):112–6.10.4103/egjp.egjp_21_22
72. Marrero JA Romano PR Nikolaeva O Steel L Mehta A Fimmel CJ GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma J Hepatol 2005 43 6 1007 1012 10.1016/j.jhep.2005.05.028 16137783
Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005;43(6):1007–12.16137783 10.1016/j.jhep.2005.05.028
73. Mao Y Yang H Xu H Lu X Sang X Du S Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma Gut 2010 59 12 1687 1693 10.1136/gut.2010.214916 20876776
Mao Y, Yang H, Xu H, Lu X, Sang X, Du S, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 2010;59(12):1687–93.20876776 10.1136/gut.2010.214916
74. Pang BY Leng Y Wang X Wang YQ Jiang LH A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma Ann Med 2023 55 1 42 61 10.1080/07853890.2022.2153163 36476015
Pang BY, Leng Y, Wang X, Wang YQ, Jiang LH. A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma. Ann Med. 2023;55(1):42–61.36476015 10.1080/07853890.2022.2153163
75. Huang F Guo J Zhao N Hou M Gai X Yang S PTEN deficiency potentiates HBV-associated liver cancer development through augmented GP73/GOLM1 J Transl Med 2024 22 1 254 10.1186/s12967-024-04976-4 38459588
Huang F, Guo J, Zhao N, Hou M, Gai X, Yang S, et al. PTEN deficiency potentiates HBV-associated liver cancer development through augmented GP73/GOLM1. J Transl Med. 2024;22(1):254.38459588 10.1186/s12967-024-04976-4
76. Bankó P Lee SY Nagygyörgy V Zrínyi M Chae CH Cho DH Technologies for circulating tumor cell separation from whole blood J Hematol Oncol 2019 12 1 48 10.1186/s13045-019-0735-4 31088479
Bankó P, Lee SY, Nagygyörgy V, Zrínyi M, Chae CH, Cho DH, et al. Technologies for circulating tumor cell separation from whole blood. J Hematol Oncol. 2019;12(1):48.31088479 10.1186/s13045-019-0735-4
77. Ferreira MM Ramani VC Jeffrey SS Circulating tumor cell technologies Mol Oncol 2016 10 3 374 394 10.1016/j.molonc.2016.01.007 26897752
Ferreira MM, Ramani VC, Jeffrey SS. Circulating tumor cell technologies. Mol Oncol. 2016;10(3):374–94.26897752 10.1016/j.molonc.2016.01.007
78. Wu Y Park KJ Deighan C Amaya P Miller B Pan Q Multiparameter evaluation of the heterogeneity of circulating tumor cells using integrated RNA in situ hybridization and immunocytochemical analysis Front Oncol 2016 6 234 10.3389/fonc.2016.00234 27878106
Wu Y, Park KJ, Deighan C, Amaya P, Miller B, Pan Q, et al. Multiparameter evaluation of the heterogeneity of circulating tumor cells using integrated RNA in situ hybridization and immunocytochemical analysis. Front Oncol. 2016;6:234.27878106 10.3389/fonc.2016.00234
79. Vona G Estepa L Béroud C Damotte D Capron F Nalpas B Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer Hepatology 2004 39 3 792 797 10.1002/hep.20091 14999698
Vona G, Estepa L, Béroud C, Damotte D, Capron F, Nalpas B, et al. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology. 2004;39(3):792–7.14999698 10.1002/hep.20091
80. Qi L-N Xiang B-D Wu F-X Ye J-Z Zhong J-H Wang Y-Y Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma Cancer Res 2018 78 16 4731 4744 10.1158/0008-5472.CAN-17-2459 29915159
Qi L-N, Xiang B-D, Wu F-X, Ye J-Z, Zhong J-H, Wang Y-Y, et al. Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma. Cancer Res. 2018;78(16):4731–44.29915159 10.1158/0008-5472.CAN-17-2459
81. Guo W Sun Y-F Shen M-N Ma X-L Wu J Zhang C-Y Circulating tumor cells with stem-like phenotypes for diagnosis, prognosis, and therapeutic response evaluation in hepatocellular carcinoma Clin Cancer Res 2018 24 9 2203 2213 10.1158/1078-0432.CCR-17-1753 29374055
Guo W, Sun Y-F, Shen M-N, Ma X-L, Wu J, Zhang C-Y, et al. Circulating tumor cells with stem-like phenotypes for diagnosis, prognosis, and therapeutic response evaluation in hepatocellular carcinoma. Clin Cancer Res. 2018;24(9):2203–13.29374055 10.1158/1078-0432.CCR-17-1753
82. Coumans FAW Doggen CJM Attard G de Bono JS Terstappen L All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer Ann Oncol 2010 21 9 1851 1857 10.1093/annonc/mdq030 20147742
Coumans FAW, Doggen CJM, Attard G, de Bono JS, Terstappen L. All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer. Ann Oncol. 2010;21(9):1851–7.20147742 10.1093/annonc/mdq030
83. Sun YF Xu Y Yang XR Guo W Zhang X Qiu SJ Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection Hepatology 2013 57 4 1458 1468 10.1002/hep.26151 23175471
Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu SJ, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology. 2013;57(4):1458–68.23175471 10.1002/hep.26151
84. Guo W Yang XR Sun YF Shen MN Ma XL Wu J Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform Clin Cancer Res 2014 20 18 4794 4805 10.1158/1078-0432.CCR-14-0251 25009297
Guo W, Yang XR, Sun YF, Shen MN, Ma XL, Wu J, et al. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform. Clin Cancer Res. 2014;20(18):4794–805.25009297 10.1158/1078-0432.CCR-14-0251
85. Zhao H Ling Y He J Dong J Mo Q Wang Y Potential targets and therapeutics for cancer stem cell-based therapy against drug resistance in hepatocellular carcinoma Drug Resist Updates 2024 74 101084 10.1016/j.drup.2024.101084
Zhao H, Ling Y, He J, Dong J, Mo Q, Wang Y, et al. Potential targets and therapeutics for cancer stem cell-based therapy against drug resistance in hepatocellular carcinoma. Drug Resist Updates. 2024;74:101084.10.1016/j.drup.2024.101084
86. Okajima W Komatsu S Ichikawa D Miyamae M Ohashi T Imamura T Liquid biopsy in patients with hepatocellular carcinoma: circulating tumor cells and cell-free nucleic acids World J Gastroenterol 2017 23 31 5650 5668 10.3748/wjg.v23.i31.5650 28883691
Okajima W, Komatsu S, Ichikawa D, Miyamae M, Ohashi T, Imamura T, et al. Liquid biopsy in patients with hepatocellular carcinoma: circulating tumor cells and cell-free nucleic acids. World J Gastroenterol. 2017;23(31):5650–68.28883691 10.3748/wjg.v23.i31.5650
87. Lu Y Yang A Quan C Pan Y Zhang H Li Y A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma Nat Commun 2022 13 1 4594 10.1038/s41467-022-32283-3 35933472
Lu Y, Yang A, Quan C, Pan Y, Zhang H, Li Y, et al. A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma. Nat Commun. 2022;13(1):4594.35933472 10.1038/s41467-022-32283-3
88. Sun Y Wu P Zhang Z Wang Z Zhou K Song M Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma Cancer Cell 2024 42 1 135 56.e17 10.1016/j.ccell.2023.11.010 38101410
Sun Y, Wu P, Zhang Z, Wang Z, Zhou K, Song M, et al. Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer Cell. 2024;42(1):135-56.e17.38101410 10.1016/j.ccell.2023.11.010
89. Rostami A Lambie M Yu CW Stambolic V Waldron JN Bratman SV Senescence, necrosis, and apoptosis govern circulating cell-free DNA release kinetics Cell Rep 2020 31 13 107830 10.1016/j.celrep.2020.107830 32610131
Rostami A, Lambie M, Yu CW, Stambolic V, Waldron JN, Bratman SV. Senescence, necrosis, and apoptosis govern circulating cell-free DNA release kinetics. Cell Rep. 2020;31(13):107830.32610131 10.1016/j.celrep.2020.107830
90. Lo YMD Han DSC Jiang P Chiu RWK Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies Science 2021 372 6538 eaaw3616 10.1126/science.aaw3616 33833097
Lo YMD, Han DSC, Jiang P, Chiu RWK. Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies. Science. 2021;372(6538):eaaw3616.33833097 10.1126/science.aaw3616
91. Sun K Jiang P Chan KC Wong J Cheng YK Liang RH Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments Proc Natl Acad Sci U S A 2015 112 40 E5503 E5512 10.1073/pnas.1508736112 26392541
Sun K, Jiang P, Chan KC, Wong J, Cheng YK, Liang RH, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A. 2015;112(40):E5503–12.26392541 10.1073/pnas.1508736112
92. Corcoran RB Chabner BA Application of cell-free DNA analysis to cancer treatment N Engl J Med 2018 379 18 1754 1765 10.1056/NEJMra1706174 30380390
Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment. N Engl J Med. 2018;379(18):1754–65.30380390 10.1056/NEJMra1706174
93. Yinzhong W Miaomiao W Xiaoxue T Qian W Meng Q Junqiang L Diagnostic accuracy of circulating-free DNA for the determination of hepatocellular carcinoma: a systematic review and meta-analysis Expert Rev Mol Diagn 2023 23 1 63 69 10.1080/14737159.2023.2167555 36633401
Yinzhong W, Miaomiao W, Xiaoxue T, Qian W, Meng Q, Junqiang L. Diagnostic accuracy of circulating-free DNA for the determination of hepatocellular carcinoma: a systematic review and meta-analysis. Expert Rev Mol Diagn. 2023;23(1):63–9.36633401 10.1080/14737159.2023.2167555
94. Zinkova A Brynychova I Svacina A Jirkovska M Korabecna M Cell-free DNA from human plasma and serum differs in content of telomeric sequences and its ability to promote immune response Sci Rep 2017 7 1 2591 10.1038/s41598-017-02905-8 28572683
Zinkova A, Brynychova I, Svacina A, Jirkovska M, Korabecna M. Cell-free DNA from human plasma and serum differs in content of telomeric sequences and its ability to promote immune response. Sci Rep. 2017;7(1):2591.28572683 10.1038/s41598-017-02905-8
95. Martignano F Cell-free DNA: an overview of sample types and isolation procedures Methods Mol Biol 2019 1909 13 27 10.1007/978-1-4939-8973-7_2 30580420
Martignano F. Cell-free DNA: an overview of sample types and isolation procedures. Methods Mol Biol. 2019;1909:13–27.30580420 10.1007/978-1-4939-8973-7_2
96. van Dessel LF Beije N Helmijr JC Vitale SR Kraan J Look MP Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions Mol Oncol 2017 11 3 295 304 10.1002/1878-0261.12037 28164427
van Dessel LF, Beije N, Helmijr JC, Vitale SR, Kraan J, Look MP, et al. Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions. Mol Oncol. 2017;11(3):295–304.28164427 10.1002/1878-0261.12037
97. Winstead E. FDA authorizes blood test for assessing risk of hereditary cancers. NCI; 2023. [updated November 2, 2023]. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2023/fda-blood-test-hereditary-cancer-risk.
98. Ako S Nouso K Kinugasa H Matsushita H Terasawa H Adachi T Human telomerase reverse transcriptase gene promoter mutation in serum of patients with hepatocellular carcinoma Oncology 2020 98 5 311 317 10.1159/000506135 32135540
Ako S, Nouso K, Kinugasa H, Matsushita H, Terasawa H, Adachi T, et al. Human telomerase reverse transcriptase gene promoter mutation in serum of patients with hepatocellular carcinoma. Oncology. 2020;98(5):311–7.32135540 10.1159/000506135
99. Xiong Y Xie CR Zhang S Chen J Yin ZY Detection of a novel panel of somatic mutations in plasma cell-free DNA and its diagnostic value in hepatocellular carcinoma Cancer Manag Res 2019 11 5745 5756 10.2147/CMAR.S197455 31303788
Xiong Y, Xie CR, Zhang S, Chen J, Yin ZY. Detection of a novel panel of somatic mutations in plasma cell-free DNA and its diagnostic value in hepatocellular carcinoma. Cancer Manag Res. 2019;11:5745–56.31303788 10.2147/CMAR.S197455
100. Cai ZX Chen G Zeng YY Dong XQ Lin MJ Huang XH Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma Int J Cancer 2017 141 5 977 985 10.1002/ijc.30798 28543104
Cai ZX, Chen G, Zeng YY, Dong XQ, Lin MJ, Huang XH, et al. Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma. Int J Cancer. 2017;141(5):977–85.28543104 10.1002/ijc.30798
101. An Y Guan YF Xu YP Han YX Wu C Bao CH The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma Am J Transl Res 2019 11 10 6462 6474 31737198
An Y, Guan YF, Xu YP, Han YX, Wu C, Bao CH, et al. The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma. Am J Transl Res. 2019;11(10):6462–74.31737198
102. Tao KS Bian ZY Zhang Q Guo X Yin C Wang Y Machine learning-based genome-wide interrogation of somatic copy number aberrations in circulating tumor DNA for early detection of hepatocellular carcinoma Ebiomedicine 2020 56 102811 10.1016/j.ebiom.2020.102811 32512514
Tao KS, Bian ZY, Zhang Q, Guo X, Yin C, Wang Y, et al. Machine learning-based genome-wide interrogation of somatic copy number aberrations in circulating tumor DNA for early detection of hepatocellular carcinoma. Ebiomedicine. 2020;56:102811.32512514 10.1016/j.ebiom.2020.102811
103. Alunni-Fabbroni M Weber S Öcal O Seidensticker M Mayerle J Malfertheiner P Circulating cell-free DNA combined to magnetic resonance imaging for early detection of HCC in patients with liver cirrhosis Cancers 2021 13 3 521 10.3390/cancers13030521 33572923
Alunni-Fabbroni M, Weber S, Öcal O, Seidensticker M, Mayerle J, Malfertheiner P, et al. Circulating cell-free DNA combined to magnetic resonance imaging for early detection of HCC in patients with liver cirrhosis. Cancers. 2021;13(3):521.33572923 10.3390/cancers13030521
104. Cai Z Zhang J He Y Xia L Dong X Chen G Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma Esmo Open 2021 6 1 100021 10.1016/j.esmoop.2020.100021 33508734
Cai Z, Zhang J, He Y, Xia L, Dong X, Chen G, et al. Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Esmo Open. 2021;6(1):100021.33508734 10.1016/j.esmoop.2020.100021
105. Cai ZX Chen G Zeng YY Dong XQ Li ZL Huang YB Comprehensive liquid profiling of circulating tumor DNA and protein biomarkers in long-term follow-up patients with hepatocellular carcinoma Clin Cancer Res 2019 25 17 5284 5294 10.1158/1078-0432.CCR-18-3477 31217202
Cai ZX, Chen G, Zeng YY, Dong XQ, Li ZL, Huang YB, et al. Comprehensive liquid profiling of circulating tumor DNA and protein biomarkers in long-term follow-up patients with hepatocellular carcinoma. Clin Cancer Res. 2019;25(17):5284–94.31217202 10.1158/1078-0432.CCR-18-3477
106. Chae H Sung PS Choi H Kwon A Kang D Kim Y Targeted next-generation sequencing of plasma cell-free DNA in Korean patients with hepatocellular carcinoma Ann Lab Med 2021 41 2 198 206 10.3343/alm.2021.41.2.198 33063681
Chae H, Sung PS, Choi H, Kwon A, Kang D, Kim Y, et al. Targeted next-generation sequencing of plasma cell-free DNA in Korean patients with hepatocellular carcinoma. Ann Lab Med. 2021;41(2):198–206.33063681 10.3343/alm.2021.41.2.198
107. Chen G Peng F Dong XQ Cai ZX Li ZL He L Identification of tumor mutations in plasma based on mutation variant frequency change (MVFC) Mol Oncol 2023 17 9 1871 1883 10.1002/1878-0261.13498 37496285
Chen G, Peng F, Dong XQ, Cai ZX, Li ZL, He L, et al. Identification of tumor mutations in plasma based on mutation variant frequency change (MVFC). Mol Oncol. 2023;17(9):1871–83.37496285 10.1002/1878-0261.13498
108. Chen H Sun LY Zheng HQ Zhang QF Jin XM Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma Pathology 2012 44 4 318 324 10.1097/PAT.0b013e328353a24c 28193336
Chen H, Sun LY, Zheng HQ, Zhang QF, Jin XM. Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma. Pathology. 2012;44(4):318–24.28193336 10.1097/PAT.0b013e328353a24c
109. Cowzer D White JB Chou JF Chen PJ Kim TH Khalil DN Targeted molecular profiling of circulating cell-free DNA in patients with advanced hepatocellular carcinoma JCO Precis Oncol 2023 7 e2300272 10.1200/PO.23.00272 37769223
Cowzer D, White JB, Chou JF, Chen PJ, Kim TH, Khalil DN, et al. Targeted molecular profiling of circulating cell-free DNA in patients with advanced hepatocellular carcinoma. JCO Precis Oncol. 2023;7:e2300272.37769223 10.1200/PO.23.00272
110. Ge ZH Helmijr JCA Jansen M Boor PPC Noordam L Peppelenbosch M Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma Transl Oncol 2021 14 7 101073 10.1016/j.tranon.2021.101073 33915518
Ge ZH, Helmijr JCA, Jansen M, Boor PPC, Noordam L, Peppelenbosch M, et al. Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma. Transl Oncol. 2021;14(7):101073.33915518 10.1016/j.tranon.2021.101073
111. Han LY Fan YC Mu NN Gao S Li F Ji XF Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B virus associated hepatocellular carcinoma Int J Med Sci 2014 11 2 164 171 10.7150/ijms.6745 24465162
Han LY, Fan YC, Mu NN, Gao S, Li F, Ji XF, et al. Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B virus associated hepatocellular carcinoma. Int J Med Sci. 2014;11(2):164–71.24465162 10.7150/ijms.6745
112. Higuera M Vargas-Accarino E Torrens M Gregori J Salcedo MT Martínez-Campreciós J Ultra deep sequencing of circulating cell-free DNA as a potential tool for hepatocellular carcinoma management Cancers 2022 14 16 3875 10.3390/cancers14163875 36010868
Higuera M, Vargas-Accarino E, Torrens M, Gregori J, Salcedo MT, Martínez-Campreciós J, et al. Ultra deep sequencing of circulating cell-free DNA as a potential tool for hepatocellular carcinoma management. Cancers. 2022;14(16):3875.36010868 10.3390/cancers14163875
113. Hu N Fan XP Fan YC Chen LY Qiao CY Han LY Hypomethylated ubiquitin-conjugating enzyme2 Q1 (UBE2Q1) gene promoter in the serum is a promising biomarker for hepatitis B virus-associated hepatocellular carcinoma Tohoku J Exp Med 2017 242 2 93 100 10.1620/tjem.242.93 28592717
Hu N, Fan XP, Fan YC, Chen LY, Qiao CY, Han LY, et al. Hypomethylated ubiquitin-conjugating enzyme2 Q1 (UBE2Q1) gene promoter in the serum is a promising biomarker for hepatitis B virus-associated hepatocellular carcinoma. Tohoku J Exp Med. 2017;242(2):93–100.28592717 10.1620/tjem.242.93
114. Huang A Zhang X Zhou SL Cao Y Huang XW Fan J Plasma circulating cell-free DNA integrity as a promising biomarker for diagnosis and surveillance in patients with hepatocellular carcinoma J Cancer 2016 7 13 1798 1803 10.7150/jca.15618 27698918
Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, Fan J, et al. Plasma circulating cell-free DNA integrity as a promising biomarker for diagnosis and surveillance in patients with hepatocellular carcinoma. J Cancer. 2016;7(13):1798–803.27698918 10.7150/jca.15618
115. Huang A Zhang X Zhou SL Cao Y Huang XW Fan J Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity J Cancer 2016 7 13 1907 1914 10.7150/jca.15823 27698932
Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, Fan J, et al. Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity. J Cancer. 2016;7(13):1907–14.27698932 10.7150/jca.15823
116. Huang GM Krocker JD Kirk JL Merwat SN Ju H Soloway RD Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma Clin Chem Lab Med 2014 52 6 899 909 10.1515/cclm-2013-0885 24406287
Huang GM, Krocker JD, Kirk JL, Merwat SN, Ju H, Soloway RD, et al. Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma. Clin Chem Lab Med. 2014;52(6):899–909.24406287 10.1515/cclm-2013-0885
117. Jiao JJ Sanchez J Thompson EJ Mao XZ McCormick JB Fisher-Hoch SP Somatic mutations in circulating cell-free DNA and risk for hepatocellular carcinoma in Hispanics Int J Mol Sci 2021 22 14 7411 10.3390/ijms22147411 34299031
Jiao JJ, Sanchez J, Thompson EJ, Mao XZ, McCormick JB, Fisher-Hoch SP, et al. Somatic mutations in circulating cell-free DNA and risk for hepatocellular carcinoma in Hispanics. Int J Mol Sci. 2021;22(14):7411.34299031 10.3390/ijms22147411
118. Kandimalla R Xu JF Link A Matsuyama T Yamamura K Parker MI EpiPanGI Dx: a cell-free DNA methylation fingerprint for the early detection of gastrointestinal cancers Clin Cancer Res 2021 27 22 6135 6144 10.1158/1078-0432.CCR-21-1982 34465601
Kandimalla R, Xu JF, Link A, Matsuyama T, Yamamura K, Parker MI, et al. EpiPanGI Dx: a cell-free DNA methylation fingerprint for the early detection of gastrointestinal cancers. Clin Cancer Res. 2021;27(22):6135–44.34465601 10.1158/1078-0432.CCR-21-1982
119. Kim SC Kim DW Cho EJ Lee JY Kim J Kwon C A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma Mol Cancer 2023 22 1 164 10.1186/s12943-023-01872-1 37803338
Kim SC, Kim DW, Cho EJ, Lee JY, Kim J, Kwon C, et al. A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma. Mol Cancer. 2023;22(1):164.37803338 10.1186/s12943-023-01872-1
120. Kumar S Nadda N Paul S Gamanagatti S Dash NR Vanamail P Evaluation of the cell-free DNA integrity index as a liquid biopsy marker to differentiate hepatocellular carcinoma from chronic liver disease Front Mol Biosci 2022 9 1024193 10.3389/fmolb.2022.1024193 36483538
Kumar S, Nadda N, Paul S, Gamanagatti S, Dash NR, Vanamail P, et al. Evaluation of the cell-free DNA integrity index as a liquid biopsy marker to differentiate hepatocellular carcinoma from chronic liver disease. Front Mol Biosci. 2022;9:1024193.36483538 10.3389/fmolb.2022.1024193
121. Kunadirek P Chuaypen N Jenjaroenpun P Wongsurawat T Pinjaroen N Sirichindakul P Cell-free DNA analysis by whole-exome sequencing for hepatocellular carcinoma: a pilot study in Thailand Cancers 2021 13 9 2229 10.3390/cancers13092229 34066484
Kunadirek P, Chuaypen N, Jenjaroenpun P, Wongsurawat T, Pinjaroen N, Sirichindakul P, et al. Cell-free DNA analysis by whole-exome sequencing for hepatocellular carcinoma: a pilot study in Thailand. Cancers. 2021;13(9):2229.34066484 10.3390/cancers13092229
122. Labgaa I Villacorta-Martin C D’Avola D Craig AJ von Felden J Martins SN A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma Oncogene 2018 37 27 3740 3752 10.1038/s41388-018-0206-3 29628508
Labgaa I, Villacorta-Martin C, D’Avola D, Craig AJ, von Felden J, Martins SN, et al. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene. 2018;37(27):3740–52.29628508 10.1038/s41388-018-0206-3
123. Lee HW Kim E Cho KJ Park HJ Seo J Lee H Applications of molecular barcode sequencing for the detection of low-frequency variants in circulating tumour DNA from hepatocellular carcinoma Liver Int 2022 42 10 2317 2326 10.1111/liv.15356 35776657
Lee HW, Kim E, Cho KJ, Park HJ, Seo J, Lee H, et al. Applications of molecular barcode sequencing for the detection of low-frequency variants in circulating tumour DNA from hepatocellular carcinoma. Liver Int. 2022;42(10):2317–26.35776657 10.1111/liv.15356
124. Liang WJ Xu ZG Kong FY Huang X Xiao YX Zhou W Circulating tumour cell combined with DNA methylation for early detection of hepatocellular carcinoma Front Genet 2022 13 1065693 10.3389/fgene.2022.1065693 36479252
Liang WJ, Xu ZG, Kong FY, Huang X, Xiao YX, Zhou W, et al. Circulating tumour cell combined with DNA methylation for early detection of hepatocellular carcinoma. Front Genet. 2022;13:1065693.36479252 10.3389/fgene.2022.1065693
125. Liao WJ Yang HY Xu HF Wang YN Ge PL Ren JJ Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing Oncotarget 2016 7 26 40481 40490 10.18632/oncotarget.9629 27248174
Liao WJ, Yang HY, Xu HF, Wang YN, Ge PL, Ren JJ, et al. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing. Oncotarget. 2016;7(26):40481–90.27248174 10.18632/oncotarget.9629
126. Ma XY Wang Z Wang SY Tian Y Xie B Li J The assessment of circulating tumor DNA associated with Wnt/β-catenin signaling pathway as a diagnostic tool for liver cancer: a systematic review and meta-analysis Expert Rev Anticancer Ther 2024 24 3–4 155 67 10.1080/14737140.2024.2312246 38299537
Ma XY, Wang Z, Wang SY, Tian Y, Xie B, Li J, et al. The assessment of circulating tumor DNA associated with Wnt/β-catenin signaling pathway as a diagnostic tool for liver cancer: a systematic review and meta-analysis. Expert Rev Anticancer Ther. 2024;24(3–4):155–67.38299537 10.1080/14737140.2024.2312246
127. Matsumae T Kodama T Myojin Y Maesaka K Sakamori R Takuwa A Circulating cell-free DNA profiling predicts the therapeutic outcome in advanced hepatocellular carcinoma patients treated with combination immunotherapy Cancers 2022 14 14 3367 10.3390/cancers14143367 35884434
Matsumae T, Kodama T, Myojin Y, Maesaka K, Sakamori R, Takuwa A, et al. Circulating cell-free DNA profiling predicts the therapeutic outcome in advanced hepatocellular carcinoma patients treated with combination immunotherapy. Cancers. 2022;14(14):3367.35884434 10.3390/cancers14143367
128. Muraoka M Maekawa S Katoh R Komiyama Y Nakakuki N Takada H Usefulness of cell-free human telomerase reverse transcriptase mutant DNA quantification in blood for predicting hepatocellular carcinoma treatment efficacy Hepatol Commun 2021 5 11 1927 1938 10.1002/hep4.1762 34558819
Muraoka M, Maekawa S, Katoh R, Komiyama Y, Nakakuki N, Takada H, et al. Usefulness of cell-free human telomerase reverse transcriptase mutant DNA quantification in blood for predicting hepatocellular carcinoma treatment efficacy. Hepatol Commun. 2021;5(11):1927–38.34558819 10.1002/hep4.1762
129. Nakatsuka T Nakagawa H Hayata Y Wake T Yamada T Kinoshita MN Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma J Gastroenterol 2021 56 5 456 469 10.1007/s00535-021-01773-4 33712873
Nakatsuka T, Nakagawa H, Hayata Y, Wake T, Yamada T, Kinoshita MN, et al. Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma. J Gastroenterol. 2021;56(5):456–69.33712873 10.1007/s00535-021-01773-4
130. Nguyen VC Nguyen TH Phan TH Tran THT Pham TTT Ho TD Fragment length profiles of cancer mutations enhance detection of circulating tumor DNA in patients with early-stage hepatocellular carcinoma BMC Cancer 2023 23 1 233 10.1186/s12885-023-10681-0 36915069
Nguyen VC, Nguyen TH, Phan TH, Tran THT, Pham TTT, Ho TD, et al. Fragment length profiles of cancer mutations enhance detection of circulating tumor DNA in patients with early-stage hepatocellular carcinoma. BMC Cancer. 2023;23(1):233.36915069 10.1186/s12885-023-10681-0
131. Ono A Fujimoto A Yamamoto Y Akamatsu S Hiraga N Imamura M Circulating tumor DNA analysis for liver cancers and its usefulness as a liquid biopsy Cell Mol Gastroenterol Hepatol 2015 1 5 516 534 10.1016/j.jcmgh.2015.06.009 28210698
Ono A, Fujimoto A, Yamamoto Y, Akamatsu S, Hiraga N, Imamura M, et al. Circulating tumor DNA analysis for liver cancers and its usefulness as a liquid biopsy. Cell Mol Gastroenterol Hepatol. 2015;1(5):516–34.28210698 10.1016/j.jcmgh.2015.06.009
132. Oversoe SK Clement MS Weber B Gronbæk H Hamilton-Dutoit SJ Sorensen BS Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma BMC Cancer 2021 21 1 376 10.1186/s12885-021-08103-0 33827453
Oversoe SK, Clement MS, Weber B, Gronbæk H, Hamilton-Dutoit SJ, Sorensen BS, et al. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma. BMC Cancer. 2021;21(1):376.33827453 10.1186/s12885-021-08103-0
133. Papatheodoridi A Chatzigeorgiou A Chrysavgis L Lembessis P Loglio A Facchetti F Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients J Viral Hepatitis 2021 28 3 464 474 10.1111/jvh.13446
Papatheodoridi A, Chatzigeorgiou A, Chrysavgis L, Lembessis P, Loglio A, Facchetti F, et al. Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients. J Viral Hepatitis. 2021;28(3):464–74.10.1111/jvh.13446
134. Qu CF Wang YT Wang P Chen K Wang MJ Zeng HM Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy Proc Natl Acad Sci U S A 2019 116 13 6308 6312 10.1073/pnas.1819799116 30858324
Qu CF, Wang YT, Wang P, Chen K, Wang MJ, Zeng HM, et al. Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy. Proc Natl Acad Sci U S A. 2019;116(13):6308–12.30858324 10.1073/pnas.1819799116
135. Villar S Le Roux-Goglin E Gouas DA Plymoth A Ferro G Boniol M Seasonal variation in TP53R249S-mutated serum DNA with aflatoxin exposure and hepatitis B virus infection Environ Health Perspect 2011 119 11 1635 1640 10.1289/ehp.1103539 21768053
Villar S, Le Roux-Goglin E, Gouas DA, Plymoth A, Ferro G, Boniol M, et al. Seasonal variation in TP53 R249S-mutated serum DNA with aflatoxin exposure and hepatitis B virus infection. Environ Health Perspect. 2011;119(11):1635–40.21768053 10.1289/ehp.1103539
136. Wang J Yang L Diao YJ Liu JY Li JJ Li R Circulating tumour DNA methylation in hepatocellular carcinoma diagnosis using digital droplet PCR J Int Med Res 2021 49 3 300060521992962 10.1177/0300060521992962 33750234
Wang J, Yang L, Diao YJ, Liu JY, Li JJ, Li R, et al. Circulating tumour DNA methylation in hepatocellular carcinoma diagnosis using digital droplet PCR. J Int Med Res. 2021;49(3):300060521992962.33750234 10.1177/0300060521992962
137. Wang JH Qin Y Li B Sun ZL Yang B Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients Clin Biochem 2006 39 4 344 348 10.1016/j.clinbiochem.2006.01.008 16527261
Wang JH, Qin Y, Li B, Sun ZL, Yang B. Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin Biochem. 2006;39(4):344–8.16527261 10.1016/j.clinbiochem.2006.01.008
138. Wang P Song QQ Ren J Zhang WL Wang YT Zhou L Simultaneous analysis of mutations and methylations in circulating cell-free DNA for hepatocellular carcinoma detection Sci Transl Med 2022 14 672 eabp8704 10.1126/scitranslmed.abp8704 36417488
Wang P, Song QQ, Ren J, Zhang WL, Wang YT, Zhou L, et al. Simultaneous analysis of mutations and methylations in circulating cell-free DNA for hepatocellular carcinoma detection. Sci Transl Med. 2022;14(672):eabp8704.36417488 10.1126/scitranslmed.abp8704
139. Wu T Fan R Bai J Yang Z Qian YS Du LT The development of a cSMART-based integrated model for hepatocellular carcinoma diagnosis J Hematol Oncol 2023 16 1 1 10.1186/s13045-022-01396-z 36600307
Wu T, Fan R, Bai J, Yang Z, Qian YS, Du LT, et al. The development of a cSMART-based integrated model for hepatocellular carcinoma diagnosis. J Hematol Oncol. 2023;16(1):1.36600307 10.1186/s13045-022-01396-z
140. Yu X Lei XZ Application of the multi-omics liquid biopsy method M2P-HCC in early liver cancer screening for high-risk individuals with hepatitis B-related liver cancer Diagnostics 2023 13 15 2484 10.3390/diagnostics13152484 37568847
Yu X, Lei XZ. Application of the multi-omics liquid biopsy method M2P-HCC in early liver cancer screening for high-risk individuals with hepatitis B-related liver cancer. Diagnostics. 2023;13(15):2484.37568847 10.3390/diagnostics13152484
141. Zhang A, Lee TJ, Jain S, Su YH, editors. Urine as an alternative to blood for cancer liquid biopsy and precision medicine. In: IEEE International Conference on Bioinformatics and Biomedicine (BIBM) - Human Genomics; 2018 Dec 03–06. Madrid: IEEE (Institute of Electrical and Electronics Engineers); 2018. 10.1109/BIBM.2018.8621453.
142. Zhang HK Dong PL Fan HL Liang H Zhang K Zhao YQ Gene body hypomethylation of pyroptosis-related genes NLRP7, NLRP2, and NLRP3 facilitate non-invasive surveillance of hepatocellular carcinoma Funct Integr Genomics 2023 23 2 198 10.1007/s10142-023-01114-z 37273114
Zhang HK, Dong PL, Fan HL, Liang H, Zhang K, Zhao YQ, et al. Gene body hypomethylation of pyroptosis-related genes NLRP7, NLRP2, and NLRP3 facilitate non-invasive surveillance of hepatocellular carcinoma. Funct Integr Genomics. 2023;23(2):198.37273114 10.1007/s10142-023-01114-z
143. Zhang HK Dong PL Guo SC Tao CC Chen W Zhao WM Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing BMC Med 2020 18 1 200 10.1186/s12916-020-01667-x 32741373
Zhang HK, Dong PL, Guo SC, Tao CC, Chen W, Zhao WM, et al. Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing. BMC Med. 2020;18(1):200.32741373 10.1186/s12916-020-01667-x
144. Zhao YT Zhao L Jin HF Xie Y Chen LYH Zhang W Plasma methylated GNB4 and Riplet as a novel dual-marker panel for the detection of hepatocellular carcinoma Epigenetics 2024 19 1 2299044 10.1080/15592294.2023.2299044 38154055
Zhao YT, Zhao L, Jin HF, Xie Y, Chen LYH, Zhang W, et al. Plasma methylated GNB4 and Riplet as a novel dual-marker panel for the detection of hepatocellular carcinoma. Epigenetics. 2024;19(1):2299044.38154055 10.1080/15592294.2023.2299044
145. Jiang P Chan CWM Chan KCA Cheng SH Wong J Wong VW-S Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients Proc Natl Acad Sci 2015 112 11 E1317 E25 10.1073/pnas.1500076112 25646427
Jiang P, Chan CWM, Chan KCA, Cheng SH, Wong J, Wong VW-S, et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci. 2015;112(11):E1317–25.25646427 10.1073/pnas.1500076112
146. Jiang P Sun K Tong YK Cheng SH Cheng THT Heung MMS Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma Proc Natl Acad Sci 2018 115 46 E10925 E10933 10.1073/pnas.1814616115 30373822
Jiang P, Sun K, Tong YK, Cheng SH, Cheng THT, Heung MMS, et al. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. Proc Natl Acad Sci. 2018;115(46):E10925–33.30373822 10.1073/pnas.1814616115
147. Zeng Y Hu S Luo Y He K Exosome cargos as biomarkers for diagnosis and prognosis of hepatocellular carcinoma Pharmaceutics 2023 15 9 2365 10.3390/pharmaceutics15092365 37765333
Zeng Y, Hu S, Luo Y, He K. Exosome cargos as biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Pharmaceutics. 2023;15(9):2365.37765333 10.3390/pharmaceutics15092365
148. Guo S Hu CX Zhai XY Sun D Circular RNA 0006602 in plasma exosomes: a new potential diagnostic biomarker for hepatocellular carcinoma Am J Transl Res 2021 13 6 6001 6015 34306340
Guo S, Hu CX, Zhai XY, Sun D. Circular RNA 0006602 in plasma exosomes: a new potential diagnostic biomarker for hepatocellular carcinoma. Am J Transl Res. 2021;13(6):6001–15.34306340
149. Lin J Lin WS Bai YN Liao YL Lin QY Chen LF Identification of exosomal hsa-miR-483-5p as a potential biomarker for hepatocellular carcinoma via microRNA expression profiling of tumor-derived exosomes Exp Cell Res 2022 417 2 113232 10.1016/j.yexcr.2022.113232 35659970
Lin J, Lin WS, Bai YN, Liao YL, Lin QY, Chen LF, et al. Identification of exosomal hsa-miR-483-5p as a potential biomarker for hepatocellular carcinoma via microRNA expression profiling of tumor-derived exosomes. Exp Cell Res. 2022;417(2):113232.35659970 10.1016/j.yexcr.2022.113232
150. Rui T Zhang XB Guo JF Xiang AZ Tang N Liu J Serum-exosome-derived miRNAs serve as promising biomarkers for HCC diagnosis Cancers 2023 15 1 205 10.3390/cancers15010205
Rui T, Zhang XB, Guo JF, Xiang AZ, Tang N, Liu J, et al. Serum-exosome-derived miRNAs serve as promising biomarkers for HCC diagnosis. Cancers. 2023;15(1):205.10.3390/cancers15010205
151. Li L-M Hu Z-B Zhou Z-X Chen X Liu F-Y Zhang J-F Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma Cancer Res 2010 70 23 9798 9807 10.1158/0008-5472.CAN-10-1001 21098710
Li L-M, Hu Z-B, Zhou Z-X, Chen X, Liu F-Y, Zhang J-F, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 2010;70(23):9798–807.21098710 10.1158/0008-5472.CAN-10-1001
152. Chen WB Jiang JJ Gong L Shu ZY Xiang DR Zhang XJ Hepatitis B virus P protein initiates glycolytic bypass in HBV-related hepatocellular carcinoma via a FOXO3/miRNA-30b-5p/MINPP1 axis J Exp Clin Cancer Res 2021 40 1 1 8 10.1186/s13046-020-01803-8 33390177
Chen WB, Jiang JJ, Gong L, Shu ZY, Xiang DR, Zhang XJ, et al. Hepatitis B virus P protein initiates glycolytic bypass in HBV-related hepatocellular carcinoma via a FOXO3/miRNA-30b-5p/MINPP1 axis. J Exp Clin Cancer Res. 2021;40(1):1–8.33390177 10.1186/s13046-020-01803-8
153. El-Maraghy SA Adel O Zayed N Yosry A El-Nahaas SM Gibriel AA Circulatory miRNA-484, 524, 615 and 628 expression profiling in HCV mediated HCC among Egyptian patients; implications for diagnosis and staging of hepatic cirrhosis and fibrosis J Adv Res 2020 22 57 66 10.1016/j.jare.2019.12.002 31956442
El-Maraghy SA, Adel O, Zayed N, Yosry A, El-Nahaas SM, Gibriel AA. Circulatory miRNA-484, 524, 615 and 628 expression profiling in HCV mediated HCC among Egyptian patients; implications for diagnosis and staging of hepatic cirrhosis and fibrosis. J Adv Res. 2020;22:57–66.31956442 10.1016/j.jare.2019.12.002
154. Zhang L Liu Q Guo Y Tian L Chen K Bai D DNA-based molecular classifiers for the profiling of gene expression signatures J Nanobiotechnol 2024 22 1 189 10.1186/s12951-024-02445-0
Zhang L, Liu Q, Guo Y, Tian L, Chen K, Bai D, et al. DNA-based molecular classifiers for the profiling of gene expression signatures. J Nanobiotechnol. 2024;22(1):189.10.1186/s12951-024-02445-0
155. Kristensen LS Jakobsen T Hager H Kjems J The emerging roles of circRNAs in cancer and oncology Nat Rev Clin Oncol 2022 19 3 188 206 10.1038/s41571-021-00585-y 34912049
Kristensen LS, Jakobsen T, Hager H, Kjems J. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol. 2022;19(3):188–206.34912049 10.1038/s41571-021-00585-y
156. Zhang F Jiang J Qian H Yan Y Xu W Exosomal circRNA: emerging insights into cancer progression and clinical application potential J Hematol Oncol 2023 16 1 67 10.1186/s13045-023-01452-2 37365670
Zhang F, Jiang J, Qian H, Yan Y, Xu W. Exosomal circRNA: emerging insights into cancer progression and clinical application potential. J Hematol Oncol. 2023;16(1):67.37365670 10.1186/s13045-023-01452-2
157. Han D Li J Wang H Su X Hou J Gu Y Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression Hepatology 2017 66 4 1151 1164 10.1002/hep.29270 28520103
Han D, Li J, Wang H, Su X, Hou J, Gu Y, et al. Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. Hepatology. 2017;66(4):1151–64.28520103 10.1002/hep.29270
158. Klingenberg M Matsuda A Diederichs S Patel T Non-coding RNA in hepatocellular carcinoma: mechanisms, biomarkers and therapeutic targets J Hepatol 2017 67 3 603 619 10.1016/j.jhep.2017.04.009 28438689
Klingenberg M, Matsuda A, Diederichs S, Patel T. Non-coding RNA in hepatocellular carcinoma: mechanisms, biomarkers and therapeutic targets. J Hepatol. 2017;67(3):603–19.28438689 10.1016/j.jhep.2017.04.009
159. Liu F Xiang G Jiang D Zhang L Chen X Liu L Ultrasensitive strategy based on PtPd nanodendrite/nano-flower-like@GO signal amplification for the detection of long non-coding RNA Biosens Bioelectron 2015 74 214 221 10.1016/j.bios.2015.06.021 26143461
Liu F, Xiang G, Jiang D, Zhang L, Chen X, Liu L, et al. Ultrasensitive strategy based on PtPd nanodendrite/nano-flower-like@GO signal amplification for the detection of long non-coding RNA. Biosens Bioelectron. 2015;74:214–21.26143461 10.1016/j.bios.2015.06.021
160. Xie H Ma H Zhou D Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma Biomed Res Int 2013 2013 136106 10.1155/2013/136106 23762823
Xie H, Ma H, Zhou D. Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. Biomed Res Int. 2013;2013:136106.23762823 10.1155/2013/136106
161. Kim SS Baek GO Ahn HR Sung S Seo CW Cho HJ Serum small extracellular vesicle-derived LINC00853 as a novel diagnostic marker for early hepatocellular carcinoma Mol Oncol 2020 14 10 2646 2659 10.1002/1878-0261.12745 32525601
Kim SS, Baek GO, Ahn HR, Sung S, Seo CW, Cho HJ, et al. Serum small extracellular vesicle-derived LINC00853 as a novel diagnostic marker for early hepatocellular carcinoma. Mol Oncol. 2020;14(10):2646–59.32525601 10.1002/1878-0261.12745
162. Kim SS Baek GO Son JA Ahn HR Yoon MK Cho HJ Early detection of hepatocellular carcinoma via liquid biopsy: panel of small extracellular vesicle-derived long noncoding RNAs identified as markers Mol Oncol 2021 15 10 2715 2731 10.1002/1878-0261.13049 34185961
Kim SS, Baek GO, Son JA, Ahn HR, Yoon MK, Cho HJ, et al. Early detection of hepatocellular carcinoma via liquid biopsy: panel of small extracellular vesicle-derived long noncoding RNAs identified as markers. Mol Oncol. 2021;15(10):2715–31.34185961 10.1002/1878-0261.13049
163. Li Y Zhao J Yu S Wang Z He X Su Y Extracellular vesicles long RNA sequencing reveals abundant mRNA, circRNA, and lncRNA in human blood as potential biomarkers for cancer diagnosis Clin Chem 2019 65 6 798 808 10.1373/clinchem.2018.301291 30914410
Li Y, Zhao J, Yu S, Wang Z, He X, Su Y, et al. Extracellular vesicles long RNA sequencing reveals abundant mRNA, circRNA, and lncRNA in human blood as potential biomarkers for cancer diagnosis. Clin Chem. 2019;65(6):798–808.30914410 10.1373/clinchem.2018.301291
164. Zhu Q Xie J Mei W Zeng C Methylated circulating tumor DNA in hepatocellular carcinoma: a comprehensive analysis of biomarker potential and clinical implications Cancer Treat Rev 2024 128 102763 10.1016/j.ctrv.2024.102763 38763055
Zhu Q, Xie J, Mei W, Zeng C. Methylated circulating tumor DNA in hepatocellular carcinoma: a comprehensive analysis of biomarker potential and clinical implications. Cancer Treat Rev. 2024;128:102763.38763055 10.1016/j.ctrv.2024.102763
165. Abou Zeid AA El-Sayed ET Ahdy JK Tawfik MR Ras association domain family 1A gene promoter methylation as a biomarker for chronic viral hepatitis C-related hepatocellular carcinoma Cureus J Med Sci 2023 15 9 e45687
Abou Zeid AA, El-Sayed ET, Ahdy JK, Tawfik MR. Ras association domain family 1A gene promoter methylation as a biomarker for chronic viral hepatitis C-related hepatocellular carcinoma. Cureus J Med Sci. 2023;15(9):e45687.
166. Araújo OC Rosa AS Fernandes A Niel C Villela-Nogueira CA Pannain V RASSF1A and DOK1 promoter methylation levels in hepatocellular carcinoma, cirrhotic and non-cirrhotic liver, and correlation with liver cancer in Brazilian patients PLoS One 2016 11 4 e0153796 10.1371/journal.pone.0153796 27078152
Araújo OC, Rosa AS, Fernandes A, Niel C, Villela-Nogueira CA, Pannain V, et al. RASSF1A and DOK1 promoter methylation levels in hepatocellular carcinoma, cirrhotic and non-cirrhotic liver, and correlation with liver cancer in Brazilian patients. PLoS One. 2016;11(4):e0153796.27078152 10.1371/journal.pone.0153796
167. Azab NI Abd El Kariem HM Mowafi T Fouad HF El Abd AM Blood Ras-association domain family 1 A gene methylation status in some liver diseases Life Sci J Acta Zhengzhou Univ Overseas Ed 2011 8 2 531 9
Azab NI, Abd El Kariem HM, Mowafi T, Fouad HF, El Abd AM. Blood Ras-association domain family 1 A gene methylation status in some liver diseases. Life Sci J Acta Zhengzhou Univ Overseas Ed. 2011;8(2):531–9.
168. Chan KCA Lai PBS Mok TSK Chan HLY Ding CM Yeung SW Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma Clin Chem 2008 54 9 1528 1536 10.1373/clinchem.2008.104653 18653827
Chan KCA, Lai PBS, Mok TSK, Chan HLY, Ding CM, Yeung SW, et al. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem. 2008;54(9):1528–36.18653827 10.1373/clinchem.2008.104653
169. Cheishvili D Wong C Karim MM Kibria MG Jahan N Das PC A high-throughput test enables specific detection of hepatocellular carcinoma Nat Commun 2023 14 1 3306 10.1038/s41467-023-39055-7 37286539
Cheishvili D, Wong C, Karim MM, Kibria MG, Jahan N, Das PC, et al. A high-throughput test enables specific detection of hepatocellular carcinoma. Nat Commun. 2023;14(1):3306.37286539 10.1038/s41467-023-39055-7
170. Chen LM Xiang L Sun WJ Zhai YJ Gao S Fan YC Diagnostic value of the hypomethylation of the WISP1 promoter in patients with hepatocellular carcinoma associated with hepatitis B virus Tohoku J Exp Med 2020 252 4 297 307 10.1620/tjem.252.297 33239483
Chen LM, Xiang L, Sun WJ, Zhai YJ, Gao S, Fan YC, et al. Diagnostic value of the hypomethylation of the WISP1 promoter in patients with hepatocellular carcinoma associated with hepatitis B virus. Tohoku J Exp Med. 2020;252(4):297–307.33239483 10.1620/tjem.252.297
171. Cheng JM Wei DK Ji Y Chen LL Yang LG Li G Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkers Genome Med 2018 10 1 42 10.1186/s13073-018-0548-z 29848370
Cheng JM, Wei DK, Ji Y, Chen LL, Yang LG, Li G, et al. Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkers. Genome Med. 2018;10(1):42.29848370 10.1186/s13073-018-0548-z
172. Di JZ Han XD Gu WY Wang Y Zheng Q Zhang P Association of hypomethylation of LINE-1 repetitive element in blood leukocyte DNA with an increased risk of hepatocellular carcinoma J Zhejiang Univ Sci B 2011 12 10 805 811 10.1631/jzus.B1000422 21960343
Di JZ, Han XD, Gu WY, Wang Y, Zheng Q, Zhang P, et al. Association of hypomethylation of LINE-1 repetitive element in blood leukocyte DNA with an increased risk of hepatocellular carcinoma. J Zhejiang Univ Sci B. 2011;12(10):805–11.21960343 10.1631/jzus.B1000422
173. Dong XY He H Zhang WY Yu DJ Wang XJ Chen YM Combination of serum RASSF1A methylation and AFP is a promising non-invasive biomarker for HCC patient with chronic HBV infection Diagn Pathol 2015 10 133 10.1186/s13000-015-0317-x 26238200
Dong XY, He H, Zhang WY, Yu DJ, Wang XJ, Chen YM. Combination of serum RASSF1A methylation and AFP is a promising non-invasive biomarker for HCC patient with chronic HBV infection. Diagn Pathol. 2015;10:133.26238200 10.1186/s13000-015-0317-x
174. Dou CY Fan YC Cao CJ Yang Y Wang K Sera DNA Methylation of CDH1, DNMT3b and ESR1 promoters as biomarker for the early diagnosis of hepatitis B virus-related hepatocellular carcinoma Dig Dis Sci 2016 61 4 1130 1138 10.1007/s10620-015-3975-3 26660680
Dou CY, Fan YC, Cao CJ, Yang Y, Wang K. Sera DNA Methylation of CDH1, DNMT3b and ESR1 promoters as biomarker for the early diagnosis of hepatitis B virus-related hepatocellular carcinoma. Dig Dis Sci. 2016;61(4):1130–8.26660680 10.1007/s10620-015-3975-3
175. El-Bendary M Nour D Arafa M Neamatallah M Methylation of tumour suppressor genes RUNX3, RASSF1A and E-Cadherin in HCV-related liver cirrhosis and hepatocellular carcinoma Br J Biomed Sci 2020 77 1 35 40 10.1080/09674845.2019.1694123 31790342
El-Bendary M, Nour D, Arafa M, Neamatallah M. Methylation of tumour suppressor genes RUNX3, RASSF1A and E-Cadherin in HCV-related liver cirrhosis and hepatocellular carcinoma. Br J Biomed Sci. 2020;77(1):35–40.31790342 10.1080/09674845.2019.1694123
176. Elsewify WA Hassan EA Mekky MA Abd El-Rehim A Sayed Z Malek MOA Usefulness of circulating methylated p16 as a noninvasive molecular biomarker for hepatitis C-related hepatocellular carcinoma with normal serum alpha-fetoprotein levels Int J Gen Med 2020 13 147 155 10.2147/IJGM.S249272 32431531
Elsewify WA, Hassan EA, Mekky MA, Abd El-Rehim A, Sayed Z, Malek MOA, et al. Usefulness of circulating methylated p16 as a noninvasive molecular biomarker for hepatitis C-related hepatocellular carcinoma with normal serum alpha-fetoprotein levels. Int J Gen Med. 2020;13:147–55.32431531 10.2147/IJGM.S249272
177. Funderburk K Bang-Christensen SR Miller BF Tan H Margolin G Petrykowska HM Evaluating stacked methylation markers for blood-based multicancer detection Cancers 2023 15 19 4826 10.3390/cancers15194826 37835520
Funderburk K, Bang-Christensen SR, Miller BF, Tan H, Margolin G, Petrykowska HM, et al. Evaluating stacked methylation markers for blood-based multicancer detection. Cancers. 2023;15(19):4826.37835520 10.3390/cancers15194826
178. Gonçalves E Gonçalves-Reis M Pereira-Leal JB Cardoso J DNA methylation fingerprint of hepatocellular carcinoma from tissue and liquid biopsies Sci Rep 2022 12 1 11512 10.1038/s41598-022-15058-0 35798798
Gonçalves E, Gonçalves-Reis M, Pereira-Leal JB, Cardoso J. DNA methylation fingerprint of hepatocellular carcinoma from tissue and liquid biopsies. Sci Rep. 2022;12(1):11512.35798798 10.1038/s41598-022-15058-0
179. Guo P Zheng HL Li YH Li YT Xiao Y Zheng J Hepatocellular carcinoma detection via targeted enzymatic methyl sequencing of plasma cell-free DNA Clin Epigenetics 2023 15 1 2 10.1186/s13148-022-01420-6 36600275
Guo P, Zheng HL, Li YH, Li YT, Xiao Y, Zheng J, et al. Hepatocellular carcinoma detection via targeted enzymatic methyl sequencing of plasma cell-free DNA. Clin Epigenetics. 2023;15(1):2.36600275 10.1186/s13148-022-01420-6
180. Hu L Chen G Yu HP Qiu XQ Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma Hepatol Int 2010 4 1 423 432 10.1007/s12072-010-9164-8 20305761
Hu L, Chen G, Yu HP, Qiu XQ. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int. 2010;4(1):423–32.20305761 10.1007/s12072-010-9164-8
181. Huang F Yang GW Jiang HQ Chen XN Yang YH Yu Q Role of plasma methylated SEPT9 for predicting microvascular invasion and tumor proliferation in hepatocellular carcinoma Technol Cancer Res Treat 2022 21 15330338221144510 10.1177/15330338221144510 36573042
Huang F, Yang GW, Jiang HQ, Chen XN, Yang YH, Yu Q, et al. Role of plasma methylated SEPT9 for predicting microvascular invasion and tumor proliferation in hepatocellular carcinoma. Technol Cancer Res Treat. 2022;21:15330338221144510.36573042 10.1177/15330338221144510
182. Huang WQ Li T Yang WL Chai XJ Chen KF Wei L Analysis of DNA methylation in plasma for monitoring hepatocarcinogenesis Genet Test Mol Biomarkers 2015 19 6 295 302 10.1089/gtmb.2014.0292 25923138
Huang WQ, Li T, Yang WL, Chai XJ, Chen KF, Wei L, et al. Analysis of DNA methylation in plasma for monitoring hepatocarcinogenesis. Genet Test Mol Biomarkers. 2015;19(6):295–302.25923138 10.1089/gtmb.2014.0292
183. Huang ZH Hu Y Hua D Wu YY Song MX Cheng ZH Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma Exp Mol Pathol 2011 91 3 702 707 10.1016/j.yexmp.2011.08.004 21884695
Huang ZH, Hu Y, Hua D, Wu YY, Song MX, Cheng ZH. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma. Exp Mol Pathol. 2011;91(3):702–7.21884695 10.1016/j.yexmp.2011.08.004
184. Jain S Chang TT Hamilton JP Lin SY Lin YJ Evans AA Methylation of the CpG sites only on the sense strand of the APC gene is specific for hepatocellular carcinoma PLoS One 2011 6 11 e26799 10.1371/journal.pone.0026799 22073196
Jain S, Chang TT, Hamilton JP, Lin SY, Lin YJ, Evans AA, et al. Methylation of the CpG sites only on the sense strand of the APC gene is specific for hepatocellular carcinoma. PLoS One. 2011;6(11):e26799.22073196 10.1371/journal.pone.0026799
185. Ji XF Fan YC Gao S Yang Y Zhang JJ Wang K MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma World J Gastroenterol 2014 20 16 4723 4729 10.3748/wjg.v20.i16.4723 24782625
Ji XF, Fan YC, Gao S, Yang Y, Zhang JJ, Wang K. MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma. World J Gastroenterol. 2014;20(16):4723–9.24782625 10.3748/wjg.v20.i16.4723
186. Jiang CG Chen Q Wu LN Wang G Ma JZ The innovative regularity and role of p16 methylation in blood during HCC development J Cancer 2018 9 11 1925 1931 10.7150/jca.23968 29896276
Jiang CG, Chen Q, Wu LN, Wang G, Ma JZ. The innovative regularity and role of p16 methylation in blood during HCC development. J Cancer. 2018;9(11):1925–31.29896276 10.7150/jca.23968
187. Johnson AM Dudek JM Edwards DK Myers TA Joseph P Laffin JJ Analytical validation of a novel multi-target blood-based test to detect hepatocellular carcinoma Expert Rev Mol Diagn 2021 21 11 1245 1252 10.1080/14737159.2021.1981290 34581651
Johnson AM, Dudek JM, Edwards DK, Myers TA, Joseph P, Laffin JJ, et al. Analytical validation of a novel multi-target blood-based test to detect hepatocellular carcinoma. Expert Rev Mol Diagn. 2021;21(11):1245–52.34581651 10.1080/14737159.2021.1981290
188. Kotoh Y Suehiro Y Saeki I Hoshida T Maeda M Iwamoto T Novel liquid biopsy test based on a sensitive methylated SEPT9 assay for diagnosing hepatocellular carcinoma Hepatol Commun 2020 4 3 461 470 10.1002/hep4.1469 32140662
Kotoh Y, Suehiro Y, Saeki I, Hoshida T, Maeda M, Iwamoto T, et al. Novel liquid biopsy test based on a sensitive methylated SEPT9 assay for diagnosing hepatocellular carcinoma. Hepatol Commun. 2020;4(3):461–70.32140662 10.1002/hep4.1469
189. Li BL Huang H Huang RH Zhang W Zhou GP Wu Z SEPT9 gene methylation as a noninvasive marker for hepatocellular carcinoma Dis Markers 2020 2020 6289063 10.1155/2020/6289063 33178361
Li BL, Huang H, Huang RH, Zhang W, Zhou GP, Wu Z, et al. SEPT9 gene methylation as a noninvasive marker for hepatocellular carcinoma. Dis Markers. 2020;2020:6289063.33178361 10.1155/2020/6289063
190. Li F Fan YC Gao S Sun FK Yang Y Wang K Methylation of serum insulin-like growth factor-binding protein 7 promoter in hepatitis B virus-associated hepatocellular carcinoma Genes Chromosom Cancer 2014 53 1 90 97 10.1002/gcc.22120 24142767
Li F, Fan YC, Gao S, Sun FK, Yang Y, Wang K. Methylation of serum insulin-like growth factor-binding protein 7 promoter in hepatitis B virus-associated hepatocellular carcinoma. Genes Chromosom Cancer. 2014;53(1):90–7.24142767 10.1002/gcc.22120
191. Liu HH Fang Y Wang JW Yuan XD Fan YC Gao S Hypomethylation of the cyclin D1 promoter in hepatitis B virus-associated hepatocellular carcinoma Medicine (Baltimore) 2020 99 20 e20326 10.1097/MD.0000000000020326 32443384
Liu HH, Fang Y, Wang JW, Yuan XD, Fan YC, Gao S, et al. Hypomethylation of the cyclin D1 promoter in hepatitis B virus-associated hepatocellular carcinoma. Medicine (Baltimore). 2020;99(20):e20326.32443384 10.1097/MD.0000000000020326
192. Liu XY Fan YC Gao S Zhao J Chen LY Li F Methylation of SOX1 and VIM promoters in serum as potential biomarkers for hepatocellular carcinoma Neoplasma 2017 64 5 745 753 10.4149/neo_2017_513 28592127
Liu XY, Fan YC, Gao S, Zhao J, Chen LY, Li F, et al. Methylation of SOX1 and VIM promoters in serum as potential biomarkers for hepatocellular carcinoma. Neoplasma. 2017;64(5):745–53.28592127 10.4149/neo_2017_513
193. Liu ZJ Huang Y Wei L He JY Liu QY Yu XQ Combination of LINE-1 hypomethylation and RASSF1A promoter hypermethylation in serum DNA is a non-invasion prognostic biomarker for early recurrence of hepatocellular carcinoma after curative resection Neoplasma 2017 64 5 795 802 10.4149/neo_2017_519 28592132
Liu ZJ, Huang Y, Wei L, He JY, Liu QY, Yu XQ, et al. Combination of LINE-1 hypomethylation and RASSF1A promoter hypermethylation in serum DNA is a non-invasion prognostic biomarker for early recurrence of hepatocellular carcinoma after curative resection. Neoplasma. 2017;64(5):795–802.28592132 10.4149/neo_2017_519
194. Lubecka K Flower K Beetch M Qiu J Kurzava L Buvala H Loci-specific differences in blood DNA methylation in HBV-negative populations at risk for hepatocellular carcinoma development Epigenetics 2018 13 6 605 626 10.1080/15592294.2018.1481706 29927686
Lubecka K, Flower K, Beetch M, Qiu J, Kurzava L, Buvala H, et al. Loci-specific differences in blood DNA methylation in HBV-negative populations at risk for hepatocellular carcinoma development. Epigenetics. 2018;13(6):605–26.29927686 10.1080/15592294.2018.1481706
195. Ma JX Jin JP Lu HS Zhang J Li YL Cai XF Exonuclease 1 is a potential diagnostic and prognostic biomarker in hepatocellular carcinoma Front Mol Biosci 2022 9 889414 10.3389/fmolb.2022.889414 35769911
Ma JX, Jin JP, Lu HS, Zhang J, Li YL, Cai XF. Exonuclease 1 is a potential diagnostic and prognostic biomarker in hepatocellular carcinoma. Front Mol Biosci. 2022;9:889414.35769911 10.3389/fmolb.2022.889414
196. Oussalah A Rischer S Bensenane M Conroy G Filhine-Tresarrieu P Debard R Plasma mSEPT9: a novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma EBioMedicine 2018 30 138 147 10.1016/j.ebiom.2018.03.029 29627389
Oussalah A, Rischer S, Bensenane M, Conroy G, Filhine-Tresarrieu P, Debard R, et al. Plasma mSEPT9: a novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma. EBioMedicine. 2018;30:138–47.29627389 10.1016/j.ebiom.2018.03.029
197. Pasha HF Mohamed RH Radwan MI RASSF1A and SOCS1 genes methylation status as a noninvasive marker for hepatocellular carcinoma Cancer Biomark 2019 24 2 241 247 10.3233/CBM-181638 30689554
Pasha HF, Mohamed RH, Radwan MI. RASSF1A and SOCS1 genes methylation status as a noninvasive marker for hepatocellular carcinoma. Cancer Biomark. 2019;24(2):241–7.30689554 10.3233/CBM-181638
198. Qian Y Wang JW Fang Y Yuan XD Fan YC Gao S Measurement of cyclin D2 (CCND2) gene promoter methylation in plasma and peripheral blood mononuclear cells and alpha-fetoprotein levels in patients with hepatitis B virus-associated hepatocellular carcinoma Med Sci Monit 2020 26 e927444 10.12659/MSM.927444 33320844
Qian Y, Wang JW, Fang Y, Yuan XD, Fan YC, Gao S, et al. Measurement of cyclin D2 (CCND2) gene promoter methylation in plasma and peripheral blood mononuclear cells and alpha-fetoprotein levels in patients with hepatitis B virus-associated hepatocellular carcinoma. Med Sci Monit. 2020;26:e927444.33320844 10.12659/MSM.927444
199. Qiao CY Li F Teng Y Zhao J Hu N Fan YC Aberrant GSTP1 promoter methylation predicts poor prognosis of acute-on-chronic hepatitis B pre-liver failure Clin Exp Med 2018 18 1 51 62 10.1007/s10238-017-0466-1 28676943
Qiao CY, Li F, Teng Y, Zhao J, Hu N, Fan YC, et al. Aberrant GSTP1 promoter methylation predicts poor prognosis of acute-on-chronic hepatitis B pre-liver failure. Clin Exp Med. 2018;18(1):51–62.28676943 10.1007/s10238-017-0466-1
200. Qiu G Fan JC He YS 5′ CpG island methylation analysis identifies the MAGE-A1 and MAGE-A3 genes as potential markers of HCC Clin Biochem 2006 39 3 259 266 10.1016/j.clinbiochem.2006.01.014 16516880
Qiu G, Fan JC, He YS. 5′ CpG island methylation analysis identifies the MAGE-A1 and MAGE-A3 genes as potential markers of HCC. Clin Biochem. 2006;39(3):259–66.16516880 10.1016/j.clinbiochem.2006.01.014
201. Shitani M Sasaki S Akutsu N Takagi H Suzuki H Nojima M Genome-wide analysis of DNA methylation identifies novel cancer-related genes in hepatocellular carcinoma Tumor Biology 2012 33 5 1307 1317 10.1007/s13277-012-0378-3 22457049
Shitani M, Sasaki S, Akutsu N, Takagi H, Suzuki H, Nojima M, et al. Genome-wide analysis of DNA methylation identifies novel cancer-related genes in hepatocellular carcinoma. Tumor Biology. 2012;33(5):1307–17.22457049 10.1007/s13277-012-0378-3
202. Sultan MQ Charfeddine B Al-Salih ARH Evaluation of the diagnostic performance of Alpha-1-Antitrypsin in early detection of hepatocellular carcinoma Cell Mol Biol (Noisy-le-grand) 2023 69 14 177 185 10.14715/cmb/2023.69.14.29 38279446
Sultan MQ, Charfeddine B, Al-Salih ARH. Evaluation of the diagnostic performance of Alpha-1-Antitrypsin in early detection of hepatocellular carcinoma. Cell Mol Biol (Noisy-le-grand). 2023;69(14):177–85.38279446 10.14715/cmb/2023.69.14.29
203. Sun FK Sun Q Fan YC Gao S Zhao J Li F Methylation of tissue factor pathway inhibitor 2 as a prognostic biomarker for hepatocellular carcinoma after hepatectomy J Gastroenterol Hepatol 2016 31 2 484 492 10.1111/jgh.13154 26313014
Sun FK, Sun Q, Fan YC, Gao S, Zhao J, Li F, et al. Methylation of tissue factor pathway inhibitor 2 as a prognostic biomarker for hepatocellular carcinoma after hepatectomy. J Gastroenterol Hepatol. 2016;31(2):484–92.26313014 10.1111/jgh.13154
204. Tan SH Ida H Lau QC Goh BC Chieng WS Loh M Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3 Oncol Rep 2007 18 5 1225 1230 17914577
Tan SH, Ida H, Lau QC, Goh BC, Chieng WS, Loh M, et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep. 2007;18(5):1225–30.17914577
205. Tang LP Zhu SS Peng WY Yin XD Tan C Yang YY Epigenetic identification of mitogen-activated protein kinase 10 as a functional tumor suppressor and clinical significance for hepatocellular carcinoma PeerJ 2021 9 e10810 10.7717/peerj.10810 33604188
Tang LP, Zhu SS, Peng WY, Yin XD, Tan C, Yang YY. Epigenetic identification of mitogen-activated protein kinase 10 as a functional tumor suppressor and clinical significance for hepatocellular carcinoma. PeerJ. 2021;9:e10810.33604188 10.7717/peerj.10810
206. Teng Y Fan YC Mu NN Zhao J Sun FK Wang K Serum SOX11 promoter methylation is a novel biomarker for the diagnosis of Hepatitis B virus-related hepatocellular carcinoma Neoplasma 2016 63 3 419 426 10.4149/311_151029N552 26925788
Teng Y, Fan YC, Mu NN, Zhao J, Sun FK, Wang K. Serum SOX11 promoter methylation is a novel biomarker for the diagnosis of Hepatitis B virus-related hepatocellular carcinoma. Neoplasma. 2016;63(3):419–26.26925788 10.4149/311_151029N552
207. Tian MM Fan YC Zhao J Gao S Zhao ZH Chen LY Hepatocellular carcinoma suppressor 1 promoter hypermethylation in serum. A diagnostic and prognostic study in hepatitis B Clin Res Hepatol Gastroenterol 2017 41 2 171 80 10.1016/j.clinre.2016.10.003 28189396
Tian MM, Fan YC, Zhao J, Gao S, Zhao ZH, Chen LY, et al. Hepatocellular carcinoma suppressor 1 promoter hypermethylation in serum. A diagnostic and prognostic study in hepatitis B. Clin Res Hepatol Gastroenterol. 2017;41(2):171–80.28189396 10.1016/j.clinre.2016.10.003
208. Wong N Lam WC Lai PB Pang E Lau WY Johnson PJ Hypomethylation of chromosome 1 heterochromatin DNA correlates with q-arm copy gain in human hepatocellular carcinoma Am J Pathol 2001 159 2 465 471 10.1016/S0002-9440(10)61718-X 11485905
Wong N, Lam WC, Lai PB, Pang E, Lau WY, Johnson PJ. Hypomethylation of chromosome 1 heterochromatin DNA correlates with q-arm copy gain in human hepatocellular carcinoma. Am J Pathol. 2001;159(2):465–71.11485905 10.1016/S0002-9440(10)61718-X
209. Wu HC Wang Q Yang HI Tsai WY Chen CJ Santella RM Global DNA methylation levels in white blood cells as a biomarker for hepatocellular carcinoma risk: a nested casecontrol study Carcinogenesis 2012 33 7 1340 1345 10.1093/carcin/bgs160 22581841
Wu HC, Wang Q, Yang HI, Tsai WY, Chen CJ, Santella RM. Global DNA methylation levels in white blood cells as a biomarker for hepatocellular carcinoma risk: a nested casecontrol study. Carcinogenesis. 2012;33(7):1340–5.22581841 10.1093/carcin/bgs160
210. Wu HC Wang Q Yang HI Tsai WY Chen CJ Santella RM Global DNA methylation in a population with aflatoxin B1 exposure Epigenetics 2013 8 9 962 969 10.4161/epi.25696 23867725
Wu HC, Wang Q, Yang HI, Tsai WY, Chen CJ, Santella RM. Global DNA methylation in a population with aflatoxin B1 exposure. Epigenetics. 2013;8(9):962–9.23867725 10.4161/epi.25696
211. Xiang L Chen LM Zhai YJ Sun WJ Yang JR Fan YC Hypermethylation of secreted frizzled related protein 2 gene promoter serves as a noninvasive biomarker for HBV-associated hepatocellular carcinoma Life Sci 2021 270 119061 10.1016/j.lfs.2021.119061 33454364
Xiang L, Chen LM, Zhai YJ, Sun WJ, Yang JR, Fan YC, et al. Hypermethylation of secreted frizzled related protein 2 gene promoter serves as a noninvasive biomarker for HBV-associated hepatocellular carcinoma. Life Sci. 2021;270:119061.33454364 10.1016/j.lfs.2021.119061
212. Xie GF Xu YX Xu F Sun LY Ye ZL Ma JJ Plasma SGIP1 methylation in diagnosis and prognosis prediction in hepatocellular carcinoma Neoplasma 2021 68 1 62 70 10.4149/neo_2020_200623N657 33118832
Xie GF, Xu YX, Xu F, Sun LY, Ye ZL, Ma JJ, et al. Plasma SGIP1 methylation in diagnosis and prognosis prediction in hepatocellular carcinoma. Neoplasma. 2021;68(1):62–70.33118832 10.4149/neo_2020_200623N657
213. Xu F Zhang LL Xu YX Song D He WT Ji XM Hypermethylation of SCAND3 and Myo1g gene are potential diagnostic biomarkers for hepatocellular carcinoma Cancers 2020 12 8 2332 10.3390/cancers12082332 32824823
Xu F, Zhang LL, Xu YX, Song D, He WT, Ji XM, et al. Hypermethylation of SCAND3 and Myo1g gene are potential diagnostic biomarkers for hepatocellular carcinoma. Cancers. 2020;12(8):2332.32824823 10.3390/cancers12082332
214. Xu ZG Du JJ Zhang X Cheng ZH Ma ZZ Xiao HS A novel liver-specific zona pellucida domain containing protein that is expressed rarely in hepatocellular carcinoma Hepatology 2003 38 3 735 744 10.1053/jhep.2003.50340 12939600
Xu ZG, Du JJ, Zhang X, Cheng ZH, Ma ZZ, Xiao HS, et al. A novel liver-specific zona pellucida domain containing protein that is expressed rarely in hepatocellular carcinoma. Hepatology. 2003;38(3):735–44.12939600 10.1053/jhep.2003.50340
215. Yan XJ Wu TY Tang M Chen DL Huang MY Zhou SC Methylation of the ataxia telangiectasia mutated gene (ATM) promoter as a radiotherapy outcome biomarker in patients with hepatocellular carcinoma Medicine (Baltimore) 2020 99 4 e18823 10.1097/MD.0000000000018823 31977876
Yan XJ, Wu TY, Tang M, Chen DL, Huang MY, Zhou SC, et al. Methylation of the ataxia telangiectasia mutated gene (ATM) promoter as a radiotherapy outcome biomarker in patients with hepatocellular carcinoma. Medicine (Baltimore). 2020;99(4):e18823.31977876 10.1097/MD.0000000000018823
216. Yang JR Wang J Li HM Gao S Fan YC Wang K IL-6 promoter hypomethylation acts as a diagnostic biomarker in hepatitis B virus-associated hepatocellular carcinoma Front Oncol 2022 12 746643 10.3389/fonc.2022.746643 35359408
Yang JR, Wang J, Li HM, Gao S, Fan YC, Wang K. IL-6 promoter hypomethylation acts as a diagnostic biomarker in hepatitis B virus-associated hepatocellular carcinoma. Front Oncol. 2022;12:746643.35359408 10.3389/fonc.2022.746643
217. Yang Y Fan YC Gao S Dou CY Zhang JJ Sun FK Methylated cysteine dioxygenase-1 gene promoter in the serum is a potential biomarker for hepatitis B virus-related hepatocellular carcinoma Tohoku J Exp Med 2014 232 3 187 194 10.1620/tjem.232.187 24646840
Yang Y, Fan YC, Gao S, Dou CY, Zhang JJ, Sun FK, et al. Methylated cysteine dioxygenase-1 gene promoter in the serum is a potential biomarker for hepatitis B virus-related hepatocellular carcinoma. Tohoku J Exp Med. 2014;232(3):187–94.24646840 10.1620/tjem.232.187
218. Yuan XD Wang JW Fang Y Qian Y Gao S Fan YC Methylation status of the T-cadherin gene promotor in peripheral blood mononuclear cells is associated with HBV-related hepatocellular carcinoma progression Pathol Res Pract 2020 216 5 152914 10.1016/j.prp.2020.152914 32147273
Yuan XD, Wang JW, Fang Y, Qian Y, Gao S, Fan YC, et al. Methylation status of the T-cadherin gene promotor in peripheral blood mononuclear cells is associated with HBV-related hepatocellular carcinoma progression. Pathol Res Pract. 2020;216(5):152914.32147273 10.1016/j.prp.2020.152914
219. Zhang C Ge S Wang J Jing XT Li HL Mei SY Epigenomic profiling of DNA methylation for hepatocellular carcinoma diagnosis and prognosis prediction J Gastroenterol Hepatol 2019 34 10 1869 1877 10.1111/jgh.14694 31038805
Zhang C, Ge S, Wang J, Jing XT, Li HL, Mei SY, et al. Epigenomic profiling of DNA methylation for hepatocellular carcinoma diagnosis and prognosis prediction. J Gastroenterol Hepatol. 2019;34(10):1869–77.31038805 10.1111/jgh.14694
220. Zhang PJ Wen XY Gu F Deng XX Li J Dong J Methylation profiling of serum DNA from hepatocellular carcinoma patients using an Infinium Human Methylation 450 BeadChip Hepatol Int 2013 7 3 893 900 10.1007/s12072-013-9437-0 26201927
Zhang PJ, Wen XY, Gu F, Deng XX, Li J, Dong J, et al. Methylation profiling of serum DNA from hepatocellular carcinoma patients using an Infinium Human Methylation 450 BeadChip. Hepatol Int. 2013;7(3):893–900.26201927 10.1007/s12072-013-9437-0
221. Zhang Y Wang JW Su X Li JE Wei XF Yang JR F-box protein 43 promoter methylation as a novel biomarker for hepatitis B virus-associated hepatocellular carcinoma Front Microbiol 2023 14 1267844 10.3389/fmicb.2023.1267844 38029156
Zhang Y, Wang JW, Su X, Li JE, Wei XF, Yang JR, et al. F-box protein 43 promoter methylation as a novel biomarker for hepatitis B virus-associated hepatocellular carcinoma. Front Microbiol. 2023;14:1267844.38029156 10.3389/fmicb.2023.1267844
222. Zhang YJ Wu HC Shen J Ahsan H Tsai WY Yang HL Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA Clin Cancer Res 2007 13 8 2378 2384 10.1158/1078-0432.CCR-06-1900 17438096
Zhang YJ, Wu HC, Shen J, Ahsan H, Tsai WY, Yang HL, et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res. 2007;13(8):2378–84.17438096 10.1158/1078-0432.CCR-06-1900
223. Zhang ZY Chen P Xie H Cao PG Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: a systematic review and meta-analysis Cancer Med 2020 9 4 1349 1364 10.1002/cam4.2799 31876977
Zhang ZY, Chen P, Xie H, Cao PG. Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Med. 2020;9(4):1349–64.31876977 10.1002/cam4.2799
224. Raos D Ulamec M Bojanac AK Bulic-Jakus F Jezek D Sincic N Epigenetically inactivated RASSF1A as a tumor biomarker Bosn J Basic Med Sci 2021 21 4 386 397 33175673
Raos D, Ulamec M, Bojanac AK, Bulic-Jakus F, Jezek D, Sincic N. Epigenetically inactivated RASSF1A as a tumor biomarker. Bosn J Basic Med Sci. 2021;21(4):386–97.33175673
225. Villanueva A Portela A Sayols S Battiston C Hoshida Y Méndez-González J DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma Hepatology 2015 61 6 1945 1956 10.1002/hep.27732 25645722
Villanueva A, Portela A, Sayols S, Battiston C, Hoshida Y, Méndez-González J, et al. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology. 2015;61(6):1945–56.25645722 10.1002/hep.27732
226. Kakehashi A Ishii N Shibata T Wei M Okazaki E Tachibana T Mitochondrial prohibitins and septin 9 are implicated in the onset of rat hepatocarcinogenesis Toxicol Sci 2011 119 1 61 72 10.1093/toxsci/kfq307 20935162
Kakehashi A, Ishii N, Shibata T, Wei M, Okazaki E, Tachibana T, et al. Mitochondrial prohibitins and septin 9 are implicated in the onset of rat hepatocarcinogenesis. Toxicol Sci. 2011;119(1):61–72.20935162 10.1093/toxsci/kfq307
227. Uhlén M Fagerberg L Hallström BM Lindskog C Oksvold P Mardinoglu A Proteomics. Tissue-based map of the human proteome Science 2015 347 6220 1260419 10.1126/science.1260419 25613900
Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.25613900 10.1126/science.1260419
228. Zhang W Dai J Hou G Liu H Zheng S Wang X SMURF2 predisposes cancer cell toward ferroptosis in GPX4-independent manners by promoting GSTP1 degradation Mol Cell 2023 83 23 4352 69.e8 10.1016/j.molcel.2023.10.042 38016474
Zhang W, Dai J, Hou G, Liu H, Zheng S, Wang X, et al. SMURF2 predisposes cancer cell toward ferroptosis in GPX4-independent manners by promoting GSTP1 degradation. Mol Cell. 2023;83(23):4352-69.e8.38016474 10.1016/j.molcel.2023.10.042
229. Tilman G Arnoult N Lenglez S Van Beneden A Loriot A De Smet C Cancer-linked satellite 2 DNA hypomethylation does not regulate Sat2 non-coding RNA expression and is initiated by heat shock pathway activation Epigenetics 2012 7 8 903 913 10.4161/epi.21107 22722874
Tilman G, Arnoult N, Lenglez S, Van Beneden A, Loriot A, De Smet C, et al. Cancer-linked satellite 2 DNA hypomethylation does not regulate Sat2 non-coding RNA expression and is initiated by heat shock pathway activation. Epigenetics. 2012;7(8):903–13.22722874 10.4161/epi.21107
230. Probst AV Okamoto I Casanova M El Marjou F Le Baccon P Almouzni G A strand-specific burst in transcription of pericentric satellites is required for chromocenter formation and early mouse development Dev Cell 2010 19 4 625 638 10.1016/j.devcel.2010.09.002 20951352
Probst AV, Okamoto I, Casanova M, El Marjou F, Le Baccon P, Almouzni G. A strand-specific burst in transcription of pericentric satellites is required for chromocenter formation and early mouse development. Dev Cell. 2010;19(4):625–38.20951352 10.1016/j.devcel.2010.09.002
231. van Niel G D’Angelo G Raposo G Shedding light on the cell biology of extracellular vesicles Nat Rev Mol Cell Biol 2018 19 4 213 228 10.1038/nrm.2017.125 29339798
van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213–28.29339798 10.1038/nrm.2017.125
232. Jeppesen DK Fenix AM Franklin JL Higginbotham JN Zhang Q Zimmerman LJ Reassessment of exosome composition Cell 2019 177 2 428 45.e18 10.1016/j.cell.2019.02.029 30951670
Jeppesen DK, Fenix AM, Franklin JL, Higginbotham JN, Zhang Q, Zimmerman LJ, et al. Reassessment of exosome composition. Cell. 2019;177(2):428-45.e18.30951670 10.1016/j.cell.2019.02.029
233. Guo X Gao C Yang D-H Li S Exosomal circular RNAs: a chief culprit in cancer chemotherapy resistance Drug Resist Updates 2023 67 100937 10.1016/j.drup.2023.100937
Guo X, Gao C, Yang D-H, Li S. Exosomal circular RNAs: a chief culprit in cancer chemotherapy resistance. Drug Resist Updates. 2023;67:100937.10.1016/j.drup.2023.100937
234. Adamczyk AM Leicaj ML Fabiano MP Cabrerizo G Bannoud N Croci DO Extracellular vesicles from human plasma dampen inflammation and promote tissue repair functions in macrophages J Extracell Vesicles 2023 12 6 e12331 10.1002/jev2.12331 37272889
Adamczyk AM, Leicaj ML, Fabiano MP, Cabrerizo G, Bannoud N, Croci DO, et al. Extracellular vesicles from human plasma dampen inflammation and promote tissue repair functions in macrophages. J Extracell Vesicles. 2023;12(6):e12331.37272889 10.1002/jev2.12331
235. Bebelman MP Smit MJ Pegtel DM Baglio SR Biogenesis and function of extracellular vesicles in cancer Pharmacol Ther 2018 188 1 11 10.1016/j.pharmthera.2018.02.013 29476772
Bebelman MP, Smit MJ, Pegtel DM, Baglio SR. Biogenesis and function of extracellular vesicles in cancer. Pharmacol Ther. 2018;188:1–11.29476772 10.1016/j.pharmthera.2018.02.013
236. Yeo W Mo FK Chan SL Leung NW Hui P Lam WY Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy Hepatology 2007 45 6 1382 1389 10.1002/hep.21572 17539025
Yeo W, Mo FK, Chan SL, Leung NW, Hui P, Lam WY, et al. Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology. 2007;45(6):1382–9.17539025 10.1002/hep.21572
237. Choi WM Kim GA Choi J Choi GH Lee YB Sinn DH Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B Gut 2024 73 4 649 658 37813567
Choi WM, Kim GA, Choi J, Choi GH, Lee YB, Sinn DH, et al. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B. Gut. 2024;73(4):649–58.37813567
238. Choi WM Yip TC Kim WR Yee LJ Brooks-Rooney C Curteis T Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: a multinational cohort study of HBeAg-positive patients Hepatology 2024 80 2 428 439 38436992
Choi WM, Yip TC, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, et al. Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: a multinational cohort study of HBeAg-positive patients. Hepatology. 2024;80(2):428–39.38436992
239. Riveiro-Barciela M Pericàs JM Buti M How to interpret viral markers in the management of chronic hepatitis B infection Clin Microbiol Infect 2022 28 3 355 361 10.1016/j.cmi.2021.10.020 34768018
Riveiro-Barciela M, Pericàs JM, Buti M. How to interpret viral markers in the management of chronic hepatitis B infection. Clin Microbiol Infect. 2022;28(3):355–61.34768018 10.1016/j.cmi.2021.10.020
240. Yoshida M Hatano N Nishiumi S Irino Y Izumi Y Takenawa T Diagnosis of gastroenterological diseases by metabolome analysis using gas chromatography–mass spectrometry J Gastroenterol 2012 47 1 9 20 10.1007/s00535-011-0493-8 22041921
Yoshida M, Hatano N, Nishiumi S, Irino Y, Izumi Y, Takenawa T, et al. Diagnosis of gastroenterological diseases by metabolome analysis using gas chromatography–mass spectrometry. J Gastroenterol. 2012;47(1):9–20.22041921 10.1007/s00535-011-0493-8
241. Xue R Lin Z Deng C Dong L Liu T Wang J A serum metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed by gas chromatography/mass spectrometry Rapid Commun Mass Spectrom 2008 22 19 3061 3068 10.1002/rcm.3708 18767022
Xue R, Lin Z, Deng C, Dong L, Liu T, Wang J, et al. A serum metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed by gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom. 2008;22(19):3061–8.18767022 10.1002/rcm.3708
242. Wu H Xue R Dong L Liu T Deng C Zeng H Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry Anal Chim Acta 2009 648 1 98 104 10.1016/j.aca.2009.06.033 19616694
Wu H, Xue R, Dong L, Liu T, Deng C, Zeng H, et al. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta. 2009;648(1):98–104.19616694 10.1016/j.aca.2009.06.033
243. Chen T Xie G Wang X Fan J Qiu Y Zheng X Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma Mol Cell Proteomics 2011 10 7 M110.004945 10.1074/mcp.M110.004945 21518826
Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics. 2011;10(7):M110.004945.21518826 10.1074/mcp.M110.004945
244. Chew V Chuang CH Hsu C Translational research on drug development and biomarker discovery for hepatocellular carcinoma J Biomed Sci 2024 31 1 22 10.1186/s12929-024-01011-y 38368324
Chew V, Chuang CH, Hsu C. Translational research on drug development and biomarker discovery for hepatocellular carcinoma. J Biomed Sci. 2024;31(1):22.38368324 10.1186/s12929-024-01011-y
245. Niu F Wang DC Lu J Wu W Wang X Potentials of single-cell biology in identification and validation of disease biomarkers J Cell Mol Med 2016 20 9 1789 1795 10.1111/jcmm.12868 27113384
Niu F, Wang DC, Lu J, Wu W, Wang X. Potentials of single-cell biology in identification and validation of disease biomarkers. J Cell Mol Med. 2016;20(9):1789–95.27113384 10.1111/jcmm.12868
246. Xing X Cai L Ouyang J Wang F Li Z Liu M Proteomics-driven noninvasive screening of circulating serum protein panels for the early diagnosis of hepatocellular carcinoma Nat Commun 2023 14 1 8392 10.1038/s41467-023-44255-2 38110372
Xing X, Cai L, Ouyang J, Wang F, Li Z, Liu M, et al. Proteomics-driven noninvasive screening of circulating serum protein panels for the early diagnosis of hepatocellular carcinoma. Nat Commun. 2023;14(1):8392.38110372 10.1038/s41467-023-44255-2
247. Nie W Yan L Lee YH Guha C Kurland IJ Lu H Advanced mass spectrometry-based multi-omics technologies for exploring the pathogenesis of hepatocellular carcinoma Mass Spectrom Rev 2016 35 3 331 349 10.1002/mas.21439 24890331
Nie W, Yan L, Lee YH, Guha C, Kurland IJ, Lu H. Advanced mass spectrometry-based multi-omics technologies for exploring the pathogenesis of hepatocellular carcinoma. Mass Spectrom Rev. 2016;35(3):331–49.24890331 10.1002/mas.21439
248. Wang Y Xie Y Qian L Ding R Pang R Chen P RAB42 overexpression correlates with poor prognosis, immune cell infiltration and chemoresistance Front Pharmacol 2024 15 1445170 10.3389/fphar.2024.1445170 39101146
Wang Y, Xie Y, Qian L, Ding R, Pang R, Chen P, et al. RAB42 overexpression correlates with poor prognosis, immune cell infiltration and chemoresistance. Front Pharmacol. 2024;15:1445170.39101146 10.3389/fphar.2024.1445170
249. Xu RH Wei W Krawczyk M Wang WQ Luo HY Flagg K Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma Nat Mater 2017 16 11 1155 + 10.1038/nmat4997 29035356
Xu RH, Wei W, Krawczyk M, Wang WQ, Luo HY, Flagg K, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017;16(11):1155-#x0002B;29035356 10.1038/nmat4997
250. Huang H Ren Z Gao X Hu X Zhou Y Jiang J Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma Genome Med 2020 12 1 102 10.1186/s13073-020-00796-5 33225985
Huang H, Ren Z, Gao X, Hu X, Zhou Y, Jiang J, et al. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma. Genome Med. 2020;12(1):102.33225985 10.1186/s13073-020-00796-5
251. Wang X Zhang A Sun H Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma Hepatology 2013 57 5 2072 2077 10.1002/hep.26130 23150189
Wang X, Zhang A, Sun H. Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma. Hepatology. 2013;57(5):2072–7.23150189 10.1002/hep.26130
252. Lee T Rawding PA Bu J Hyun S Rou W Jeon H Machine-learning-based clinical biomarker using cell-free DNA for hepatocellular carcinoma (HCC) Cancers 2022 14 9 2061 10.3390/cancers14092061 35565192
Lee T, Rawding PA, Bu J, Hyun S, Rou W, Jeon H, et al. Machine-learning-based clinical biomarker using cell-free DNA for hepatocellular carcinoma (HCC). Cancers. 2022;14(9):2061.35565192 10.3390/cancers14092061
253. Li M Wang L Cong L Wong CC Zhang X Chen H Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma Hepatology 2024 79 3 560 574 37733002
Li M, Wang L, Cong L, Wong CC, Zhang X, Chen H, et al. Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Hepatology. 2024;79(3):560–74.37733002
254. Zhang S Deshpande A Verma BK Wang H Mi H Yuan L Integration of clinical trial spatial multiomics analysis and virtual clinical trials enables immunotherapy response prediction and biomarker discovery Cancer Res 2024 84 16 2734 2748 10.1158/0008-5472.CAN-24-0943 38861365
Zhang S, Deshpande A, Verma BK, Wang H, Mi H, Yuan L, et al. Integration of clinical trial spatial multiomics analysis and virtual clinical trials enables immunotherapy response prediction and biomarker discovery. Cancer Res. 2024;84(16):2734–48.38861365 10.1158/0008-5472.CAN-24-0943
255. Rebouissou S Nault JC Advances in molecular classification and precision oncology in hepatocellular carcinoma J Hepatol 2020 72 2 215 229 10.1016/j.jhep.2019.08.017 31954487
Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol. 2020;72(2):215–29.31954487 10.1016/j.jhep.2019.08.017
256. Trevisani F Vitale A Kudo M Kulik L Park JW Pinato DJ Merits and boundaries of the BCLC staging and treatment algorithm: learning from the past to improve the future with a novel proposal J Hepatol 2024 80 4 661 669 10.1016/j.jhep.2024.01.010 38266658
Trevisani F, Vitale A, Kudo M, Kulik L, Park JW, Pinato DJ, et al. Merits and boundaries of the BCLC staging and treatment algorithm: learning from the past to improve the future with a novel proposal. J Hepatol. 2024;80(4):661–9.38266658 10.1016/j.jhep.2024.01.010
257. Zhang XP Jiang N Zhu L Lin ZY Guo WX Chen X Short-term and long-term outcomes after robotic versus open hepatectomy in patients with large hepatocellular carcinoma: a multicenter study Int J Surg 2024 110 2 660 667 10.1097/JS9.0000000000000873 37983785
Zhang XP, Jiang N, Zhu L, Lin ZY, Guo WX, Chen X, et al. Short-term and long-term outcomes after robotic versus open hepatectomy in patients with large hepatocellular carcinoma: a multicenter study. Int J Surg. 2024;110(2):660–7.37983785 10.1097/JS9.0000000000000873
258. Liu G Wang K Li J Xia Y Lu L Wan X Changes in serum alpha fetoprotein in patients with recurrent hepatocellular carcinoma following hepatectomy J Gastroenterol Hepatol 2015 30 9 1405 1411 10.1111/jgh.12953 25801981
Liu G, Wang K, Li J, Xia Y, Lu L, Wan X, et al. Changes in serum alpha fetoprotein in patients with recurrent hepatocellular carcinoma following hepatectomy. J Gastroenterol Hepatol. 2015;30(9):1405–11.25801981 10.1111/jgh.12953
259. Wei W-X Yang Z-S Lu L-H Li J Lei Z-Q Wang K Long-term survival after partial hepatectomy for sub-stage patients with intermediate stage hepatocellular carcinoma Int J Surg 2018 56 256 63 10.1016/j.ijsu.2018.06.020 29935368
Wei W-X, Yang Z-S, Lu L-H, Li J, Lei Z-Q, Wang K, et al. Long-term survival after partial hepatectomy for sub-stage patients with intermediate stage hepatocellular carcinoma. Int J Surg. 2018;56:256–63.29935368 10.1016/j.ijsu.2018.06.020
260. Jin GZ Yu WL Dong H Zhou WP Gu YJ Yu H SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma J Hepatol 2013 59 3 510 517 10.1016/j.jhep.2013.04.028 23665285
Jin GZ, Yu WL, Dong H, Zhou WP, Gu YJ, Yu H, et al. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma. J Hepatol. 2013;59(3):510–7.23665285 10.1016/j.jhep.2013.04.028
261. Yamamoto K Imamura H Matsuyama Y Kume Y Ikeda H Norman GL AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC J Gastroenterol 2010 45 12 1272 1282 10.1007/s00535-010-0278-5 20625772
Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol. 2010;45(12):1272–82.20625772 10.1007/s00535-010-0278-5
262. Toyoda H Kumada T Tada T Niinomi T Ito T Kaneoka Y Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy J Hepatol 2012 57 6 1251 1257 10.1016/j.jhep.2012.07.018 22824818
Toyoda H, Kumada T, Tada T, Niinomi T, Ito T, Kaneoka Y, et al. Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy. J Hepatol. 2012;57(6):1251–7.22824818 10.1016/j.jhep.2012.07.018
263. Chan AWH Zhong J Berhane S Toyoda H Cucchetti A Shi K Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection J Hepatol 2018 69 6 1284 1293 10.1016/j.jhep.2018.08.027 30236834
Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol. 2018;69(6):1284–93.30236834 10.1016/j.jhep.2018.08.027
264. Shirakawa H Suzuki H Shimomura M Kojima M Gotohda N Takahashi S Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma Cancer Sci 2009 100 8 1403 1407 10.1111/j.1349-7006.2009.01206.x 19496787
Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci. 2009;100(8):1403–7.19496787 10.1111/j.1349-7006.2009.01206.x
265. Wang L Pan L Yao M Cai Y Dong Z Yao D Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma Oncotarget 2016 7 27 42150 10.18632/oncotarget.9892 27286460
Wang L, Pan L, Yao M, Cai Y, Dong Z, Yao D. Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma. Oncotarget. 2016;7(27):42150.27286460 10.18632/oncotarget.9892
266. Ning S Bin C Na H Peng S Yi D Xiang-hua Y Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients Mol Biol Rep 2012 39 1 351 357 10.1007/s11033-011-0745-y 21655958
Ning S, Bin C, Na H, Peng S, Yi D, Xiang-hua Y, et al. Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients. Mol Biol Rep. 2012;39(1):351–7.21655958 10.1007/s11033-011-0745-y
267. Yorita K Takahashi N Takai H Kato A Suzuki M Ishiguro T Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma Liver Int 2011 31 1 120 131 10.1111/j.1478-3231.2010.02359.x 20964802
Yorita K, Takahashi N, Takai H, Kato A, Suzuki M, Ishiguro T, et al. Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. Liver Int. 2011;31(1):120–31.20964802 10.1111/j.1478-3231.2010.02359.x
268. Haruyama Y Yorita K Yamaguchi T Kitajima S Amano J Ohtomo T High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy Int J Cancer 2015 137 7 1643 1651 10.1002/ijc.29518 25784484
Haruyama Y, Yorita K, Yamaguchi T, Kitajima S, Amano J, Ohtomo T, et al. High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy. Int J Cancer. 2015;137(7):1643–51.25784484 10.1002/ijc.29518
269. Wang YL Zhu ZJ Teng DH Yao Z Gao W Shen ZY Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation World J Gastroenterol 2012 18 19 2408 2414 10.3748/wjg.v18.i19.2408 22654434
Wang YL, Zhu ZJ, Teng DH, Yao Z, Gao W, Shen ZY. Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation. World J Gastroenterol. 2012;18(19):2408–14.22654434 10.3748/wjg.v18.i19.2408
270. Wang Y Shen Z Zhu Z Han R Huai M Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC Hepat Mon 2011 11 3 195 22087143
Wang Y, Shen Z, Zhu Z, Han R, Huai M. Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC. Hepat Mon. 2011;11(3):195.22087143
271. Yu M-C Lee Y-S Lin S-E Wu H-Y Chen T-C Lee W-C Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin Ann Surg Oncol 2012 19 455 463 10.1245/s10434-011-1946-2 21792513
Yu M-C, Lee Y-S, Lin S-E, Wu H-Y, Chen T-C, Lee W-C, et al. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. Ann Surg Oncol. 2012;19:455–63.21792513 10.1245/s10434-011-1946-2
272. Feng J Zhu R Chang C Yu L Cao F Zhu G CK19 and glypican 3 expression profiling in the prognostic indication for patients with HCC after surgical resection PLoS One 2016 11 3 e0151501 10.1371/journal.pone.0151501 26977595
Feng J, Zhu R, Chang C, Yu L, Cao F, Zhu G, et al. CK19 and glypican 3 expression profiling in the prognostic indication for patients with HCC after surgical resection. PLoS One. 2016;11(3):e0151501.26977595 10.1371/journal.pone.0151501
273. Yuan SX Yang F Yang Y Tao QF Zhang J Huang G Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients’ poor recurrence-free survival after hepatectomy Hepatology 2012 56 6 2231 2241 10.1002/hep.25895 22706893
Yuan SX, Yang F, Yang Y, Tao QF, Zhang J, Huang G, et al. Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients’ poor recurrence-free survival after hepatectomy. Hepatology. 2012;56(6):2231–41.22706893 10.1002/hep.25895
274. Zheng J Yan X Lu T Song W Li Y Liang J CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect J Exp Clin Cancer Res 2023 42 1 63 10.1186/s13046-023-02624-1 36922872
Zheng J, Yan X, Lu T, Song W, Li Y, Liang J, et al. CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect. J Exp Clin Cancer Res. 2023;42(1):63.36922872 10.1186/s13046-023-02624-1
275. Shi J Li Y Liang S Zeng J Liu G Mu F Circulating tumour cells as biomarkers for evaluating cryosurgery on unresectable hepatocellular carcinoma Oncol Rep 2016 36 4 1845 1851 10.3892/or.2016.5050 27573435
Shi J, Li Y, Liang S, Zeng J, Liu G, Mu F, et al. Circulating tumour cells as biomarkers for evaluating cryosurgery on unresectable hepatocellular carcinoma. Oncol Rep. 2016;36(4):1845–51.27573435 10.3892/or.2016.5050
276. Polyak K Weinberg RA Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits Nat Rev Cancer 2009 9 4 265 273 10.1038/nrc2620 19262571
Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265–73.19262571 10.1038/nrc2620
277. Satelli A Brownlee Z Mitra A Meng QH Li S Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response Clin Chem 2015 61 1 259 266 10.1373/clinchem.2014.228122 25336717
Satelli A, Brownlee Z, Mitra A, Meng QH, Li S. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response. Clin Chem. 2015;61(1):259–66.25336717 10.1373/clinchem.2014.228122
278. Kelley RK Magbanua MJM Butler TM Collisson EA Hwang J Sidiropoulos N Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls BMC Cancer 2015 15 206 10.1186/s12885-015-1195-z 25884197
Kelley RK, Magbanua MJM, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, et al. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015;15:206.25884197 10.1186/s12885-015-1195-z
279. Yu JJ Xiao W Dong SL Liang HF Zhang ZW Zhang BX Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma BMC Cancer 2018 18 1 835 10.1186/s12885-018-4744-4 30126375
Yu JJ, Xiao W, Dong SL, Liang HF, Zhang ZW, Zhang BX, et al. Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma. BMC Cancer. 2018;18(1):835.30126375 10.1186/s12885-018-4744-4
280. Shen J Wang WS Zhu XL Ni CF High epithelial cell adhesion molecule-positive circulating tumor cell count predicts poor survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization J Vasc Interv Radiol 2018 29 12 1678 1684 10.1016/j.jvir.2018.07.030 30392801
Shen J, Wang WS, Zhu XL, Ni CF. High epithelial cell adhesion molecule-positive circulating tumor cell count predicts poor survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. J Vasc Interv Radiol. 2018;29(12):1678–84.30392801 10.1016/j.jvir.2018.07.030
281. Agopian VG Harlander-Locke M Zarrinpar A Kaldas FM Farmer DG Yersiz H A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients J Am Coll Surg 2015 220 4 416 427 10.1016/j.jamcollsurg.2014.12.025 25690672
Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg. 2015;220(4):416–27.25690672 10.1016/j.jamcollsurg.2014.12.025
282. Marelli L Stigliano R Triantos C Senzolo M Cholongitas E Davies N Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies Cardiovasc Intervent Radiol 2007 30 6 25 10.1007/s00270-006-0062-3 17103105
Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6–25.17103105 10.1007/s00270-006-0062-3
283. Gillmore R Stuart S Kirkwood A Hameeduddin A Woodward N Burroughs AK EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization J Hepatol 2011 55 6 1309 1316 10.1016/j.jhep.2011.03.007 21703196
Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55(6):1309–16.21703196 10.1016/j.jhep.2011.03.007
284. Martin SP Fako V Dang H Dominguez DA Khatib S Ma L PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma J Exp Clin Cancer Res 2020 39 1 99 10.1186/s13046-020-01605-y 32487192
Martin SP, Fako V, Dang H, Dominguez DA, Khatib S, Ma L, et al. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020;39(1):99.32487192 10.1186/s13046-020-01605-y
285. Sefrioui D Verdier V Savoye-Collet C Beaussire L Ghomadi S Gangloff A Circulating DNA changes are predictive of disease progression after transarterial chemoembolization Int J Cancer 2022 150 3 532 541 10.1002/ijc.33829 34622951
Sefrioui D, Verdier V, Savoye-Collet C, Beaussire L, Ghomadi S, Gangloff A, et al. Circulating DNA changes are predictive of disease progression after transarterial chemoembolization. Int J Cancer. 2022;150(3):532–41.34622951 10.1002/ijc.33829
286. Cornell L Munck JM Alsinet C Villanueva A Ogle L Willoughby CE DNA-PK—a candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival Clin Cancer Res 2015 21 4 925 933 10.1158/1078-0432.CCR-14-0842 25480831
Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L, Willoughby CE, et al. DNA-PK—a candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival. Clin Cancer Res. 2015;21(4):925–33.25480831 10.1158/1078-0432.CCR-14-0842
287. Niizeki T Sumie S Torimura T Kurogi J Kuromatsu R Iwamoto H Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy J Gastroenterol 2012 47 6 686 695 10.1007/s00535-012-0555-6 22382631
Niizeki T, Sumie S, Torimura T, Kurogi J, Kuromatsu R, Iwamoto H, et al. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. J Gastroenterol. 2012;47(6):686–95.22382631 10.1007/s00535-012-0555-6
288. Lyu N Wang X Li JB Lai JF Chen QF Li SL Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1) J Clin Oncol 2022 40 5 468 480 10.1200/JCO.21.01963 34905388
Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1). J Clin Oncol. 2022;40(5):468–80.34905388 10.1200/JCO.21.01963
289. Llovet JM Pinyol R Yarchoan M Singal AG Marron TU Schwartz M Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma Nat Rev Clin Oncol 2024 21 4 294 311 10.1038/s41571-024-00868-0 38424197
Llovet JM, Pinyol R, Yarchoan M, Singal AG, Marron TU, Schwartz M, et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat Rev Clin Oncol. 2024;21(4):294–311.38424197 10.1038/s41571-024-00868-0
290. Doyle A Gorgen A Muaddi H Aravinthan AD Issachar A Mironov O Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients J Hepatol 2019 70 5 866 873 10.1016/j.jhep.2018.12.027 30615906
Doyle A, Gorgen A, Muaddi H, Aravinthan AD, Issachar A, Mironov O, et al. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. J Hepatol. 2019;70(5):866–73.30615906 10.1016/j.jhep.2018.12.027
291. Shiina S Tateishi R Arano T Uchino K Enooku K Nakagawa H Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors Am J Gastroenterol 2012 107 4 569 77; quiz 78 10.1038/ajg.2011.425 22158026
Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107(4):569–77; quiz 78.22158026 10.1038/ajg.2011.425
292. Pompili M Saviano A de Matthaeis N Cucchetti A Ardito F Federico B Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey J Hepatol 2013 59 1 89 97 10.1016/j.jhep.2013.03.009 23523578
Pompili M, Saviano A, de Matthaeis N, Cucchetti A, Ardito F, Federico B, et al. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey. J Hepatol. 2013;59(1):89–97.23523578 10.1016/j.jhep.2013.03.009
293. Canale M Ulivi P Foschi FG Scarpi E De Matteis S Donati G Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma Crit Rev Oncol Hematol 2018 129 44 53 10.1016/j.critrevonc.2018.06.017 30097237
Canale M, Ulivi P, Foschi FG, Scarpi E, De Matteis S, Donati G, et al. Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. Crit Rev Oncol Hematol. 2018;129:44–53.30097237 10.1016/j.critrevonc.2018.06.017
294. Hameed B Mehta N Sapisochin G Roberts JP Yao FY Alpha-fetoprotein level> 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria Liver Transpl 2014 20 8 945 951 10.1002/lt.23904 24797281
Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level> 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20(8):945–51.24797281 10.1002/lt.23904
295. Berry K Ioannou GN Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma Liver Transpl 2013 19 6 634 645 10.1002/lt.23652 23536495
Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl. 2013;19(6):634–45.23536495 10.1002/lt.23652
296. Matsumura M Shiratori Y Niwa Y Tanaka T Ogura K Okudaira T Presence of alpha-fetoprotein mRNA in blood correlates with outcome in patients with hepatocellular carcinoma J Hepatol 1999 31 2 332 339 10.1016/S0168-8278(99)80232-3 10453948
Matsumura M, Shiratori Y, Niwa Y, Tanaka T, Ogura K, Okudaira T, et al. Presence of alpha-fetoprotein mRNA in blood correlates with outcome in patients with hepatocellular carcinoma. J Hepatol. 1999;31(2):332–9.10453948 10.1016/S0168-8278(99)80232-3
297. Lemoine A Le Bricon T Salvucci M Azoulay D Pham P Raccuia J Prospective evaluation of circulating hepatocytes by alpha-fetoprotein mRNA in humans during liver surgery Ann Surg 1997 226 1 43 50 10.1097/00000658-199707000-00006 9242336
Lemoine A, Le Bricon T, Salvucci M, Azoulay D, Pham P, Raccuia J, et al. Prospective evaluation of circulating hepatocytes by alpha-fetoprotein mRNA in humans during liver surgery. Ann Surg. 1997;226(1):43–50.9242336 10.1097/00000658-199707000-00006
298. Jin J Niu X Zou L Li L Li S Han J AFP mRNA level in enriched circulating tumor cells from hepatocellular carcinoma patient blood samples is a pivotal predictive marker for metastasis Cancer Lett 2016 378 1 33 37 10.1016/j.canlet.2016.04.033 27160647
Jin J, Niu X, Zou L, Li L, Li S, Han J, et al. AFP mRNA level in enriched circulating tumor cells from hepatocellular carcinoma patient blood samples is a pivotal predictive marker for metastasis. Cancer Lett. 2016;378(1):33–7.27160647 10.1016/j.canlet.2016.04.033
299. Kong SY Park JW Kim JO Lee NO Lee JA Park KW Alpha-fetoprotein and human telomerase reverse transcriptase mRNA levels in peripheral blood of patients with hepatocellular carcinoma J Cancer Res Clin Oncol 2009 135 8 1091 1098 10.1007/s00432-009-0549-9 19184104
Kong SY, Park JW, Kim JO, Lee NO, Lee JA, Park KW, et al. Alpha-fetoprotein and human telomerase reverse transcriptase mRNA levels in peripheral blood of patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135(8):1091–8.19184104 10.1007/s00432-009-0549-9
300. Mazzaferro V Regalia E Doci R Andreola S Pulvirenti A Bozzetti F Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 1996 334 11 693 700 10.1056/NEJM199603143341104 8594428
Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–700.8594428 10.1056/NEJM199603143341104
301. Onaca N Davis GL Goldstein RM Jennings LW Klintmalm GB Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation Liver Transpl. 2007 13 3 391 399 10.1002/lt.21095 17318865
Onaca N, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl. 2007;13(3):391–9. 10.1002/lt.21095.17318865 10.1002/lt.21095
302. Hong G Suh K-S Suh S-W Yoo T Kim H Park M-S Alpha-fetoprotein and 18F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation J Hepatol 2016 64 4 852 9 10.1016/j.jhep.2015.11.033 26658686
Hong G, Suh K-S, Suh S-W, Yoo T, Kim H, Park M-S, et al. Alpha-fetoprotein and 18F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. J Hepatol. 2016;64(4):852–9.26658686 10.1016/j.jhep.2015.11.033
303. Kim Y-I Paeng JC Cheon GJ Suh K-S Lee DS Chung J-K Prediction of posttransplantation recurrence of hepatocellular carcinoma using metabolic and volumetric indices of 18F-FDG PET/CT J Nucl Med 2016 57 7 1045 51 10.2967/jnumed.115.170076 26985057
Kim Y-I, Paeng JC, Cheon GJ, Suh K-S, Lee DS, Chung J-K, et al. Prediction of posttransplantation recurrence of hepatocellular carcinoma using metabolic and volumetric indices of 18F-FDG PET/CT. J Nucl Med. 2016;57(7):1045–51.26985057 10.2967/jnumed.115.170076
304. Kang YK Choi JY Paeng JC Kim YI Kwon HW Cheon GJ Composite criteria using clinical and FDG PET/CT factors for predicting recurrence of hepatocellular carcinoma after living donor liver transplantation Eur Radiol 2019 29 11 6009 6017 10.1007/s00330-019-06239-z 31115626
Kang YK, Choi JY, Paeng JC, Kim YI, Kwon HW, Cheon GJ, et al. Composite criteria using clinical and FDG PET/CT factors for predicting recurrence of hepatocellular carcinoma after living donor liver transplantation. Eur Radiol. 2019;29(11):6009–17.31115626 10.1007/s00330-019-06239-z
305. Li WX Li Z Gao PJ Gao J Zhu JY Histological differentiation predicts post-liver transplantation survival time Clin Res Hepatol Gastroenterol 2014 38 2 201 208 10.1016/j.clinre.2013.11.002 24388339
Li WX, Li Z, Gao PJ, Gao J, Zhu JY. Histological differentiation predicts post-liver transplantation survival time. Clin Res Hepatol Gastroenterol. 2014;38(2):201–8.24388339 10.1016/j.clinre.2013.11.002
306. Lu Y Chan Y-T Wu J Feng Z Yuan H Li Q CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress Drug Resist Updates 2023 71 101015 10.1016/j.drup.2023.101015
Lu Y, Chan Y-T, Wu J, Feng Z, Yuan H, Li Q, et al. CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress. Drug Resist Updates. 2023;71:101015.10.1016/j.drup.2023.101015
307. Yu J Park R Kim R Promising novel biomarkers for hepatocellular carcinoma: diagnostic and prognostic insights J Hepatocell Carcinoma 2023 10 1105 1127 10.2147/JHC.S341195 37483311
Yu J, Park R, Kim R. Promising novel biomarkers for hepatocellular carcinoma: diagnostic and prognostic insights. J Hepatocell Carcinoma. 2023;10:1105–27.37483311 10.2147/JHC.S341195
308. Shuen TWH Alunni-Fabbroni M Öcal E Malfertheiner P Wildgruber M Schinner R Extracellular vesicles may predict response to radioembolization and sorafenib treatment in advanced hepatocellular carcinoma: an exploratory analysis from the SORAMIC trial Clin Cancer Res 2022 28 17 3890 3901 10.1158/1078-0432.CCR-22-0569 35763041
Shuen TWH, Alunni-Fabbroni M, Öcal E, Malfertheiner P, Wildgruber M, Schinner R, et al. Extracellular vesicles may predict response to radioembolization and sorafenib treatment in advanced hepatocellular carcinoma: an exploratory analysis from the SORAMIC trial. Clin Cancer Res. 2022;28(17):3890–901.35763041 10.1158/1078-0432.CCR-22-0569
309. Goyal L Zheng H Abrams TA Miksad R Bullock AJ Allen JN A phase II and biomarker study of sorafenib combined with modified FOLFOX in patients with advanced hepatocellular carcinoma Clin Cancer Res 2019 25 1 80 89 10.1158/1078-0432.CCR-18-0847 30190369
Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, et al. A phase II and biomarker study of sorafenib combined with modified FOLFOX in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2019;25(1):80–9.30190369 10.1158/1078-0432.CCR-18-0847
310. El Shorbagy S abuTaleb F Labib HA Ebian H Harb OA Mohammed MS Prognostic significance of VEGF and HIF-1 α in hepatocellular carcinoma patients receiving sorafenib versus metformin sorafenib combination J Gastrointest Cancer 2021 52 1 269 79 10.1007/s12029-020-00389-w 32212089
El Shorbagy S, abuTaleb F, Labib HA, Ebian H, Harb OA, Mohammed MS, et al. Prognostic significance of VEGF and HIF-1 α in hepatocellular carcinoma patients receiving sorafenib versus metformin sorafenib combination. J Gastrointest Cancer. 2021;52(1):269–79.32212089 10.1007/s12029-020-00389-w
311. Chan YT Wu J Lu Y Li Q Feng Z Xu L Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC Mol Cancer 2024 23 1 74 10.1186/s12943-024-01988-y 38582885
Chan YT, Wu J, Lu Y, Li Q, Feng Z, Xu L, et al. Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC. Mol Cancer. 2024;23(1):74.38582885 10.1186/s12943-024-01988-y
312. Lee SH Yim SY Jeong YS Li QX Kang SH Sohn BH Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes Hepatology 2022 76 6 1634 48 10.1002/hep.32490 35349735
Lee SH, Yim SY, Jeong YS, Li QX, Kang SH, Sohn BH, et al. Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes. Hepatology. 2022;76(6):1634–48.35349735 10.1002/hep.32490
313. Fernández-Tussy P Rodríguez-Agudo R Fernández-Ramos D Barbier-Torres L Zubiete-Franco I Davalillo SL Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity Cell Death Dis 2021 12 6 555 10.1038/s41419-021-03827-0 34050139
Fernández-Tussy P, Rodríguez-Agudo R, Fernández-Ramos D, Barbier-Torres L, Zubiete-Franco I, Davalillo SL, et al. Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. Cell Death Dis. 2021;12(6):555.34050139 10.1038/s41419-021-03827-0
314. Li J Shi L Zhang X Sun B Yang Y Ge N pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma Oncotarget 2016 7 3 2646 2659 10.18632/oncotarget.6104 26544731
Li J, Shi L, Zhang X, Sun B, Yang Y, Ge N, et al. pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncotarget. 2016;7(3):2646–59.26544731 10.18632/oncotarget.6104
315. Fu Y Yang Z Hu Z Yang Z Pan Y Chen J Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies Hepatol Int 2022 16 4 868 878 10.1007/s12072-022-10348-1 35674872
Fu Y, Yang Z, Hu Z, Yang Z, Pan Y, Chen J, et al. Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies. Hepatol Int. 2022;16(4):868–78.35674872 10.1007/s12072-022-10348-1
316. Myojin Y Kodama T Maesaka K Motooka D Sato Y Tanaka S ST6GAL1 is a novel serum biomarker for lenvatinib-susceptible FGF19-driven hepatocellular carcinoma Clin Cancer Res 2021 27 4 1150 1161 10.1158/1078-0432.CCR-20-3382 33288659
Myojin Y, Kodama T, Maesaka K, Motooka D, Sato Y, Tanaka S, et al. ST6GAL1 is a novel serum biomarker for lenvatinib-susceptible FGF19-driven hepatocellular carcinoma. Clin Cancer Res. 2021;27(4):1150–61.33288659 10.1158/1078-0432.CCR-20-3382
317. Zhang P Sun H Wen P Wang Y Cui Y Wu J circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma Mol Ther Nucleic Acids 2022 27 293 303 10.1016/j.omtn.2021.12.001 35024242
Zhang P, Sun H, Wen P, Wang Y, Cui Y, Wu J. circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma. Mol Ther Nucleic Acids. 2022;27:293–303.35024242 10.1016/j.omtn.2021.12.001
318. Wang Y Deng B Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers Cancer Metastasis Rev 2023 42 3 629 652 10.1007/s10555-023-10084-4 36729264
Wang Y, Deng B. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev. 2023;42(3):629–52.36729264 10.1007/s10555-023-10084-4
319. Yan T Yu L Zhang N Peng C Su G Jing Y The advanced development of molecular targeted therapy for hepatocellular carcinoma Cancer Biol Med 2022 19 6 802 817 10.20892/j.issn.2095-3941.2021.0661 35699406
Yan T, Yu L, Zhang N, Peng C, Su G, Jing Y, et al. The advanced development of molecular targeted therapy for hepatocellular carcinoma. Cancer Biol Med. 2022;19(6):802–17.35699406 10.20892/j.issn.2095-3941.2021.0661
320. Scheiner B Pomej K Kirstein MM Hucke F Finkelmeier F Waidmann O Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score J Hepatol 2022 76 2 353 363 10.1016/j.jhep.2021.09.035 34648895
Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol. 2022;76(2):353–63.34648895 10.1016/j.jhep.2021.09.035
321. Yang Z, Fu Y, Wang Q, Pan Y, Wang J, Chen J, et al. Dynamic changes of serum α-fetoprotein predict the prognosis of bevacizumab plus immunotherapy in hepatocellular carcinoma. Int J Surg. 2024. 10.1097/JS9.0000000000001860.
322. Weng J Wang Z Hu Z Xu W Sun JL Wang F Repolarization of immunosuppressive macrophages by targeting SLAMF7-regulated CCL2 signaling sensitizes hepatocellular carcinoma to immunotherapy Cancer Res 2024 84 11 1817 1833 10.1158/0008-5472.CAN-23-3106 38484085
Weng J, Wang Z, Hu Z, Xu W, Sun JL, Wang F, et al. Repolarization of immunosuppressive macrophages by targeting SLAMF7-regulated CCL2 signaling sensitizes hepatocellular carcinoma to immunotherapy. Cancer Res. 2024;84(11):1817–33.38484085 10.1158/0008-5472.CAN-23-3106
323. Winograd P Hou S Sadeghi S Finn R DiPardo B Li Q Evaluation of hepatocellular carcinoma circulating tumor cells expressing programmed death-ligand 1 HPB 2018 20 S2 S3 10.1016/j.hpb.2018.02.004
Winograd P, Hou S, Sadeghi S, Finn R, DiPardo B, Li Q, et al. Evaluation of hepatocellular carcinoma circulating tumor cells expressing programmed death-ligand 1. HPB. 2018;20:S2–3.10.1016/j.hpb.2018.02.004
324. Hong JY Cho HJ Sa JK Liu X Ha SY Lee T Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial Genome Med 2022 14 1 1 10.1186/s13073-021-00995-8 34986867
Hong JY, Cho HJ, Sa JK, Liu X, Ha SY, Lee T, et al. Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Med. 2022;14(1):1.34986867 10.1186/s13073-021-00995-8
325. Li Y Jin H Li Q Shi L Mao Y Zhao L The role of RNA methylation in tumor immunity and its potential in immunotherapy Mol Cancer 2024 23 1 130 10.1186/s12943-024-02041-8 38902779
Li Y, Jin H, Li Q, Shi L, Mao Y, Zhao L. The role of RNA methylation in tumor immunity and its potential in immunotherapy. Mol Cancer. 2024;23(1):130.38902779 10.1186/s12943-024-02041-8
326. Huang XY Zhang PF Wei CY Peng R Lu JC Gao C Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis Mol Cancer 2020 19 1 92 10.1186/s12943-020-01213-6 32430013
Huang XY, Zhang PF, Wei CY, Peng R, Lu JC, Gao C, et al. Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. Mol Cancer. 2020;19(1):92.32430013 10.1186/s12943-020-01213-6
327. Zhu AX Abbas AR de Galarreta MR Guan Y Lu S Koeppen H Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma Nat Med 2022 28 8 1599 1611 10.1038/s41591-022-01868-2 35739268
Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28(8):1599–611.35739268 10.1038/s41591-022-01868-2
328. Campani C Bamba-Funck J Campion B Sidali S Blaise L Ganne-Carrié N Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab Liver Int 2023 43 3 708 717 10.1111/liv.15487 36444741
Campani C, Bamba-Funck J, Campion B, Sidali S, Blaise L, Ganne-Carrié N, et al. Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab. Liver Int. 2023;43(3):708–17.36444741 10.1111/liv.15487
329. Shi J Liu J Tu X Li B Tong Z Wang T Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy J Immunother Cancer 2022 10 1 e003133 10.1136/jitc-2021-003133 35101942
Shi J, Liu J, Tu X, Li B, Tong Z, Wang T, et al. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy. J Immunother Cancer. 2022;10(1):e003133.35101942 10.1136/jitc-2021-003133
330. Ruiz M Bresnahan E Molina-Sánchez P Lindblad KE Maier B Sia D β-catenin activation promotes immune escape and resistance to anti-pd-1 therapy in hepatocellular carcinoma Cancer Discov 2019 9 8 1124 41 10.1158/2159-8290.CD-19-0074 31186238
Ruiz M, Bresnahan E, Molina-Sánchez P, Lindblad KE, Maier B, Sia D, et al. β-catenin activation promotes immune escape and resistance to anti-pd-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9(8):1124–41.31186238 10.1158/2159-8290.CD-19-0074
331. Ye Z Wang Y Yuan R Ding R Hou Y Qian L Vesicle-mediated transport-related genes predict the prognosis and immune microenvironment in hepatocellular carcinoma J Cancer 2024 15 12 3645 3662 10.7150/jca.94902 38911369
Ye Z, Wang Y, Yuan R, Ding R, Hou Y, Qian L, et al. Vesicle-mediated transport-related genes predict the prognosis and immune microenvironment in hepatocellular carcinoma. J Cancer. 2024;15(12):3645–62.38911369 10.7150/jca.94902
332. He H Chen S Fan Z Dong Y Wang Y Li S Multi-dimensional single-cell characterization revealed suppressive immune microenvironment in AFP-positive hepatocellular carcinoma Cell Discov 2023 9 1 60 10.1038/s41421-023-00563-x 37336873
He H, Chen S, Fan Z, Dong Y, Wang Y, Li S, et al. Multi-dimensional single-cell characterization revealed suppressive immune microenvironment in AFP-positive hepatocellular carcinoma. Cell Discov. 2023;9(1):60.37336873 10.1038/s41421-023-00563-x
333. Sepich-Poore GD Zitvogel L Straussman R Hasty J Wargo JA Knight R The microbiome and human cancer Science 2021 371 6536 eabc4552 10.1126/science.abc4552 33766858
Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA, Knight R. The microbiome and human cancer. Science. 2021;371(6536):eabc4552.33766858 10.1126/science.abc4552
334. McQuade JL Daniel CR Helmink BA Wargo JA Modulating the microbiome to improve therapeutic response in cancer Lancet Oncol 2019 20 2 e77 e91 10.1016/S1470-2045(18)30952-5 30712808
McQuade JL, Daniel CR, Helmink BA, Wargo JA. Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncol. 2019;20(2):e77–91.30712808 10.1016/S1470-2045(18)30952-5
335. Schwabe RF Greten TF Gut microbiome in HCC - mechanisms, diagnosis and therapy J Hepatol 2020 72 2 230 238 10.1016/j.jhep.2019.08.016 31954488
Schwabe RF, Greten TF. Gut microbiome in HCC - mechanisms, diagnosis and therapy. J Hepatol. 2020;72(2):230–8.31954488 10.1016/j.jhep.2019.08.016
336. Silveira MAD Bilodeau S Greten TF Wang XW Trinchieri G The gut-liver axis: host microbiota interactions shape hepatocarcinogenesis Trends Cancer 2022 8 7 583 597 10.1016/j.trecan.2022.02.009 35331674
Silveira MAD, Bilodeau S, Greten TF, Wang XW, Trinchieri G. The gut-liver axis: host microbiota interactions shape hepatocarcinogenesis. Trends Cancer. 2022;8(7):583–97.35331674 10.1016/j.trecan.2022.02.009
337. Kang Y Cai Y Yang Y The gut microbiome and hepatocellular carcinoma: implications for early diagnostic biomarkers and novel therapies Liver Cancer 2022 11 2 113 125 10.1159/000521358 35634424
Kang Y, Cai Y, Yang Y. The gut microbiome and hepatocellular carcinoma: implications for early diagnostic biomarkers and novel therapies. Liver Cancer. 2022;11(2):113–25.35634424 10.1159/000521358
338. Zheng Y Wang T Tu X Huang Y Zhang H Tan D Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma J Immunother Cancer 2019 7 1 193 10.1186/s40425-019-0650-9 31337439
Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer. 2019;7(1):193.31337439 10.1186/s40425-019-0650-9
339. Zhang L Chen C Chai D Li C Guan Y Liu L The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors Front Immunol 2022 13 956533 10.3389/fimmu.2022.956533 36059512
Zhang L, Chen C, Chai D, Li C, Guan Y, Liu L, et al. The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors. Front Immunol. 2022;13:956533.36059512 10.3389/fimmu.2022.956533
340. Wu H Zheng X Pan T Yang X Chen X Zhang B Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma Int J Cancer 2022 151 8 1321 1334 10.1002/ijc.34118 35579980
Wu H, Zheng X, Pan T, Yang X, Chen X, Zhang B, et al. Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma. Int J Cancer. 2022;151(8):1321–34.35579980 10.1002/ijc.34118
341. Fulgenzi CAM Effect of early antibiotic exposure on survival of patients receiving atezolizumab plus bevacizumab but not sorafenib for unresectable HCC: A sub-analysis of the phase III IMbrave150 study JCO. 2023 41 597 597 10.1200/JCO.2023.41.4_suppl.597
Fulgenzi CAM, et al. Effect of early antibiotic exposure on survival of patients receiving atezolizumab plus bevacizumab but not sorafenib for unresectable HCC: A sub-analysis of the phase III IMbrave150 study. JCO. 2023;41:597–597. 10.1200/JCO.2023.41.4_suppl.597.10.1200/JCO.2023.41.4_suppl.597
342. Lee PC Wu CJ Hung YW Lee CJ Chi CT Lee IC Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma J Immunother Cancer 2022 10 6 e004779 10.1136/jitc-2022-004779 35738801
Lee PC, Wu CJ, Hung YW, Lee CJ, Chi CT, Lee IC, et al. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer. 2022;10(6):e004779.35738801 10.1136/jitc-2022-004779
343. Nault JC Villanueva A Biomarkers for hepatobiliary cancers Hepatology 2021 73 Suppl 1 115 127 10.1002/hep.31175 32045030
Nault JC, Villanueva A. Biomarkers for hepatobiliary cancers. Hepatology. 2021;73(Suppl 1):115–27.32045030 10.1002/hep.31175
344. Wang B Qi FZ Chen P Qian LM Su HS Wang Y Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma Int J Biol Sci 2024 20 5 1634 1651 10.7150/ijbs.92211 38481819
Wang B, Qi FZ, Chen P, Qian LM, Su HS, Wang Y, et al. Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma. Int J Biol Sci. 2024;20(5):1634–51.38481819 10.7150/ijbs.92211
345. Qi S Su L Li J Zhao P Zhang Q Niu X YIPF2 is a novel Rab-GDF that enhances HCC malignant phenotypes by facilitating CD147 endocytic recycle Cell Death Dis 2019 10 6 462 10.1038/s41419-019-1709-8 31189879
Qi S, Su L, Li J, Zhao P, Zhang Q, Niu X, et al. YIPF2 is a novel Rab-GDF that enhances HCC malignant phenotypes by facilitating CD147 endocytic recycle. Cell Death Dis. 2019;10(6):462.31189879 10.1038/s41419-019-1709-8
346. Zhao P Zhang W Wang SJ Yu XL Tang J Huang W HAb18G/CD147 promotes cell motility by regulating annexin II-activated RhoA and Rac1 signaling pathways in hepatocellular carcinoma cells Hepatology 2011 54 6 2012 2024 10.1002/hep.24592 21809360
Zhao P, Zhang W, Wang SJ, Yu XL, Tang J, Huang W, et al. HAb18G/CD147 promotes cell motility by regulating annexin II-activated RhoA and Rac1 signaling pathways in hepatocellular carcinoma cells. Hepatology. 2011;54(6):2012–24.21809360 10.1002/hep.24592
347. Qi S Su L Li J Zhang C Ma Z Liu G Arf6-driven endocytic recycling of CD147 determines HCC malignant phenotypes J Exp Clin Cancer Res 2019 38 1 471 10.1186/s13046-019-1464-9 31752956
Qi S, Su L, Li J, Zhang C, Ma Z, Liu G, et al. Arf6-driven endocytic recycling of CD147 determines HCC malignant phenotypes. J Exp Clin Cancer Res. 2019;38(1):471.31752956 10.1186/s13046-019-1464-9
348. Qi FZ Su HS Wang B Qian LM Wang Y Wang CH Hypoxia-activated ADCC-enhanced humanized anti-CD147 antibody for liver cancer imaging and targeted therapy with improved selectivity MedComm (2020) 2024 5 3 e512 38469549
Qi FZ, Su HS, Wang B, Qian LM, Wang Y, Wang CH, et al. Hypoxia-activated ADCC-enhanced humanized anti-CD147 antibody for liver cancer imaging and targeted therapy with improved selectivity. MedComm (2020). 2024;5(3):e512.38469549
349. Zhu AX Gold PJ El-Khoueiry AB Abrams TA Morikawa H Ohishi N First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma Clin Cancer Res 2013 19 4 920 928 10.1158/1078-0432.CCR-12-2616 23362325
Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohishi N, et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013;19(4):920–8.23362325 10.1158/1078-0432.CCR-12-2616
350. Abou-Alfa GK Yen CJ Hsu CH O’Donoghue J Beylergil V Ruan S Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) Cancer Chemother Pharmacol 2017 79 2 421 429 10.1007/s00280-017-3241-9 28120036
Abou-Alfa GK, Yen CJ, Hsu CH, O’Donoghue J, Beylergil V, Ruan S, et al. Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). Cancer Chemother Pharmacol. 2017;79(2):421–9.28120036 10.1007/s00280-017-3241-9
351. Abou-Alfa GK Puig O Daniele B Kudo M Merle P Park JW Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma J Hepatol 2016 65 2 289 295 10.1016/j.jhep.2016.04.004 27085251
Abou-Alfa GK, Puig O, Daniele B, Kudo M, Merle P, Park JW, et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol. 2016;65(2):289–95.27085251 10.1016/j.jhep.2016.04.004
352. Jin ZC Chen JJ Zhu XL Duan XH Xin YJ Zhong BY Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study EClinicalMedicine 2024 72 102622 10.1016/j.eclinm.2024.102622 38745965
Jin ZC, Chen JJ, Zhu XL, Duan XH, Xin YJ, Zhong BY, et al. Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study. EClinicalMedicine. 2024;72:102622.38745965 10.1016/j.eclinm.2024.102622
353. Bai L Sun M Xu A Bai Y Wu J Shao G Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma J Clin Oncol 2021 39 15_suppl 4101 10.1200/JCO.2021.39.15_suppl.4101
Bai L, Sun M, Xu A, Bai Y, Wu J, Shao G, et al. Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma. J Clin Oncol. 2021;39(15_suppl):4101.10.1200/JCO.2021.39.15_suppl.4101
354. Hussein MS Li Q Mao R Peng Y He Y TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma Front Immunol 2023 14 1114770 10.3389/fimmu.2023.1114770 37215108
Hussein MS, Li Q, Mao R, Peng Y, He Y. TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma. Front Immunol. 2023;14:1114770.37215108 10.3389/fimmu.2023.1114770
355. A phase 1, single-arm, open-label, dose-escalation study of AFP specific T cell receptor transduced T cells injection (HRYZ-T102) in patients with AFP positive advanced hepatocellular carcinoma and other solid tumors. 2024. Available from: https://clinicaltrials.gov/study/NCT06515314.
356. Sun L Guo H Jiang R Lu L Liu T He X Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma Tumour Biol 2016 37 1 799 806 10.1007/s13277-015-3845-9 26250457
Sun L, Guo H, Jiang R, Lu L, Liu T, He X. Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma. Tumour Biol. 2016;37(1):799–806.26250457 10.1007/s13277-015-3845-9
357. Xu J Shen J Gu S Zhang Y Wu L Wu J Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial Clin Cancer Res 2021 27 4 1003 1011 10.1158/1078-0432.CCR-20-2571 33087333
Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial. Clin Cancer Res. 2021;27(4):1003–11.33087333 10.1158/1078-0432.CCR-20-2571
358. Hashimoto A Sarker D Reebye V Jarvis S Sodergren MH Kossenkov A Upregulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and patients with cancer Clin Cancer Res 2021 27 21 5961 5978 10.1158/1078-0432.CCR-21-0986 34407972
Hashimoto A, Sarker D, Reebye V, Jarvis S, Sodergren MH, Kossenkov A, et al. Upregulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and patients with cancer. Clin Cancer Res. 2021;27(21):5961–78.34407972 10.1158/1078-0432.CCR-21-0986
359. Chan SL Schuler M Kang YK Yen CJ Edeline J Choo SP A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors J Exp Clin Cancer Res 2022 41 1 189 10.1186/s13046-022-02383-5 35655320
Chan SL, Schuler M, Kang YK, Yen CJ, Edeline J, Choo SP, et al. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. J Exp Clin Cancer Res. 2022;41(1):189.35655320 10.1186/s13046-022-02383-5
360. Chen WT Lin SM Lee WC Wu TJ Lin CC Shen CH GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial Hepatol Int 2022 16 1 148 158 10.1007/s12072-021-10283-7 34982369
Chen WT, Lin SM, Lee WC, Wu TJ, Lin CC, Shen CH, et al. GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial. Hepatol Int. 2022;16(1):148–58.34982369 10.1007/s12072-021-10283-7
361. Zhou M Zhu S Xu C Liu B Shen J A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma Invest New Drugs 2023 41 1 162 167 10.1007/s10637-023-01335-w 36763233
Zhou M, Zhu S, Xu C, Liu B, Shen J. A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma. Invest New Drugs. 2023;41(1):162–7.36763233 10.1007/s10637-023-01335-w
362. Woei AJF Weijl NI Burgmans MC Fariña Sarasqueta A van Wezel JT Wasser M Neoadjuvant treatment with angiogenesis-inhibitor dovitinib prior to local therapy in hepatocellular carcinoma: a phase II study Oncologist 2021 26 10 854 864 10.1002/onco.13901 34251745
Woei AJF, Weijl NI, Burgmans MC, Fariña Sarasqueta A, van Wezel JT, Wasser M, et al. Neoadjuvant treatment with angiogenesis-inhibitor dovitinib prior to local therapy in hepatocellular carcinoma: a phase II study. Oncologist. 2021;26(10):854–64.34251745 10.1002/onco.13901
363. Fountzilas C Gupta M Lee S Krishnamurthi S Estfan B Wang K A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma Br J Cancer 2020 122 7 963 970 10.1038/s41416-020-0737-6 32037403
Fountzilas C, Gupta M, Lee S, Krishnamurthi S, Estfan B, Wang K, et al. A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. Br J Cancer. 2020;122(7):963–70.32037403 10.1038/s41416-020-0737-6
364. Giannelli G Santoro A Kelley RK Gane E Paradis V Cleverly A Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib PLoS One 2020 15 3 e0222259 10.1371/journal.pone.0222259 32210440
Giannelli G, Santoro A, Kelley RK, Gane E, Paradis V, Cleverly A, et al. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. PLoS One. 2020;15(3):e0222259.32210440 10.1371/journal.pone.0222259
365. Kelley RK Ryoo BY Merle P Park JW Bolondi L Chan SL Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial ESMO Open 2020 5 4 e000714 10.1136/esmoopen-2020-000714 32847838
Kelley RK, Ryoo BY, Merle P, Park JW, Bolondi L, Chan SL, et al. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open. 2020;5(4):e000714.32847838 10.1136/esmoopen-2020-000714
366. Venturini N Marron T Casanova-Acebes M Mandeli J Doroshow D Lucas N 629 neoadjuvant nivolumab combined with CCR2/5 inhibitor or anti-IL-8 antibody in non-small cell lung cancer and hepatocellular carcinoma J Immunother Cancer 2022 10 Suppl 2 A661
Venturini N, Marron T, Casanova-Acebes M, Mandeli J, Doroshow D, Lucas N, et al. 629 neoadjuvant nivolumab combined with CCR2/5 inhibitor or anti-IL-8 antibody in non-small cell lung cancer and hepatocellular carcinoma. J Immunother Cancer. 2022;10(Suppl 2):A661.
367. Cai M Hong X Guo Y Shi W Huang W Liang L 173P A phase II trial of donafenib plus sintilimab for advanced stage hepatocellular carcinoma Ann Oncol 2024 35 S79 10.1016/j.annonc.2024.05.182
Cai M, Hong X, Guo Y, Shi W, Huang W, Liang L, et al. 173P A phase II trial of donafenib plus sintilimab for advanced stage hepatocellular carcinoma. Ann Oncol. 2024;35:S79.10.1016/j.annonc.2024.05.182
368. Cheon J Jung S Kang B Kim H Kim C Chon H Organ-specific responses to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma J Clin Oncol 2022 40 16_suppl 4076 10.1200/JCO.2022.40.16_suppl.4076
Cheon J, Jung S, Kang B, Kim H, Kim C, Chon H. Organ-specific responses to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2022;40(16_suppl):4076.10.1200/JCO.2022.40.16_suppl.4076
369. Vienot A Jacquin M Rebucci-Peixoto M Pureur D Ghiringhelli F Assenat E Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82) BMC Cancer 2023 23 1 710 10.1186/s12885-023-11065-0 37516867
Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, et al. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82). BMC Cancer. 2023;23(1):710.37516867 10.1186/s12885-023-11065-0
370. A phase Ib/II, two-part, non-randomized, open-label study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of chidamide in combination with regorafenib in patients with hepatocellular carcinoma. 2023. Available from: https://clinicaltrials.gov/study/NCT05770882.
371. Cabozantinib treatment in a phase II study for patients with hepatocellular carcinoma (HCC) refractory to PD-1 inhibitors. 2021. Available from: https://clinicaltrials.gov/study/NCT04767906.
372. VETC-based precision adjuvant therapy for postoperative hepatocellular carcinoma: a prospective multicenter cohort study. 2024. Available from: https://clinicaltrials.gov/study/NCT06311929.
373. Phase I/II study of PTX-9908 injection as an inhibitor of cancer progression in patients with non-resectable hepatocellular carcinoma following transarterial chemoembolization treatment. 2019. Available from: https://clinicaltrials.gov/study/NCT03812874.
374. A phase 2, randomized study to evaluate the optimized dose, safety, and efficacy of livmoniplimab in combination with budigalimab for locally advanced or metastatic hepatocellular carcinoma (HCC) patients who have progressed after an immune checkpoint inhibitor containing regimen in first-line HCC. 2023. Available from: https://clinicaltrials.gov/study/NCT05822752.
375. Efficacy and safety of serplulimab combined with bevacizumab biosimilar and HAIC in advanced hepatocellular carcinoma (HCC) patients. 2024. Available from: https://clinicaltrials.gov/study/NCT06370065.
376. Efficacy and safety of transarterial chemoembolization in combination with PD-1/PD-L1 inhibitors and molecular target therapies (VEGF-TKI/Bevacizumab) for intermediate stage HCC. 2022. Available from: https://clinicaltrials.gov/study/NCT05332496.
377. Epigenetic therapeutics to overcome resistance against immune checkpoint inhibitors in hepatocellular carcinoma: a proof-of-concept clinical trial. 2023. Available from: https://clinicaltrials.gov/study/NCT05873244.
378. An open-label, multi-center, dose-escalation phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of ETN101 in patients with advanced hepatocellular carcinoma. 2024. Available from: https://clinicaltrials.gov/study/NCT06326502.
379. A randomized, double-blind, placebo-controlled, multicenter phase 3 study of anlotinib hydrochloride capsules combined with penpulimab injection in patients with high risk of relapse after radical surgery or ablation of hepatocellular carcinoma (HCC). 2023. Available from: https://clinicaltrials.gov/study/NCT05862337.
380. A single-arm, non-randomized, single-center study to evaluate lenvatinib in combination with camrelizumab as first-line therapy in patients with advanced hepatocellular carcinoma. 2020. Available from: https://clinicaltrials.gov/study/NCT04443309.
381. Ablation in combination with lenvatinib and anti-PD-1 antibodies in patients with early recurrence after radical resection/ablation of HCC: a prospective, randomized, controlled clinical study. 2023. Available from: https://clinicaltrials.gov/study/NCT05803928.
382. A phase II study to evaluate the efficacy and safety of cryoablation combined with tislelizumab plus lenvatinib as first-line treatment in patients with advanced hepatocellular carcinoma. 2023. Available from: https://clinicaltrials.gov/study/NCT05897268.
383. Transarterial chemoembolization combined with lenvatinib and Iodion-125 seeds brachytherapy for hepatocellular carcinoma with portal vein branch tumor thrombus: a single center, prospective, randomized control trail. 2021. Available from: https://clinicaltrials.gov/study/NCT04967495.
384. A phase I study of SBRT vaccination with atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma. 2022. Available from: https://clinicaltrials.gov/study/NCT05488522.
385. A prospective, single-arm study of downstaging protocol containing immunotherapy for HCC beyond the Milan criteria before liver transplantation. 2022. Available from: https://clinicaltrials.gov/study/NCT05475613.
386. A open-label, multi-center, single arm study to evaluate the efficacy and safety of tislelizumab combined with sitravatinib as adjuvant therapy in participants with hepatocellular carcinoma who are at high risk of recurrence after curative hepatic resection. 2022. Available from: https://clinicaltrials.gov/study/NCT05407519.
387. A phase Ib clinical study to evaluate the efficacy and safety of TQB2618 injection combined with penpulimab injection and anlotinib hydrochloride capsules as first-line treatment for advanced hepatocellular carcinoma. 2023. Available from: https://clinicaltrials.gov/study/NCT05975645.
388. Regorafenib plus tislelizumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma (HCC). 2019. Available from: https://clinicaltrials.gov/study/NCT04183088.
389. Efficacy and safety of stereotactic body radiotherapy followed by adebrelimab and lenvatinib for hepatocellular carcinoma with abdominal lymph node metastases: a two-arm, phase II trial. 2024. Available from: https://clinicaltrials.gov/study/NCT06261125.
390. Safety and efficacy of lenvatinib combined with VIC-1911 in the treatment of lenvatinib-unresponsive or lenvatinib-resistant hepatocellular carcinoma. 2023. Available from: https://clinicaltrials.gov/study/NCT05718882.
391. Safety and efficacy study of pembrolizumab in combination with lenvatinib in participants with hepatocellular carcinoma (HCC) before liver transplant as neoadjuvant therapY--PLENTY randomized clinical trial. 2020. Available from: https://clinicaltrials.gov/study/NCT04425226.
392. An open label, randomized, controlled, clinical trial of adoptive autologous invariant natural killer T cells for the treatment of progressed hepatocellular carcinoma continuing on PD-1 inhibitor therapy. 2023. Available from: https://clinicaltrials.gov/study/NCT05962450.
393. A phase 1b dose-escalation and cohort-expansion study of the safety/tolerability, and efficacy of oncolytic virotherapy plus PD-1 inhibitor and lenvatinib for patients with advanced hepatocellular carcinoma. 2022. Available from: https://clinicaltrials.gov/study/NCT05675462.
394. A phase 2 study on immune checkpoint inhibitors and radioembolisation for previously untreated metastatic hepatocellular carcinoma. 2023. Available from: https://clinicaltrials.gov/study/NCT05809869.
395. Observation study of sequential regorafenib combined with immunocheckpoint inhibitors after hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. 2022. Available from: https://clinicaltrials.gov/study/NCT05573282.
396. Regorafenib combined with PD-1 inhibitor therapy for second-line treatment of hepatocellular carcinoma: a single arm, nonrandomized, single center clinical study. 2021. Available from: https://clinicaltrials.gov/study/NCT05048017.
397. Non-invasive CT-based hepatic venous pressure gradient assessment for predicting the prognosis of hepatocellular carcinoma with transarterial chemoembolization (CHANCE-CHESS 2302): a multicenter retrospective study. 2023. Available from: https://clinicaltrials.gov/study/NCT05704192.
398. A multi-centre single-arm phase II study on durvalumab (MEDI 4736) with stereotactic body radiation therapy (SBRT) in patients with inoperable/unresectable hepatocellular carcinoma. 2021. Available from: https://clinicaltrials.gov/study/NCT04913480.
399. A phase II, open-label, multi-cohort, multicenter study in patients with unresectable hepatocellular carcinoma and Child-Pugh B7 and B8 cirrhosis. 2023. Available from: https://clinicaltrials.gov/study/NCT06096779.
400. Intra-tumor delivery of double checkpoint inhibitors, chemodrug, and/or bevacizumab therapy as first line for hepatocellular carcinoma. 2024. Available from: https://clinicaltrials.gov/study/NCT06482801.
401. A single-arm, prospective, open clinical study of palbociclib for backline treatment of advanced hepatocellular carcinoma. 2024. Available from: https://clinicaltrials.gov/study/NCT06478927.
402. Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene. 2022. Available from: https://clinicaltrials.gov/study/NCT05497453.
403. A phase II randomized study of atezolizumab plus multi-kinase inhibitor versus multi-kinase inhibitor alone in subjects with unresectable, advanced hepatocellular carcinoma who previously received atezolizumab plus bevacizumab. 2021. Available from: https://clinicaltrials.gov/study/NCT05168163.
404. A phase 1/2 exploratory study of the TBL1 inhibitor, tegavivint (BC2059), in patients with advanced hepatocellular carcinoma. 2023. Available from: https://clinicaltrials.gov/study/NCT05797805.
405. Lenvatinib combined toripalimab in advanced hepatocellular carcinoma: a single-center, single-arm, non-randomized clinical study. 2020. Available from: https://clinicaltrials.gov/study/NCT04368078.
406. Adjuvant treatment of patients with high risk of recurrent hepatocellular carcinoma after radical surgery with donafenib in combination with envafolimab: a prospective, multicentre, single-arm phase II clinical study. 2024. Available from: https://clinicaltrials.gov/study/NCT06498622.
407. A phase II study of transcatheter arterial chemoembolization (TACE) combined with anti-PD-1 antibody (IBI308) in patients with advanced hepatocellular carcinoma. 2020. Available from: https://clinicaltrials.gov/study/NCT04297280.
408. Phase II study evaluating the efficacy of tremelimumab (T) plus durvalumab (D) with lenvatinib combined with concurrent hepatic arterial infusion chemotherapy (HAIC) in patients (Pts) with unresectable hepatocellular carcinoma (uHCC). 2024. Available from: https://clinicaltrials.gov/study/NCT06364007.
409. Hepatic artery infusion chemotherapy (HAIC) combined with camrelizumab and tyrosine kinase inhibitor for unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization (TACE) failure: a single-arm and open-label prospective study. 2021. Available from: https://clinicaltrials.gov/study/NCT05135364.
410. Combined hepatic arterial infusion chemotherapy, tyrosine kinase inhibitor/ anti-VEGF antibody, and anti-PD-1/ PD-L1 antibody as conversion therapy for unresectable hepatocellular carcinoma. 2023. Available from: https://clinicaltrials.gov/study/NCT05713994.
411. Phase II study of FGFR inhibitor futibatinib in combination with anti-PD-1 antibody pembrolizumab in patients with advanced or metastatic hepatocellular carcinoma with FGF19 expression after first line therapy. 2021. Available from: https://clinicaltrials.gov/study/NCT04828486.
412. Lenvatinib in recurrent hepatocellular carcinoma after liver transplantation. 2021. Available from: https://clinicaltrials.gov/study/NCT05103904.
413. An observational study in patients with unresectable hepatocellular carcinoma (uHCC) following treatment with atezolizumab plus bevacizumab (AB) or with another approved immuno-oncology immune checkpoint inhibitor combination in first-line. 2023. Available from: https://clinicaltrials.gov/study/NCT06117891.
414. Combined transarterial chemoembolization, tyrosine kinase inhibitor/ anti-VEGF antibody, and anti-PD-1/ PD-L1 antibody as conversion therapy for advanced hepatocellular carcinoma: a multicenters, real-world, ambispective cohort study. 2023. Available from: https://clinicaltrials.gov/study/NCT05717738.
415. A study to evaluate the effects of radiotherapy combined with tyrosine kinase inhibitor (TKI) and anti-PD-1 antibody for stage IIIA hepatocellular carcinoma with portal vein tumor thrombus (PVTT). 2023. Available from: https://clinicaltrials.gov/study/NCT06061445.
416. A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma. 2020. Available from: https://clinicaltrials.gov/study/NCT04248569.
417. Efficacy of HAIC combined with lenvatinib and PD-1 inhibitor in infiltrative hepatocellular carcinoma: an observational, real-world study. 2024. Available from: https://clinicaltrials.gov/study/NCT06333561.
418. Safety and efficacy study of durvalumab in combination with lenvatinib in participants with locally advanced and metastatic hepatocellular carcinoma-- DULECT2020-1 trial. 2020. Available from: https://clinicaltrials.gov/study/NCT04443322.
419. Trametinib combined with everolimus and lenvatinib in the treatment of recurrent/refractory advanced solid tumors: a phase II clinical trial. 2021. Available from: https://clinicaltrials.gov/study/NCT04803318.
420. Efficacy of locoregional therapy combined with bevacizumab and PD1/L1 inhibitor in advanced hepatocellular carcinoma: a multicenter, observational, real-world study. 2024. Available from: https://clinicaltrials.gov/study/NCT06323382.
421. Phase II trial of palliative hypofractionated radiotherapy followed by durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after progression on prior PD-1 inhibition. 2020. Available from: https://clinicaltrials.gov/study/NCT04430452.
422. Intra-tumor injection of drug-eluting microspheres loading with chemodrug plus checkpoint inhibitors and IL2 for treatment of advanced solid tumors. 2020. Available from: https://clinicaltrials.gov/study/NCT04770207.
423. A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with hepatocellular carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score. 2022. Available from: https://clinicaltrials.gov/study/NCT05622071.
424. A phase 1B/2, open-label study of Q702 in combination with intravenous pembrolizumab in patients with selected advanced solid tumors. 2022. Available from: https://clinicaltrials.gov/study/NCT05438420.
425. A phase II trial of cabozantinib in the treatment of recurrent hepatocellular carcinoma post liver transplant. 2019. Available from: https://clinicaltrials.gov/study/NCT04204850.
426. A single-arm, multicenter phase Ib clinical trial of the efficacy and safety of TQB2450 injection combined with anlotinib hydrochloride capsule neoadjuvant in the treatment of resectable hepatocellular carcinoma with a high risk of recurrence or metastasis. 2021. Available from: https://clinicaltrials.gov/study/NCT04888546.
427. Zeng Q Klein C Caruso S Maille P Laleh NG Sommacale D Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology J Hepatol 2022 77 1 116 127 10.1016/j.jhep.2022.01.018 35143898
Zeng Q, Klein C, Caruso S, Maille P, Laleh NG, Sommacale D, et al. Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. J Hepatol. 2022;77(1):116–27.35143898 10.1016/j.jhep.2022.01.018
428. Calderaro J Seraphin TP Luedde T Simon TG Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma J Hepatol 2022 76 6 1348 1361 10.1016/j.jhep.2022.01.014 35589255
Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol. 2022;76(6):1348–61.35589255 10.1016/j.jhep.2022.01.014
